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vABSTRACT
Functional genomics aspires to explain how a transcription factor (TF) and its mea-
sured biochemical occupancy relates to the enhancer activity of the underlying
sequence elements. Tissue-specific TFs exhibit remarkable selectivity and repro-
ducibility in the available genome-wide sequence motifs accessed. A consistent
central conclusion is that, irrespective of the element selection criteria used, ~50%
of candidate Enhancers score as transcriptionally active in both mouse and human
cell types, while the remaining 50% of similarly biochemically marked regions are
unable to activate transcription on their own. This finding is based on an integrated
comparison of a group of functionally assayed elements containing TF-occupied el-
ements, evolutionarily conserved elements, and TF agnostic elements with hallmark
biochemical signatures of known enhancers. Quantitatively, the level of TF occu-
pancy signal was the best predictor of the proportion of active enhancers detected,
but overall (and contrary to expectation) it is a weak predictor of the magnitude
of enhancer activity readout. In specific cell types, elements can display all of
the hallmark signatures of enhancers, but can remain inactively poised prior to a
stimulus that either activates them or releases a repressive factor. Against previous
expectations these poised occupancy sites, once released, behave comparatively in
magnitude of enhancer activity as their counterparts that are only directly accessed
upon stimulation. Based on our findings, the vast majority of active enhancers in
the genome, including some of the most individually powerful ones, are expected
to display relatively modest biochemical signatures. Finally, the combined set of
over a hundred genomic regions that lacked biochemical marks, even while con-
taining the motifs known to be necessary to bind the relevant TFs, did not support
significant enhancer function. We also found evidence that both enhancer orienta-
tion and combinations of relatively closely spaced candidate Enhancers, can yield
vi
additive functions, with possible fine tuning of the enhancer activity controlled by
the type and the distance between individually accessed motifs. In special cases,
these elements might cooperate to recruit stable complexes resulting in a syner-
gistic transcriptional activation, suggesting that both local “super-enhancers” and
recruited multi-element combinatorics are likely to play an important role in vivo.
These findings provide an expectation for enhancer function in the comprehensive
annotations provided by the new ENCODE encyclopedia and may help guide fu-
ture efforts to define the mechanisms by which enhancer activity is achieved and
conferred selectively to target genes. Surprisingly, elements that deeply sample the
biochemical occupancy of complex loci, match a random population of selected
elements remarkably well. Our findings also indicate that carefully designed and
lower throughput approaches, rather than high numerical assays that focus on the
outstanding features, will bring widely applicable answers to the remaining ques-
tions of how relative enhancers are tuned and how seemingly identical regions at a
biochemical and motif level are selected for or against function.
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1C h a p t e r 1
INTRODUCTION
1.1 Thesis Outline
Chapter 1 provides a review of the key components currently understood to regulate
the transcription of genes and sets the context necessary to interpret the findings
presented in this thesis.
Chapter 2 outlines the candidate Enhancer selection, development and limits of my
enhancer assay.
Chapter 3 presents my draft manuscript outlining the combined findings of our
collaboration by contrasting enhancer activity proportion and magnitude from can-
didate regions selected in each cell types.
Chapter 4 pertains to the relative activities of individual candidate Enhancer ele-
ments within complex loci.
Chapter 5 proposes models and key experiments for future developments.
1.2 Gene Regulatory Networks
As developmental biologists, we aspire to obtain a complete understanding of the
process that decodes the genomic blueprint using the maternal inputs found in the
oocyte, to produce the hundreds of cell types needed in an adult. During this
process, each cell has to juggle many concurrent regulatory programs to support
the establishment and maintenance of cell type-specific functions (Huang L, 2000;
Ma JY, 2013; HoughEvans BR, 1977; Wang DG, 1995) while carrying on the
common “housekeeping” (ie. metabolic and homeostatic) functions shared by
most cell types. (Eisenberg E, 2003) Both the housekeeping and cell type-specific
2functions are regulated by gene regulatory networks (GRNs) orchestrated by the
sum of many ubiquitous and selectively expressed regulatory proteins known as
Transcription Factors (TFs). (Davidson EH, 2005) These, in turn, occupy cis
Regulatory Elements (cREs) — stretches of DNA containing the necessary TF
binding sequences— in response to either internal feedback loops or stimuli external
to the cell. (Longabaugh WJ, 2005; Yee SP, 1993; Cameron R, 1997) In order to
understand the drivers behind this process, many labs, including several here at
Caltech, began studying and dissecting these functional elements of the genome.
Yet despite the combined knowledge of numerous examples of functional regions,
the motifs bound by individual factors, the TFs expressed in each system, and the
regions of the genome occupied by each TF, we are still unable to predict the
functional logic of individual cis-regulatory elements that are used to guide the
developmental process from their DNA sequences.
1.3 DNA sequence mediating TF occupancy
Transcription factors (TFs) are proteins that are able to bind DNA directly in a
sequence specific manner to decode to the transcriptomic instructions contained in
the genome based on the cellular context. This property distinguishes them from
transcriptional co-factor proteins, which define the context, and are recruited to the
DNA through protein-protein interactions with the TFs. EMSA (Electrophoretic
Mobility Shift Assay) and Selex (multiple rounds of oligonucleotide selection and
TF binding) studies allowed for the identification of the DNA sequence bound by
individual TFs. For example, MyoD, a TF able to transdifferentiate fibroblasts
into muscle can bind to the CAGSTG motif called an Ebox. (Davis RL, 1987;
Blackwell TK, 1990; Kabadi AM, 2015; Wright WE, 1991) The mapping of TF
binding sites to a sequenced genome might seem like an easy step once the recog-
nition sequences are known. (Kophengnavong T, 2000) Unfortunately, the genome
3provides huge numbers of such motifs and identifying active cREs used to control
these transcriptomic processes proved to be a challenge. (Cirillo LA, 2002) For
example, in the mouse genome, there are over 2.1 million instances of the Ebox
motif alone, which is several orders of magnitude more than the number of genes.
This numerical imbalance raises questions as to which of the available motifs are
biochemically accessed and howmuch of the genome supports biological regulatory
function. (Kirilusha A, 2014 thesis)
1.4 Identifying candidate Regulatory Elements
A goal for the field has thus been to identify, map and characterize all regulatory
DNA sequences in the genome, sometimes called the cis-regulome. This effort
has used a combination of biochemical correlates for regulatory activities, direct
functional assays and mutagenesis perturbations of cis-elements to identify and
define regulatory elements. The scale of this effort has increased from discovery
and dissection of single genes and their associated regulatory elements to larger
locus-level studies and finally to the whole-genome scale.
Mutagenesis screens and random integration events were first used to identify DNA
elements that result in phenotypical variations in Drosophila. (OKane CJ, 1987)
Reviewed in: (Rossant J, 1992) However these methods are inefficient when applied
to large mammalian genomes. (Weihner H, 1984; Queen C, 1984) Long contiguous
pieces of DNA (eventually large BACs) from upstream of key genes were tested
for their ability to support a given temporal/spatial expression pattern during de-
velopment. (Mautner J, 1995; Springer PS, 2000; Carvajal JJ, 2001) These assays
can also support deletion analysis of smaller target regions within the test DNA to
identify local sequence features that support a given expression pattern. For exam-
ple, the myf5 gene is driven with different temporal dynamics in different spatial
domains of the developing mouse embryo by multiple, separable, large elements in
4a 100kb upstream segment of DNA within a yeast artificial chromosome (YAC)
(Hadchouel J, 2000). The 14kb region immediately spanning the Myf5/MRF4 lo-
cus, which controls the early epaxial expression of myf5, can be further subdivided
and contains individual enhancers with separable functions (Summerbell D, 2000;
Teboul L, 2002). Separability of functional elements is also true for muscle-specific
control elements located in a region ~50kb upstream of myf5 that are required for
later expression. (Hadchouel J, 2003) However, these designs are also numerically
limited by both time and expense. (Carvajal JJ, 2001; Johnson JE, 1989; Jaynes
JB, 1988; Hadchouel J, 2003) Deletions in transgenic BACs that result in loss of
function also have limited interpretability, because they cannot identify whether
a loss of function is due to removal of one or more positive-acting cREs within
the deletion. Conversely, if a gain-of-function is detected upon making a deletion,
it cannot be known whether the loss of a negative acting element (insulators or
silencers) normally contributes to the functional output of the region. Although
transgenic BACmethods support the idea that functional elements are separable and
can be assayed out of their normal genomic context, they raise the possibility that
motifs which function in the normal genomic context may not individually function
in an experiment, unless they are provided the context of other control elements.
In order to increase the detection of likely candidate enhancers that can support
tissue specific expression patterns, targeted mutations or DNAse hypersensitivity
mappings in representative cell lines could be used to identify the sequences most
likely responsible for the identified function of a larger fragment of DNA.
At the time biochemical measurements over such vast regions as a BAC (and much
less genome-wide) were not feasible but the use of evolutionary sequence con-
servation permitted to identify candidate Regulatory Elements on a local scale by
comparing the upstream sequences across species of a few genes identified by ge-
netic screens such as myoglobin. (Blanchetot A, 1986) The eventual sequencing of
5multiple genomes allowed for large scale comparisons and the identification of can-
didate enhancers in a way that facilitated detection of regulatory elements positioned
at more distal locations from genes. For example, the olfactory receptor enhancer H
region was first identified by a large deletion that was then narrowed using sequence
conservation between mouse and human to a smaller distal 2kb region for further
study. (Serizawa S, 2003)
These candidate cis-regulatory elements identified using sequence conservation
were again characterized for function using the combined power of CAT reporters
(function test), (Weintraub H, 1989; Weintraub H, 1990; Weintraub H, 1991) LacZ
based embryo reporter assays (function, localization and temporal pattern) and cis-
element knock-out experiments (necessity). (Gossett LA, 1989; Fickett JW, 2000;
Hardison R, 1997a; Hardison R, 1997b; Brown CT, 2002; Gottgens B, 2000; Clay-
ton CE, 1982; Chandler KJ, 2009; Teboul L, 2002; Rosenthal N, 1990; Hockheimer
A, 2003; Levine M, 2003; Morokuma J, 2003) Once identified and tested these en-
hancers led to the identification of the key characteristics of genomic elements with
discernible functions. Enhancers or Silencers were functionally defined genomic el-
ements that over short distances or through physical connections (sometimes guided
by insulator/blocker elements) to bridge more distant ones, modulate the transcrip-
tional output provided by the basal promoter. (Long L, 2013; KiefferKwon KR,
2013; Dekker J, 2002; Banerji J, 1981; Butler JE, 2001; Yuh CH, 1996)
1.5 Defining the biological functions of Regulatory Element
The basal promoter contains a local collection of regulatory elements that will only
work in one orientation, guided by TF binding to recruit the machinery necessary to
enable the production of a transcript from a transcription start site (TSS). (Sartorelli
V, 1999; Mikhaylichenko O, 2018; Levine M, 2003; Andres ME, 1999) The TSS
proximal region can, but does not always, contain additional regulatory elements
6beyond what is minimally necessary to enable the start of transcription. (Goldhamer
Dj, 1995) For example, individual promoter regions can contain DNA elements
which provide some level of enhancement or repression either interdigitated within
the basal promoter sequence itself or immediately proximal. Indeed this region,
especially for genes that must work across different cell types, needs to support
occupancy of different sequence specific TFs and biological function in a relatively
compact region, putting it under an unusual evolutionary constraint when compared
to the average gene distal region. Since the TSS of each gene can be identified
from the highly conserved exons, the relative functional output of similarly sized
promoter regions was compared across hundreds of genes showing that promoters
have varied levels of activity conferred by cis-elements localizedwithin the promoter
proximal region. (Cooper SJ, 2006) The occupancy of TF binding sites thus acts
as a regulatory gate to transcriptional regulatory functions, including fine tuning by
the combinations of off-DNA cofactors which are able to recruit other complexes
and by the modification of histones or modification of the proteins themselves.
(Sartorelli V, 1999) These TF controlled DNA elements can modulate both spatial
and temporal gene expression during development of the mouse embryo. (Gutman
A, 1994; Hadchouel J, 2003; Carvajal JJ, 2001; Peter IS, 2011) It has since become
clear that transcription can be further modulated by the integrated contributions of
distal elements, DNA methylation and regulation of transcriptional pausing. (Li B,
2007; Kouzarides T, 2007; Barski A, 2007; Taft RJ, 2009; Core LJ, 2008; Rahl A,
2010; Schwartz YB, 2007; Schor IE, 2017; Cheng TS, 1993) While this definition,
which combines positional and experimentally determined criteria seems clear, there
turns out to be considerable room for confusion because the underlying biochemical
mechanisms and their relationships to DNA sequence features are still not fully
understood.
Indeed some “promoter proximal” regulatory elements described above can also
7meet the experimental definition of “enhancer”, while others fall outside the oper-
ational definition of “enhancer”. Unlike promoters, one of the generally accepted
characteristics of an enhancer is that it is able to function in both orientations and
with independence of position relative to its TSS. Exceptions to this principle do
exist as some intronic enhancers are position-sensitive relative to the promoter in
specific cell contexts. (Banerji J, 1981; Tai PWL, 2011; Zomorodipour A, 2017)
The logic encoded in DNA and accessed by transcription factors is largely modular
and can be transported (at least in some specific cases) from one gene to another or
even to an exogenous test system. (Yuh CH, 1996; Kirchhamer CV, 1996) Reviewed
in Fickett JW, 2000. Some of these enhancer elements are relatively compact while
others can require individual cREs to be integrated over a larger region for the correct
interpretation of the functional output. The varying size of these elements can make
identifying the complete logic for a gene difficult as external elements might provide
additional inputs over great distances. (Long L, 2013; KiefferKwonKR, 2013) In all
of these instances to decode these instructions transcription factors act as the master
regulators responsible for recruiting co-factors (of both activating and repressive
natures), non-coding RNAs (to modulate a variety of functions including recruiting
and tethering complexes), enzymes responsible for histone marking and modifica-
tion of the TF/cofactors themselves. (Katayama S, 2005; He XJ, 2009; Faghihi MA,
2009; Aravin AA, 2008; Bartel DP, 2009) While much of the focus of this thesis is
on enhancer elements, in order to maintain functional genomic DNA domains which
are accessible in a cell type, insulator/anchor elements mark chromatin boundaries
and function as anchors for bridging certain DNA domains in physical proximity
to each other. (Barkess G, 2012; Fudenberg G, 2018; West A, 2002) For example
these elements are used to either exclude (through looping) or allow for the inter-
action of an enhancer with a nearby gene. (KiefferKwon KR, 2013) They can also
form chromatin boundaries that separate (“insulate”) inaccessible heterochromatin
8domains from relatively more accessible regions. (Reviewed in Laat W, 2013) The
functional orientation requirement of chromatin insulator elements, which when
changed in orientation can result in the rewiring of chromatin-chromatin contacts,
raises questions as to whether and how this observation can also apply to select target
genes for enhancer and silencer elements. (Ghirlando R, 2016) (Further discussed
in section 1.13) In contrast to enhancers, silencer elements bind repressors (ie Oct-
1, NRSF) and dampen the transcriptional level of a gene, either by binding at the
promoter proximal region directly or also through looping a distal silencer element
to a promoter. (Lawinger P, 2000; Hwang SS, 2016; Becker NA, 2013) Silencer
elements have been observed to have similar positional dependence to that more
recently observed in some enhancer elements; where changing relative position to
a promoter affects the biological activity of an element. (Chow KL, 1990; Edwards
JG, 1992; MouraNeto V, 1996; Bessis A, 1997; Cheng CK, 2002; Kim MK, 1996)
1.6 Developmental model systems
The differentiation of a precursor into a mature cell type has long been used to
characterize the key functions of factors that bind regulatory elements, as it provides
a differential where biochemical measurements can be contrasted to a prior state. As
an example, during myogenesis, undifferentiated specified myoblast cells become
differentiated into myocyte muscle cells. This process is primarily regulated by four
key basic Helix Loop Helix (BHLH) TFs known as Myogenic Regulatory Factors
(MRFs) which heterodimerize with E-proteins to bind DNA and function along
with numerous other TFs and cofactors, such as MEF2, Pbx1 and co-activators
(EP300/pCAF). (Taylor SM, 1979; Davis RL, 1987; Hasty P, 1993; Wright WE,
1993; BuckinghamM, 2014; Hu P, 2008; Hernandez JM, 2017; Neuhold LA, 1993;
Fong AP, 2015; Conerly ML, 2016; Cao Y, 2010; Weintraub H, 1991).
The mouse C2C12 cell line (Yaffe D, 1977) (derived from normal mouse thigh
9muscle following a crushing injury) provides the main cell culture model system
for studying this transition from myoblast to myocyte, which can be experimentally
controlled by the researcher by changing the composition of the culture medium.
(Figure 1.1) In C2C12s, the key specification MRF detected at high levels in my-
oblasts is MyoD while myogenin is the predominant differentiation TF expressed in
myocytes. (Figure 1.1) (Davis RL, 1987; Cornelison DD, 2000) The remaining two
MRFs are Myf5 (early specification in the embryo) and Myf6 (late differentiation)
and are quantitatively very minor in the C2C12 system. (Braun T, 1989; Miner JH,
1990) MyoD was originally isolated for its ability to convert different cell types in
vitro to the myoblast lineage (Davis RL, 1987) including the 10T1/2 cell line, which
normally provides a mesodermal precursor that normally does not express MRFs
and does not normally differentiate into muscle. (Mordan LJ, 1982) Since MyoD
and myogenin are not expressed in 10T1/2 cells, this is a useful experimental system
to test for specificity of enhancer activity where neither of the two keyMRFs present
in C2C12s are expressed. (Figure 1.1) This cell line also allows to identify cREs
which respond to serum starvation and exposure to insulin, both of which are used as
a stimulus to induce muscle differentiation of C2C12 cells and are conditions known
to induce changes in gene expression. (Keeton AB, 2002; Pirkmajer S, 2011)
During early myogenesis, the expression of myogenin and several other key genes
is kept off in myoblasts even though MyoD is present. This has been hypothesized
to be controlled by Snai1 which is thought to repress key genes by occupying the
same Ebox motifs preferred by myogenin in myoblasts, until Snai1 is later targeted
by an inhibitory microRNA, releasing the repression of terminal differentiation
genes. (Soleimani VD, 2012) Zeb1 has also been found to bind preferentially to the
promoter of terminal differentiation genes, potentially working as a repressor that
is released through a yet to be understood mechanism. (Siles L, 2013) Musculin is
a third repressor expressed during myogenesis. In muscle, musculin was found to
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compete for available E2A proteins (which are a positive regulator of HAT activity in
select cell types) indicating that the mechanism through which musculin functions
as a sequence specific repressor might be context dependent. (Kumar D, 2007;
Hyndman BD, 2012; Wu C, 2017; Yuh L, 2003; Yuh L, 2004)
Using modern RNA-seq measurements, we showed that 8704 genes are detected at a
level of 10 FPKMs ormore in C2C12smyocytes. (Kirilusha A, 2014 thesis) Of these
8704 genes, as a direct result of myogenin expression and its downstream targets
(including Mef2C), a small but important set of 628 genes are transcriptionally up-
regulated at least 3-fold compared to the myoblast state. For at least for a subset of
these genes the "classic" form of the muscle enhancer is responsible for generating
this response, including the enhancer 1kb upstream of the CKMTSS fromwhich the
combination of cis-acting sequences that bind MEF2 (CTAAAAATAG) and MRFs
(RRCAGSTG– the Ebox)motifs was derived. (Amacher SL, 1993; Andres V, 1995)
In contrast, a set of 824 genes are downregulated including several antagonists to
the process (IDs, MSC, snail, msx1) by unknown regulatory mechanisms upon the
expression of myogenin. (Taylor SM, 1979; Davis RL, 1987; Hasty P, 1993; Wright
WE, 1991; Buckingham M, 2014; Hu P, 2008; Hernandez JM, 2017; Neuhold LA,
1993; Fong AP, 2015; Conerly ML, 2016; Cao Y, 2010; Weintraub H, 1991) The
ID family of proteins are also involved in repression of the myogenic progression by
sequestering theMRFs from their BHLH partner proteins E2 and HEB to which they
have the greatest affinity. (Langlands K, 1997; Liu CJ, 2002) The ID family proteins
also bind MYOD and Myf5, but not significantly to myogenin, thus providing a way
to circumvent this block once myogenin molecules are present in effective numbers.
(Langlands K, 1997; Liu CJ, 2002)
Hematopoiesis can be used as a second developmental process involving a distinct
set of elements also derived from tissue specific factors to contrast or validate
any findings from myogenic ccREs. Mouse G1E cells have served as the key
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model system for erythropoiesis for many years. (Weiss MJ, 1997) These cells
are derived from in vitro differentiated mouse embryonic stem cells in which the
endogenous GATA1 gene has been knocked out; a subclone of them, termed G1E-
ER4, constitutively expresses a GATA1-ER fusion that can be specifically activated
by estradiol exposure, allowing for differentiation to be triggered rapidly and in a
controlled manner. (Tsang AP, 1997; Rylski M, 2003) Lineage commitment during
the process of erythropoiesis is accomplished through the so called GATA switch.
(KanekoH, 2010) The onset of terminal differentiation is marked by the replacement
of the GATA2 transcription factor pioneering for occupancy at thousands of sites
occupied by GATA1, which then regulate the expression of the genes involved in
red blood cell development and functions, with the bHLH protein SCL/TAL1 being
an important cofactor of GATA1, often forming closely spaced heterodimers with
it. (Han GC, 2015; Wu W, 2014; Tripic T, 2009; Yu M, 2009) GATA1 binds to a
WGATAA consensus recognition motif, while TAL1 is a bHLH factor targeting a
CAGMTG Ebox. (Han GC, 2015)
1.7 ChIP-seq maps global occupancy profiles
ChIP-seq data provides high resolution genome-scale occupancy maps of direct
DNA interacting factors. (Johnson DS, 2007) With small technical adjustments,
this approach can also map general coactivators such as EP300 to identify candidate
active enhancers. This quite general biochemical approach is independent of se-
quence conservation or motif content and identifies candidate enhancers missed by
those approaches. (BlowMJ, 2010; Hong JW, 2008; Levine M, 2003) For example,
these new measurements effectively identify candidate enhancers in tissues such as
heart, where phylogenic conservation failed to be effective, as well as a novel class
of candidate enhancer elements found within otherwise highly conserved regions
of genes. (Blow MJ, 2010; Ponting CP, 2011; Hong JW, 2008; Berthelot C, 2018;
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Wong ES, 2015) Taken together, these non-coding candidate regulatory elements,
highlighted by preferential sequence conservation and/or by various biochemical
signatures, possess the characteristics correlated with regulatory function. (Sec-
tions 1.8 and 1.10) This collection of elements derived from these biochemical
measurements across many tissues number in the millions but it remains uncertain
how many can, in fact, function as enhancers when tested experimentally. (Yue F,
2014; ENCODE, 2012) In addition, some apparently exceptional systems suggest
there are enhancer elements with previously undefined properties. For example, the
H enhancer element in the olfactory receptor system, together with a small set of
similarly biochemically marked function specific enhancers in the genome, feature
highly selective action aimed at just one among hundreds of OR genes, selected on
a cell by cell basis, and operating efficiently across chromosomes. (Markenscoff E,
2014) However, only a subset of these identified enhancers are in physical contact
with the active gene; raising questions about whether specific enhancers are targeted
to pre-established genes. These experiments also suggests that elements can display
the biochemical hallmarks of enhancers, function as enhancers in a cell type, but
need not display physical connectivity to a TSS in all cases while awaiting hete-
rochromatin formation over the enhancer element. (Lyons DB, 2013; Magklara A,
2011)
In order to help understand part of the control mechanism behind the process of
myogenic differentiation in culture, a fellow labmembermeasured the occupancy for
MyoD (specification factor) and myogenin (differentiation factor) in C2C12 cells.
(Kirilusha A, 2014 thesis) Of the occupied sites, 40% of elements are proximal
to gene models while the remaining 60% need to be physically brought to distant
promoters. The MRF ChIP-seq occupied regions can be sub-selected for ones that
contain conserved elements, and our lab showed that they contain ~400bp long
conserved elements with the Ebox enriched towards the center of each region.
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(Pepke S, 2009) Overall the expected Ebox motif is found in >90% of MyoD
or myogenin occupancy sites. However, the p=0.05 significantly bound 14,088
myogenin sites determined by ChIP-Seq occupy only ~0.5% of muscle class Ebox
motifs (CAGSTG) in the mouse genome. (Kirilusha A, 2014 thesis) Both factors
occupy a highly overlapped set of sites with the majority containing an extended
RRCAGSTG form of the muscle Ebox. Moncaut N, 2013; Tapscott SJ, 2005;
Molkentin JD, 1996; Yun K, 1996; Valdez MR, 2000 Many possible combinations
of flanking nucleotides to the Ebox are detected within the ChIP-seq measurements
and the actual motif preference is likely dictated by the individual combinations of
the MRFs and the heterodimeric partners. (Yin Y, 2017; Yun K, 1996; Neuhold
LA, 1993; Lu Y, 2002) However, over-expression of MyoD in murine embryonic
fibroblasts (MEF) shows ChIPSeq occupancy that highly overlaps the native MyoD
occupancy sites indicating the possibility that additional identical motif sites may
be kept inaccessible at the chromatin level. (Yao Z, 2013) This selectivity of which
motifs are being accessed in the genome also raises questions as to the minimum
number of motifs required to support biological function such as an enhancer.
1.8 Mapping ChIP-seq measured occupancy to validated enhancer regions
The classic 2R-TK-CAT experiment inmuscle demonstrated that 2 copies of the right
Ebox from the CKM -1kb enhancer are sufficient for enhancer function. (Weintraub
H, 1990; Weintraub H, 1991) However, 4 copies of the motif were necessary to
recapitulate the native enhancer activity, which contains 2 Eboxes and a Mef2
motif. (Weintraub H, 1990; Weintraub H, 1991) Indeed the combination of motif
types, numbers and distances are likely the key driver by which the level of enhancer
activity is encodedwithin in themore compact promoter proximal regions to provide
a local logic that can be further modified by the contribution of distal elements.
(Istrail S, 2005; Vockley CM, 2016) The myogenin ChIP-seq regions contain from
14
single to multiple Eboxes. (Kirilusha A, 2014 thesis) A significant portion of the
myogenin occupancy regions (over 25%) contain two Eboxes and are most similar
to the 2R-TK-CAT construct. The ChIP-seq regions with a single Ebox sometimes
contain a paired Mef2 and Ebox motifs, suggesting an initial test of the relative
enhancer contribution for each class of elements (Ebox/Ebox and Ebox/Mef2) paired
at varying distances. (Kirilusha A, in drafting) While many combinations of sites
exist within the occupancy these two simple examples might set the ground rules
for enhancer function. (Vockley CM, 2016) As previously discussed, ChIP-seq
experiments also revealed that many potentially important sites and even entire new
classes of sites had not been studied. (Levine M, 2003; Barolo S, 2013; Hong JW,
2008) In the context of muscle these included candidate Enhancers that differentially
bind MyoD across differentiation, multiple factor binding sites and non-conserved
candidate Enhancers.
However, the biochemical measurements done by ChIP-seq only denote the oc-
cupancy by a factor, and can result from the chemical bridge to another protein
depending on the amount, temperature and type of fixative agent(s) used. (Vockley
CM, 2016) Our current methods for TF occupancy mapping allow for only a limited
understanding of the signaling context due to the poor availability of antibodies that
reliably detect such modifications. Even so, the highly selective occupancy relative
to the number of motifs available in the genome (14K accessed vs 2.1M available)
displayed by the sequence specific TF myogenin (Kirilusha A, 2014 thesis) raised
key questions as to whether such specificity in the biochemical occupancy always
results in biological function (indicating that ChIP-seq is perhaps under sensitive)
or that conversely much of ChIP-seq is noise in the lower ranked signals.
Unfortunately, initial functional studies have often focused only on the most out-
standing biochemical signatures (Visel A, 2007), thus obtaining deceptively high
success rates that some have generalized as expectations for all reproducible sites
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of occupancy. For example, a study focused on some of the top signals from among
the first available but limited quality EP300 occupancy measurements in limb and
brain tissue to find that 80% of the conserved and occupied sites are active enhancers
versus 40% by conservation alone. (Visel A, 2007) Several follow-up studies con-
firmed that absence of conservation within a biochemically occupied region does
not imply non-functionality. (Visel A, 2009; Berthelot C, 2018; Wong ES, 2015;
Ballester B, 2014) This 80% estimate of elements functionally validated is likely an
upper bound due to the quality of ChIP occupancy data and the way candidates were
selected. (Landt SG, 2012) Within the context of muscle MyoD is known to interact
with EP300 and recruits this cofactor together with Mef2 to cREs. This should
allow for potential enhancer sensitivity comparisons, albeit limited to the top signal
EP300 sites, between ones selected from within the occupancy an individual tissue
specific factor compared to this "TF agnostic" EP300 based selection. (Chapters 2
and 3) (Eckner R, 1996; Yuan W, 1996; Puri PL, 1997; Sartorelli V, 1997)
A collection of 24 previously characterized “gold standard” enhancer regions derived
from the literature (Appendix E) contain at least one core recognition motif for
MyoD/Myogenin (CAGSTG) and show significant MRF occupancy signals (Figure
1.2), though the magnitude of the occupancy signals varied by more than an order
of magnitude (Figure 1.3). The histogram summary of these validated enhancers
adapted from Landt SG, 2012 clearly illustrates that these functional elements map
throughout the range of ChIP-seq signal (Figure 1.3). Nevertheless, the manner in
which these elements were selected and their relatively small number mean that one
cannot make a statistical case for the power of ChIP to predict enhancer activity
or its magnitude. Because of discovery bias for these long-studied enhancers most
are promoter proximal elements associated with genes highly transcribed in our
muscle cell model system. As a result, there are multiple reasons why they do
not accurately represent the myogenin genomic occupancy repertoire as a whole,
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which includes 14088 sites; many of which are found near genes of more diverse
behaviors, including ones that are not expressed. (Kirilusha A, 2014 thesis) I also
selected another set of 24 enhancers from the literaturewhich are affiliatedwith genes
specifically expressed in T-cell and neuron development. These literature validated
"non muscle" enhancer regions were selected to contain muscle MRF-class Ebox
motifs which are shared by paralogs of the Tal or NeuroD families responsible for
the development of those cell types. In muscle these genes are not transcribed, and
the validated enhancer regions show no occupancy in our ChIP-seq measurements
for the muscle specific factors or non-tissue specific co-activators such as EP300.
(Figure 1.2) In contrast NRSF occupancy is detected at comparable rates in both
populations of muscle and non-muscle enhancers (Figure 1.2). When I began this
work, it was unclear whether this tissue specific occupancy (and function) would
be retained in a transient transfection assay where naked DNA is introduced (and at
high copy number) without any prior epigenetic history. Although the specificity
of enhancer function was largely maintained in our assay for biochemically marked
regions (Chapter 3) sufficient flanking DNA context might be necessary. (further
discussed in 1.15)
1.9 Relating ChIP-seq observations to physical occupancy
In vivomolecular footprinting experiments (which quantify the physical occupancy)
of the well-characterized CKM -1kb enhancer demonstrate that the reproducibly
modest but statistically significant ChIP-seq signal detected in this cRE does not
correlate with the physical occupancy (over 90%). (Mueller PR, 1989; Garrity PA,
1992; Buskin JN, 1989; Horlick RA, 1990; Cserjesi P, 1994; Horlick RA, 1989) This
disparity between ChIP signal strength, occupancy level and enhancer function level
could be explained if the stably bound and active MRF-recruited complex involving
multiple proteins provides poorer physical access to the ChIP antibody. These stable
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complexes at enhancers might however be necessary to provide the transcriptional
bursting frequency observed for strongly transcribed genes. (Fujita K, 2016) The
CKM enhancer observation, together with the weak myogenin occupancy signal
observed for a small set of literature-validated enhancers (Figure 1.3), also raises
the question of whether ChIP-seq, for both a TF such as myogenin or a cofactor such
as EP300 are equally sensitive for enhancers across different signal strengths.
1.10 Derivation of large scale biochemical signatures for cREs
The genome-wide mapping of candidate REs has been a major activity of the EN-
Cyclopedia Of DNA Elements (ENCODE) consortium, including our contributions
for skeletal muscle and C2C12 cells. (ENCODE, 2011; Yue F, 2014; Moore J,
2018) To this end, measurements of DNAse hypersensitivity, multiple histone mod-
ifications, hundreds of sequence-specific transcription factors, and RNA transcripts
across many cell types and tissues were performed to provide an increasingly com-
prehensive biochemical annotation of the human and mouse genomes. (ENCODE,
2011; Yue F, 2014; ENCODE, 2012; Moore J, 2018) Previously characterized cis-
regulatory elements (such as the ones in Appendix E) provided a framework that
is substantially supported by contemporary genome-wide biochemical data, with
many findings being “rediscovered” in the literature over the last decade. Indeed,
interpreting the genome-scale biochemical data in light of previously characterized
regulatory elements was the first step in creating a dictionary of benchmark bio-
chemical signatures that could be extrapolated to other similarly indexed regions.
(Schor IE, 2017; Visel A, 2007)
As discussed in section 1.5; promoters, enhancers, and insulators are sequence
specific elements that are each associated with specific molecular functions in the
control of transcriptional processes, and when active these elements are eachmarked
by distinctive biochemical signatures. (Riethoven JJ, 2010) For example, active pro-
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moters in eukaryotes feature the trimethylation of lysine 4 on histone 3 (H3K4me3)
(Vermeulen M, 2010) and the H3K27ac histone mark. These regions often display
several ChIPSeq signals for TFs and polymerase. (Thurman RE, 2012; Visel A,
2009) Enhancer elements exhibit their own biochemical signature where sequence
specific transcription factors recruit EP300, and as a result of a yet to be defined bio-
logical activity also feature the H3K27ac histone mark deposited on nearby histones.
(Figure 3.1A) (Creyghton MP, 2010; RadaIglesias A, 2011; Thurman RE, 2012)
Transcription factor occupancy also allows for increased accessibility of chromatin
organized DNA by DNAses, allowing for the TF agnostic detection of the union set
of occupied regions in individual cell types. The correlation of significant DNAse
HyperSensitivity (DHS) with TF occupancy and the histone marks that result from
this biological function are strong when all data are of high quality. However,
the appearance of histone marks can sometimes lag active regulatory changes in
which regulatory elements and promoters can become active and DHS sensitive
before histone marks appear, or conversely, they can be shut down before the marks
disappear or change. While the H3K4me1 mark had been proposed, with initial
enthusiasm, as a landmark signature for active enhancers, we and others are finding
that it marks only a subset of activating TF occupied elements, and is also found at
many promoters. (Cheng J, 2014)
Conversely, the presence of PolII and the basal transcriptional machinery is now also
well documented at distal enhancers, and at least some active enhancers produce
enhancer RNAs (eRNAs). However, the transcripts produced are non-coding, often
short, and apparently short-lived. This phenomenon however blurs a previously clar-
ifying biochemical distinction between promoters and enhancer functions in the face
of histone mark and TF occupancy overlaps. (Koch F, 2011) At least in Drosophila,
it was shown that the level of these eRNAs correlate positively with enhancer activ-
ity, that some intergenic enhancers can work as weak promoters, and that conversely
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alternative gene promoters can work as weak developmental enhancers. A corollary
is that cell type and temporal transcription of eRNAs is largely specific to active
enhancers, though their detection requires the use of methods that do not depend on
polyadenylation and provide relatively high sensitivity. (Mikhaylichenko O, 2018)
In mammalian cells, however, there are reports of active enhancers that do not pro-
duce detectable eRNA, indicating that this property is not obligatory, making eRNA
a limited positive predictor of enhancer activity with yet to be determined sensitivity.
(Andersson R, 2014) Moreover, promoters can be “stalled” and show very similar
characteristics with POLII occupancy, H3K27ac and sometimes detectable aborted
transcripts. (Adelman K, 2005; Wu JQ, 2008)
In the context of muscle, MyoD andMyogenin show both H3K27 histone acetylation
(H3K27Ac) and EP300 occupancy at 50-60% of their respective occupancy sites for
bothmyoblasts andmyocytes. MyoD has been shown to interact with Histone Acetyl
Transferases (HATs) EP300 and pCAF/KAT2b (which are thought to have partially
redundant functions) as well as a wide variety of other cofactors. (DelaSerna A,
2005; Berkes CA, 2005) There is at least one more significantly expressed HAT
in our system (KAT2A) which is expressed in both myoblasts and myocytes at a
level comparable to EP300. While we do not find EP300 at all elements demarked
by (H3K27ac) and myogenin or MyoD occupancy this could be explained by the
presence of these other HATs which we were not able to ChIP due to the lack of
a ChIP-grade antibody. Interestingly, E2A (the key MRF heterodimeric partner)
has also been suggested as a positive regulator of Histone AcetylTransferase (HAT)
activity, providing a possible mechanism through which ID family proteins can
dampen the onset of differentiation. (Soleimani VD, 2012; Hyndman BD, 2012)
As expected from previous studies reporting a lagging histone mark pattern, we also
find significant H3K27ac present in DHS negative regions, especially in develop-
mental systems. (Zhang JA, 2012) The converse mechanism where an enhancer
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might be primed for function at the biochemical level but unable to function until
it is activated by occupancy by specific factor is also observed. For example, al-
though MyoD and Myf5, the two specification factors, occupy a largely overlapping
set of sites when both are expressed, displaying the same hallmarks of enhancers
including occupancy and H3K27ac there is evidence for distinct functions where
MyoD is needed to efficiently recruit Pol II and mediate strong activation of early
myogenic genes. (Weintraub H, 1991; ConerlyML, 2016) However, in order to fully
execute the myogenic differentiation program myogenin appears able to access sites
occupied by either myf5 or MyoD on top of ones only occupied upon its expression.
(Conerly ML, 2016)
Additional questions about the mechanism of early steps in CRM recognition, occu-
pancy, histone modification and regulatory activity comes from the fact that several
different TFs, depending on the cellular context, can bind to identical motifs. How-
ever, in different genomic locations the occupancy pattern appears to depend on
the pioneered status of the site and/or the presence of specific co-factors (and their
post translational modifications (PTMs)). (Casey BH, 2018) While the detailed
molecular mechanisms and dynamics are not fully understood, the genome-scale
maps show that this machinery coordinates events at tens of thousands of genomic
sites, with individual TFs typically occupying in the range of one to fifty thousand
sites in each cell type.
1.11 Cross-tissue motif and occupancy comparisons
MyoDwas one of the first identified trans-differentiation factors, followed byNeuroD
which was able to differentiate cells to neurons. (Davis RL, 1987; Lee TC, 1994)
The transcription factors NeuroD andMyoD independently function as heterodimers
with an E-protein that specifies occupancy for an Ebox sequence motif (CANNTG).
This shared motif is an essential component of the cell-type specific gene regulatory
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networks in neurons and muscle respectively. (Yao Z, 2013) ChIP-seq allowed
the field of genomics to refine and contrast the consensus motifs of TFs that were
previously known to recognize this Ebox. From these measurements of DNA
occupancy we learned that these two factors share a common core CAGCTG Ebox,
with NeuroD also accessing CAGATG and MyoD occupying CAGGTG motifs.
The nucleotides immediately external to the hexamer core motif are thought to be a
shared RR-core-G (MyoD) and RR-core-GG (NeuroD2) which are hypothesized to
specify binding by heterodimers containing the common E-protein partner. (Yao Z,
2013) Domain-swap experiments have demonstrated that the MyoD BHLH domain
is sufficient to drive NeuroD occupancy to the majority of myogenic sites (GC core
Eboxes), while PBX1 is responsible for specifying the remaining subset (GG core) of
occupancy. (Fong AP, 2015) ChIP-Seq experiments also show that motifs bound by
the musculin repressor andMyoD share a common central Ebox motif, but musculin
occupancy maps to sites with different flanking nucleotides to the muscle Ebox
(CCAGCTGG). (Macquarrie KL, 2013; Yao Z, 2014) A second example of ChIP-
seq being used to refine occupancymotifs are PFT1A (pancreatic TF1A) andASCL1
(also known to bind the CANNTG Ebox) occupancy having been mapped in neural
tube tissue where these TFs regulate the expression of several factors important for
proper development. (Borromeo MD, 2014) In that study, motif mapping analysis
revealed a "muscle" class Ebox (CAGCTG) in 85% of common occupancy sites, and
a G-CAGCTG-C Ebox in 73.6% of ASCL1 exclusive occupancy sites (Borromeo
MD, 2014), whereas PTF1 specific occupancy is enriched for CAGATG and RBPJ
motifs. (Borromeo MD, 2014)
Even though the motifs can be refined, comparing the genomic locations of ASCL1
occupancy with that of the MRF factors measure in our system, I found a relatively
low (22%) overlap. I also found minimal (1%) overlap when comparing the MRFs
to PTF1 which use different motifs. Comparing the occupancy regions of key TFs
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related to the establishment of the muscle and erythroid lineage (Tal1 and MRFs,
both of which recognize the Ebox) resulted in a similarly low overlap of ~10%.
Based on the low TF occupancy overlap for factors that access identical or very
similar motifs in different cell types, especially at distal occupancy regions (Figure
3.1D), it is expected that cross-testing the function of elements in different cell types
by transient transfection assay might not be directly informative of native activity
for the majority of the candidate cRE population. Because these regions are largely
selected for cell-type specificity, the introduction of naked DNA fragments within
cells that allow access to identical binding motifs could result in non-native gene
expression in non-homologous cell types. (discussed further in section 1.15 and
chapter 2) This exclusivity of genomic occupancy regions accessed by factors that
recognize identical sequence motifs suggests that set of sites accessed in a given
cell-type relies on additional molecular regulation external to the cell type specific
TFs. One possibility is the leading effect of pioneering factors that bind at or near the
location of final TFs. (Soufi A, 2015) This possibility poses other questions about
the initial specificity of the pioneer(s), as suggested by the requirement of Pbx1 for
MyoD to access its exclusive set of occupancy sites in domain swap experiments.
(Fong AP, 2015) Despite currently unresolved questions about how TF pioneering
activity is achieved, the idea of multi-layered controls that may include repressors
and heterochromatic states as the starting quiescent substrate that is then penetrated
and activated by multiple coordinated and even cooperative steps is emerging as the
model for controlling the onset of myogenesis.
A stratified system of control can prevent inappropriate activation by regulating TF
activity by the onset of expression of necessary co-factors, or by post-translational
modification and subcellular compartmentalization. This complex systemof control,
alongwith cell population effects in our current measurements, pioneering of sites in
developmental stages, and the redundancy of occupancy by multiple factors renders
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difficult the attribution of the effects of transcript expression to any one individual
input. Any attempt to correlate observed changes in expression to the biochemical
inputs is further complicated by any gene which has multiple cREs, especially distal
or previously undetected ones, contributing to its expression level, or where multiple
cREs contribute in a partly redundant manner. (Barolo S, 2013; Levine M, 2003;
Osterwalder M, 2018; Casey BH, 2018)
1.12 Regulatory functional themes confirmed by a standardized catalog of
enhancer marks
While transcriptional regulatory elements can be defined using combinatorial bio-
chemical inputs because there is considerable redundancy between select individual
biochemical marks cREs can also be identified by following simpler rules. For ex-
ample, candidate enhancers occupied by sequence specific TFs, TSS proximal and
distal alike, generally exhibit DNAse Hypersensitivity. These TFs appear to cause at
least some local histone rearrangement and recruit acetyltransferases (e.g. EP300)
which deposit the H3K27ac mark on nearby histones. (Figure 3.1B) (Camerini RD,
1976; Hatzi K, 2013) It is however unclear as to whether activating transcription
factors and these matching biochemical patterns (often peak called by different
bioinformatic methods) remain similarly predictive across different tissue types or
between developmental and established cell types. DNAseHypersensitivity patterns
and H3K27Ac deposition patterns have provided two over-arching biochemical sig-
natures that are now being standardized and used for the compilation of candidate
cis-regulatory elements (ccREs). As of the writing of this thesis, DNAse-seq maps,
CTCF occupancy, and histone mark profiles across many cell types allowed the EN-
CODE consortium to annotate 1.31M and 0.53M ccREs in the human and mouse
genomes respectively. (ENCODE, 2012; Moore J, 2018) It is important to note that
while active regulatory elements often exhibit characteristic biochemical signatures,
24
the reverse— that characteristic signatures always infer activity in all of the possible
spatial and temporal localizations where they are found— does not necessarily hold
true. (Kellis M, 2014) Biochemical marks by themselves do not provide a direct
understanding of how functional REs are specified, or exercise their function since
some may be concurrent while others may be setting up for, or lagging behind, the
functional output. Any inference of active biological function is further complicated
by the observation that biochemical signatures exist on a quantitative continuum be-
tween outstanding features — often the first to be assayed — and what is likely
biochemical background noise. (Figure 3.1C) For example, it is far from clear that
all transcription factor binding sites of a characterized trans-activator, which can be
reproducibly identified using ChIP-seq, are in fact active enhancers. (Fisher WW,
2012) Therefore, individual ccREs in the catalogs compiled by efforts such as the
ENCODE and mouseENCODE consortia (ENCODE, 2012; Yue F, 2014) have to
be subsequently tested and functionally characterized in detail.
Also, ChIP-seq does not allow us to distinguish between direct binding vs recruit-
ment of TFs, two fundamentally different interactions. In the first case, the TF is
interacting physically with the DNA while in the latter case, a protein is recruited to
the DNA by a secondary protein-protein interaction. (Johnson DS, 2007) What was
perhaps most surprising from genome-wide enhancer mark data is that each gene,
especially genes dynamically expressed and involved in developmental contexts,
presented a much larger than expected number of candidate enhancers, many of
them distally located to their linked promoters. In contrast, the majority of house-
keeping genes appear to rely largely on a strong promoter control mechanism, with
proximal elements. Another surprising finding is that occupancy sites appear able
to promiscuously recruit up to hundreds of different TFs in a broad population of
cells. (Partridge C. 2018 in drafting) It is unclear how this overall promiscuous
occupancy, which might result in occupancy by sets of different TFs in individual
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cells of a population can be beneficial for the controlled expression of nearby genes.
1.13 Enhancer to promoter targeting
The important but still difficult task of assigning distal elements to their correct
gene (or genes) and understanding how multiple active distal element inputs are
integrated at a given promoter are central problems. While most enhancers are able
to function in either orientation relative to their targeted promoter a peculiar insight
into enhancer/promoter targeting is found in a specific cRE found in the CKM first
intron. This cRE exhibits a cell-type-specific position dependency in the valence it
provides to its targeted promoter. It can act as a suppressor of gene transcription
when placed upstream of its native promoter in cardiomyocytes, but not in skeletal
muscle cells. (Banerji J, 1981; Tai PWL, 2011) These findings suggest specific
targeting of enhancers to promoters.
As a second example, at the combined Myf5/Myf6(MRF4) locus, the A17 enhancer
selectively targets either gene using anatomical and temporal cueswithin the embryo.
(Chang TH, 2007; Yoon JK, 1997) A promoter deletion of the natural target gene
caused the upstream enhancer to retarget the nearby Myf6/MRF4 promoter as well
as several cryptic Myf5 promoters. This result resolved long standing confusion
about mixed results obtained by severalMyf6 gene targeting strategies from different
labs which generated different expression patterns across development. (Chang TH,
2004; Chang TH, 2007; Zammit PS, 2004) The originally proposed model for this
equilibrium involves nonproductive interactions between the enhancers andmultiple
promoters. (Carvajal JJ, 2008) Elements that are involved with multiple promoters
at the same spatial/temporal locus go against the previous models described for
the regulation of the ß-globin locus by the LCR and the Drosophila abd-B gene
suggesting that enhancer to promoter targeting may be a somewhat random process
that can also bridge multiple promoters or enhancers together, rather than enhancers
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always to a single promoter. (Wilderme M, 1995; Zhou J, 1999)
These examples raise the key question of how individual promoters in a region are
excluded from the activity of nearby strong cREs driving the expression of genes
involved in the differentiation of muscle. The information could be encoded at
the promoter or it could be regulated at the chromatin level from the combined
sequence near the gene. In addition to binding profiles for the MRFs and several
cofactors, we have two CTCF ChIP-Seq data sets produced from C2C12 cells from
our lab and the Broad Institute to integrate into our analysis and experimental
design. (unpublished data) The CTCF insulator TF has been shown to have two
distinct activities. It can act as both a block between enhancer/promoter interactions
by creating looped domains as well as provide a barrier between heterochromatin
and active transcription domains. This makes it a likely candidate to function as a
buffer between the strong CREs and the TSS of nearby genes with moderate or no
transcription. (Felsenfeld G, 2004; Oti M, 2016) While CTCF insulator boundaries
have provided a way to begin to restrict the chromosomal domains in which a given
distal element could access a target gene, we know that only some CTCF sites act
as boundary sites. This means that mere motif presence or even ChIP-detectable
occupancy by CTCF is not sufficient.
A second possible molecular mechanism for selective promoter targeting could
rely on TAF3/TRF3 transcription initiation complex subunits. These subunits are
selectively switched during muscle differentiation as indicated by genome-wide
occupancy measurements. (Deato MDE, 2007) This paper reported evidence that
the composition of the Holo-TFIID was altered across differentiation from myoblast
tomyocyte by the substitution of a novel subunit. This switching of the core promoter
subunits provides a potential molecular mechanism to selectively target promoters
for activation and or silencing. In collaborative work with the Tijan laboratory we
could not replicate these findings, and subsequent studies suggest that the antibody
27
for TAF3was not as specific as originally believed, allowing the possibility that other
TAFs normally present in the system were mistakenly detected. A previous study
however suggested that a switch of the core machinery might be necessary only for
function in the postmitotic state which might not have been reliably detectable in
early differentiated C2C12 cells. (Apone LM, 1996)
A third possible mechanism for selective promoter usage might be encoded by the
combination of context present and established pioneering in each cell type. This
is supported by the observation that cell type specific TFs from different lineages
occupy separate regions of the genome whereas TFs within the same context (eg
MYF5 and MyoD) occupy an highly overlapped set of sites. This suggests that
site selection is either mediated by recruitment of co-expressed co-factors or TFs
pioneering the correct sites (or a combination of the two). The combination of
access to distal and proximal sites in a cell type, together with the CTCF occupancy,
is likely a key driver of at least some of the specificity observed. For example in
muscle, PBX1, a protein thought to have a role in recruiting myoD to certain sites in
C2C12, is present where MyoD alone occupies the E-box motif but Myogenin does
not (Heatmaps in Chapter 3 Supplemental Figure 5). (Yao Z, 2013; Macquarrie
KL, 2013; Maves L, 2007; Weintraub H, 1989; Fong AP, 2015) It is not yet clear
exactly how PBX1 contributes to pioneering, and it might be necessary mainly to
stabilizeMyoD binding rather than truly pioneering on its own. (Grebbin BM, 2017)
This view has been further supported by evidence that specific histone variants are
needed for PBX1 recruitment, and histone substitution is thought to come after
pioneering rather than before. (DellOrso S, 2016) Further, even though Myf5 and
MyoD share their occupancy, their function is not the same, as MyoD is required for
activating transcription; whereas Myf5 is limited to occupancy and recruitment of
H3K27Ac at certain genomic locations. The latter observation might appear to be
conflicting to current models that suggest that the histone marks are the result of the
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biological activity at the occupancy sites. A role for EP300 in modifying the Myf5
protein, similar to that observed for MyoD, might explain this observation. Yet
this mechanism provides yet another switch by which two identically marked sites
might only be active enhancers when the correct TF is present (such as myogenin)
or when known repressors (IDs) are ineffective. (Further discussed in Chapter 5) It
also remains unclear whether myogenin can access all of its native sites without this
prior pioneering by PBX1 and MyoD, indeed during development of the embryo
different compartment show varying orders to the onset of the four MRF factors,
which might specify slightly different sets of genes being accessed.
To provide an example of pioneering which might be required for later occupancy
and possibly correct promoter targeting, Pbx1/Meis is responsible for recruiting
myogenin to the promoter proximal site for the myogenin gene itself. (Yao Z, 2013;
Macquarrie KL, 2013) In this specific case, the 1092bp region upstream of the
myogenin TSS is able to support a specific activation in the myotome of the embryo
(independently replicated in our laboratory in a lentiviral context). The short stretch
called the myogHCE (myogenin Highly Conserved Element) is responsible for most
of this function based on mutagenesis experiments, and partially overlaps an MSY3
occupancy motif previously characterized in our lab and occupied in myoblasts by
MSY3 inChIP-seq assays. TheGZ133 (133bp upstreamof TSS) andGZ188 (188bp)
and GZ1092 (1092bp) cREs tested from this region show modestly increasing
amounts of enhancer activity respectively in an exogenous reporter assay.(Yee SP,
1993) Removing just a few base pairs (Figure 4.9; MYOG125) containing the PBX1
site (125bp) kills all remaining activity. Notably, this mutation also prevents Meis
occupancy. (Berkes CA, 2005) This element could therefore function as a bistable
switch between MSY3-mediated repression and a Pbx-mediated positive Myod
state. (Berghella L, 2008; DeAngelis L, 2015) This bistable quality might also be
the mechanism by which MSY3 maintains myogenin repression in differentiated
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myotubes after innervation, whenMRF4 takes over the MRF role. This is consistent
with the measured activity of the 1092-133myogenin promoter fragment in different
cell types when tested with an HSP68 target promoter-reporter, where it loses its
muscle specificity and displays strong ectopic expression. (Yee SP, 1993)A coherent
interpretation is that both Enhancer and Silencer sub-elements within this CRM are
equally important for specifying cell type specific expression and that an element
that functions as an enhancer in one tissue might very well be an active silencer in
another. (Howard ML, 2004; Istrail S, 2005)
While the mechanism by which promoters are targeted is not yet fully understood,
a Pol II ChIA-PET map (Fisher K, Thesis 2016) can reveal which genomic regions
are brought into physical proximity and enrich for regions occupied by RNA POLII,
a mark largely associated with active transcription. This measurement found that
candidate Enhancers (and even characterized enhancers) can skip over several silent
genes and loop to their targetswhich are sometimes located several hundred kilobases
away from a reproducible gene target. (LongL, 2013; KiefferKwonKR, 2013) These
data however, raise an additional question as to whether the physical connectivity
mapped in this way captures mainly functional elements, as the assay was initially
designed to do. For example, one might want to ask if the portion of elements
selected for myogenin occupancy which are connected, are enriched for activity
when compared to the myogenin occupancy elements which are not connected.
This part may be difficult to assess reliably because many non-connected elements
may be false negatives where the connection was not successfully captured, or may
simply be a less “stable” connection. These findings suggest that the targeting is
tightly controlled as several genes closest to even very strong enhancers are kept
silent, while the correct gene is modulated.
Functional testing should be performed against a promoter element that is permis-
sive in the cell system and is able to pair with the candidate functional element
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tested. However, we do not fully understand the range and mechanism(s) underlying
proximal promoter “permissivity”. For the vast majority of function studies that, as
in this work, use a single, invariant proximal element to allow for direct comparisons
of varying distal elements, three main promoter types have been employed.
The most conservative strategy employs a very minimal promoter, including few
base-pairs other than a TATA box, which generally produces substantially lower
signals for bona fide enhancers. This means that weaker enhancers might be cast
aside due to the lower signal to noise ratio, and any other unintended start sites
(including vector sequences) might assume a large and potentially confounding role.
The use of a minimal promoter that has previously been shown to be permissive for
the cell type(s) and enhancer class being surveyed might improve overall sensitivity
for enhancer function over a very minimal TATA-like promoter. These historically
included viral promoters (HSVtk; CMV; SV40T antigen) or unregulated portions of
the HSP or beta globin, among others. Especially relevant to my studies are a set of
important prior experiments in C2C12 cells, including ones aimed at exploring the
minimal number of muscle class E-boxes which could comprise an active enhancer.
They were performed using a Thymidine Kinase (TK) viral promoter. (McKnight
SL, 1982; Weintraub H, 1990; Weintraub H, 1991; Molkentin JD, 1996) Figure 1.4
compares the basal level of CytoMegaloVirus (CMV), Thymidine Kinase (TK) and
Simian Virus 40 (SV40) promoter driven Renilla co-transfected with several test
enhancer constructs in both myoblasts (MB) and myocytes (MC). (Figure 1.4)
A final strategy used in the literature is to select a proximal promoter that is “native”
to a locus of special interest or represents activity in a particular cell type or
differentiation state that matches a group of enhancers to be tested. The majority of
the enhancer control sequences cited in this chapter were derived from historically
studied elements that are preferentially located near to their native TSS, and they
are also often preferentially conserved. Those tested as part of the study were
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not selected for TSS-proximity nor for preferential conservation, but rather for
significant occupancy by myogenin (Fig 1.2) At a few key loci, additional elements
were tested based on nuclease accessibility in the model cell system (C2C12),
regardless of the factor occupancy profile (Chapter 4).
The overall upshot of reporter designs, and of a few more detailed studies of
promoter-distal element interactions (Yee SP, 1993; Teboul L, 2002; Summerbell D,
2000, Appendix E) is that practical considerations have led to design compromises
for single-promoter reporters that future larger-scale multiplex studies should ad-
dress via distal element/promoter combinatorics. At present, these considerations
play a role in interpreting single-reporter studies. For the muscle assays presented
here we selected the same TK promoter because of its historic use and because it
offered a lower starting signal to measure fold activation. We note that a key weak-
ness of most current MPRA assays is that they require a relatively strong promoter
which allows to sort signal-positive cells prior to sequencing in order to achieve
sensitivity against a noisy background of transcripts from the whole genome.
The ultimate functional characterization of candidate enhancers must involve a
combination of loss-of-function assays and direct assays for enhancer, silencer or
promoter activity without confounding factors, across a very broad range of cellular
contexts. Loss of function assays have been (until recently) technically challenging,
but are becoming more commonplace with the advent of large-scale CRISPR/Cas9
mediated mutagenesis techniques. (Korkmaz G, 2016; Fulco CP, 2016) In order
to approach some of these issues I focused on studying the predictive power for
enhancer function of TFoccupancy and biochemicalmarkswithin the developmental
process of myogenesis and contrasted it to that of other systems against a single
promoter.
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1.14 Massively Parallel Reporter Assays
High-throughput sequencing has enabled the development of assays that go beyond
the one-by-one testing of individual cREs by using very large numbers of sequences
analyzed in parallel. In these assays the readout is based on sequencing transcribed
DNA tags associated with the cRE (cRE-seq) or sequencing the transcribed cRE
itself (STARR-seq). These assays are usually referred to collectively as MPRAs
(massively parallel reporter assays) (Inoue F, 2015) and a number of variations have
been successfully applied to different biological systems. (Patwardhan RP, 2009;
Kinney JB, 2010; Kwasnieski JC, 2012; Melnikov A, 2012; Patwardhan RP, 2012;
Arnold CD, 2013; MurthaM, 2014) This method has also been used for testing cREs
for activity by the ENCODE Consortium. (Kheradpour P, 2013; Kwasnieski JC,
2014; Ernst J, 2016) MPRA designs are attractive because they allow the functional
characterization of larger numbers of elements across the genome individually,
providing a more comprehensive survey that should be more statistically persuasive
for subclasses of infrequent elements. However, several quite substantial issues
complicate the interpretation of current MPRA experiments. The nature of MPRA
designs, so far, is that the elements tested are short (in the 80-250bp range) compared
to the size spectrum of conservation within known enhancer elements, within the
occupancy of a TF (~400bp) or compared to the size of thousands of conserved
noncoding nucleotide elements in the genome (Chapter 3, Supplemental Figure
1). Assuming that conserved non-coding sequences represent a major subset of
functional enhancers, and the regions of conservation are a minimal estimation of
a complete cRE (Chapter 3), these assays thus truncate many elements and may
generate significant numbers of false negatives. Alternatively, the magnitude of
enhancer activity detected might not be complete as other nearby elements are not
included within the test element, and these short regions might also lead to a loss of
cell-type specificity in some cases. (White MA, 2013) For example, it is not unusual
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for CRMs to contain repressor binding sites as well as sites for positive acting factors.
Deleting a repressing cis-sequence could leave the remaining element de-repressed
in a cellular context where the full element would normally be “off” or “poised”,
yet not active. More generally, the high-throughput tests in their current forms do
not capture the combinatorial factor array often found to occupy multiple binding
sites within a ChIP-Seq region when testing such small fragments for enhancer
function. (White MA, 2013; Kwasnieski JC, 2014) Even within genome integrated
tests, similarly low activity estimates of upwards of 28% of active elements are
observed indicating that the size of elements are key to faithfully replicating the
activity observed in the chromosome. (Murtha M, 2014)
Pertinent to both high throughput and more conventional reporter assays, it was re-
cently discovered that the bacterial origin of replication (ORI) can cause interference
with the test promoter. This results mainly in constitutive background activity, the
magnitude of which appears to depend on the promoter used to drive the reporter.
(Muerdter F, 2018) Whether a competing promoter entity is provided by vector
sequence or by other unintended elements in a construct, it is expected to increase
noise and degrade sensitivity. If different enhancers are differentially “attracted”
to the ORI, it is expected to confound quantitative output relationships. (Conte C,
2002)
This issue is also likely to affect the system used in this thesis, which relies on a
single plasmid in each cell culture well to measure enhancer activity. However, this
problem in our system is not compounded by the presence of multiple enhancers
concurrently as in high-throughputMPRA assays. Further, in specific cases, some of
the regulatory elements studied in this thesis have been assayed in multiple formats,
including integrated transgenics and lentiviral test systems, with similar results for a
small set of our muscle elements. The possibility that we may be also underscoring
due to a subset of elements favoring interaction with the ORI is however possible
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and should be tested.
Other concerns with MPRA interpretation relate to issues that have become better
appreciated in individual element assays. It is very difficult to control the number of
constructs going into each individual cell in transfection experiments, and MPRA
features large numbers of different cREs being tested concurrently. By explicitly
titrating mixtures of two well-characterized constructs, initial design work for this
thesis documented significant “cross-talk” between two well-defined test reporters.
These results led us and our collaborating labs in ENCODE to focus the work on
single reporter measurements rather than the superficially elegant, yet ultimately
misleading, dual reporter ratio designs.
In the future, these and related concerns can be addressed by using genome-
integration (Maricque BB, n.d.; Inoue F, 2016; Muerdter F, 2018), which we hope
to combine with longer insert MPRA insert libraries. However, the short length of
constructs tested remains a significant issue, and might be responsible for the low
positive rates reported by MPRAs. (Vockley CM, 2016)
1.15 Validation of biochemical mark predictions with longer cRE assays
One of the cheapest and most straightforward ways to validate an enhancer for
activity has been to test cREs using an exogenous plasmid construct combining a
cRE, a promoter and a reporter gene. Numerous enhancers (including developmental
ones) have been characterized following this approach. (Appendix E) (Visel A,
2007; Visel A, 2009; May D, 2011; Fisher WW, 2012)
My aim was to develop a robust enhancer test (described in the next chapter) in the
muscle system that would allow us to ascertain both function and relative activity
of full sized myogenin occupied regions (~1kb) from the full quantitative range of
biochemical signal detected by ChIP-seq. The results from this assay are presented
in chapter 3 which contains a draft manuscript that reports on the findings from
35
my assay and contrasts them to other similar assays in other tissue types from our
collaborators within ENCODE.
It must be noted that a negative result from a test in a single cell-type context does
not predict negative results in all other possible cellular contexts. (Moore J, 2018)
It is important to remember that exogenous tests for enhancer activity are done in
limited cellular contexts, often against a single promoter element and in cell lines
that are established from a single origin. This approach may not reveal the activity
level in the native chromosomal context and may miss combinatorial contributions
from other nearby elements in either the native locus or in the site of integration. It
only measures both the existence and magnitude of effect by single elements. These
assays cannot measure the contribution of these enhancers within their native locus
which can only be achieved by targeted deletion of the cRE and observing the effects
on the nearby genes. (Hnisz D, 2013; Kvon EV, 2016; Dickel DE, 2018) This type
of assay does however allow to measure the combined contributions of limited pairs
of elements associated with a gene by cloning them into the same test construct.
Transient reporter assays, where the DNA is not integrated into the genome, are
criticized as being unable to reflect the native chromatin context; which might
be worse for MPRAs due to the diminutive size of the DNA cloned as 250bp is
barely sufficient to support one natively positioned nucleosome; compared to <4
in the larger regions tested in these single plasmid assays. Due to this difference
it is important to properly control such experiments with large sets of negative
control elements which might be expected to be chromatin silent, such as the
promoter proximal regions of genes that might result, if expressed, in catastrophic
consequences to proper development of a cell type. For example, STARR-seq
can now even encompass the entire genome for enhancer tests (albeit at poor fold
coverage), but the reliability of such tests in a context that includes regions of
less than 1 nucleosome is unclear as enhancer function is detected even in regions
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which are not natively accessible. Whether this remains true in a larger test system
remains unclear. (Muerdter F, 2018; Liu Y, 2017) Indeed this smaller structure
might prevent in some cases the formation or displacement of the histones observed
in vivo at thousands of occupancy sites across different tissues. (Figure 3.1A)
One of the key benefits of controlled integration is that it minimizes the random
effects of integration on the test construct and on the nearby location which might
be affected differently on a cell to cell basis where some might be silenced, some
might be upregulated and others might disrupt other important genes nearby. The
controlled integration site provides a test within a native chromatin approach for a
locus that is known to be generally accessible (not heterochromatinized) across most
cell types. For example, the mouse genome ROSA 26 locus was identified by gene
trapping as a candidate for controlling the locus of integration and low copy number
both of which are impossible in transient transfection assays. (Zambetti GP, 1992)
Although tests of all of these variables are possible they are expensive and currently
limited to smaller numbers. A first pass screen requires a scalable platform that en-
ables testing several hundred elements at a reasonable cost and in a relatively short
timeframe. Medium-throughput luminescence reporter based transfection systems,
such as the 96 well based assay that I robotized as part of my thesis work (chapter
2), have proven to be a robust method to assay full size candidate enhancer element
activity across cell lines. (Trinklein ND, 2004) With this assay, as part of the EN-
CODE Project Consortium efforts towards functional validation of cREs, we tested
the regulatory activity of hundreds of candidate enhancer elements (cEnhs) using
constructs designed to capture full-length cREs of both mouse and human origin.
These cEnhs were selected from a wide range of biochemical signature strengths,
using both TF-centric selection criteria (identified directly from TFs occupancy)
and machine learning "TF-agnostic" approaches (identified from combinatorial bio-
chemical signatures of enhancers) across diverse mammalian cell lines.
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Concurrent with our own study, several ongoing studies at LBNL used injection
of DNA into developing mouse embryos to temporally and spatially map enhancer
function for full size cREs (~1800bp regions - Chan AW, 1999) in randomly inte-
grated genomic locations, in tissues where promoter function is not limiting. (Visel
A, 2009; Wang Z, 2005) Scoring the database of the combination of these pronuclear
injection studies (n=1993), reveals that 50% of test elements are active enhancers
in at least one tissue. (Chan AW, 1999) This result is comparable to our own find-
ings on the proportion of active elements presented in Chapter 3, and to that in the
current ENCODE encyclopedia paper indicating that for sufficiently large elements,
chromatin integration may not be required for faithful reproduction of the enhancer
function for individual elements. (Moore J, 2018)We expect that the findings in this
thesis will help guide efforts towards the comprehensive cataloging of functional
elements in the human genome, and we discuss the implications of our findings in
the context of models of gene regulation mediated by the action of distal enhancers.
Given recent technological developments and some of the initial results that we
have today, I would have tested smaller sets of individual enhancers, and more
varied combinations of enhancers. I would also have assayed these elements in
both orientations, upstream and downstream of native promoter elements affiliated
by connectivity. (Garrity PA, 1990) These would be contrasted for activity to
generic promoters that contain muscle-type motifs, promoters that do not contain
muscle-type motifs and finally TATA vs non-TATA promoters. In this way, the
encoded specificity of action for functional regulatory elements might be better
understood. We could then begin systematic tests of the molecular logic driving the
developmental transition of myogenesis. (Howard ML, 2004; Arnone MI, 1997;
Butler JE, 2001)
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1.16 Figures (Chapter 1)
Figure 1.1: Expression pattern of MyoD and myogenin across myocyte differentia-
tion. MyoD is expressed in bothC2C12 undifferentiatedmyoblasts and differentiated
myocytes whereas myogenin is expressed solely in differentiated myocytes. In con-
trast neither is expressed in the mesodermal precursor represented by the 10T1/2
cell line.
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Figure 1.2: Occupancy of two of the myogenic regulatory factors and one non-
muscle TFs at function validated Muscle and Non-Muscle Enhancers. 95% of a
large set of previously known muscle related Enhancers display significant binding
of key myogenic regulatory factors (MRFs) in our global measurement. (blue) In
contrast ~10% of non muscle enhancers identified as active in neuronal and t-cell
lineages display binding of these key MRFs. (purple) Similarly only ~15% of the
muscle related CREs showed binding of NRSF although some of these may be false
positives due to background ChIP signals at transcriptional start sites (TSS). Fisher’s
exact test p values comparing the proportion of TF occupied muscle vs non-muscle
enhancers are presented above each TF name.
40
Figure 1.3: Histogram representing myogenin ChIP-Seq signal strength binned by
RPM over the medium confidence ERANGE calls. Overlaid are the corresponding
ChIP-Seq signature strength for 13 validated enhancer regions selected from the
literature (Figure 1.2). Adapted from (Landt SG, 2012).
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Figure 1.4: Behavior of promoter driven Renilla cotransfectants with several test
constructs. Blue = CMV; Green = SV40; Purple = TK and Red = Empty Control
promoters in myoblast (MB) and myocyte (MC) C2C12s. (A) Full range of values.
(B) Rescaled values for the range of signal pertinent to the selected TK promoter.
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C h a p t e r 2
TRANSFECTION ASSAY DEVELOPMENT
2.1 Introduction
Skeletal Muscle Actin (Acta1) is one of the most prominently detected transcripts
(2855 FPKM) expressed selectively, like myogenin (819 KPKM) after the onset of
differentiation. (Figure 1.1) My earliest enhancer assay tests used several mutants
produced by the Sharp Lab at CSU-LA for the promoter regions ofActa1 and ID2 (78
FPKM, myoblast selective gene) region driving a luciferase reporter. The mutants
from the Sharp Lab, done in a conventional luciferase assay, show that much of the
enhancer activity for this fragment of DNA depends on the binding of myogenic
factors at the Eboxes 5 and 6 (Figure 2.1a and c).
These cell type selective promoter proximal regions, and relative scale of activity of
these Acta1 mutant constructs (Figure 2.1a and b) allowed me to refine an assay that
was both technically reproducible, sensitive over a wide range and able to function
in both the myoblast and myocyte cell types. After seemingly unending testing of
different conditions, I was able to replicate their assay successfully in a 96 well
format compatible for testing in the order of hundreds of constructs. (Figure 2.1b).
In addition, to validate the assay, I tested 39 human promoter constructs selected
from the available switchgear collection that showed myogenin and MyoD binding
in the correspondingmouse regions. (ENCODE, 2007) Only 12 (30%) of the human
gene promoters reported as significantly active, and only 5 matched the expected
activity pattern based on their associated gene transcript behavior. (Figure 2.1d)
Since conservation of the occupancy motif was not required for selection, actual
expectations for activity remain uncertain.
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The different behavior of these promoter elements underscores the importance of
comparing the relative activity of candidate enhancers against a single promoter
element. (Section 1.24) Indeed, testing each enhancer against their native promoter,
while ideal, would result in data that is not directly comparable as select promoters
might be tightly gated at one of the two differential stages; resulting in a negative
readout, even when the candidate enhancer itself is functional.
2.2 Structure of a ChIP-seq measurement, enhancer assay development and
candidate selection
Our early knowledge of the muscle transcription factor network mapped to about
15,000 occupied sites out of 2.2X10E6 CAGSTG genome wide. Even though less
than ~1% of all available Eboxes were found occupied and even after the motif was
refined to an RRCAGSTG (and occupancy at 1.5% of such Eboxes in the genome
(Kirilusha A, 2014 thesis)) We thought it possible that several elements identified
by ChIP are either inert or simply “parking” sites for excess factors in the nucleus.
(Casey BH, 2018) This seemingly simple task of assigning enhancer function to
candidate signatures remains difficult today, even with many biochemical maps that
now span CTCF, several cofactors (E proteins, Mef2 and PBX1 in our case); EP300
and histone marks.
The transient transfection assay I developed provides a baseline comparative mea-
surement of relative enhancer activity over a wide range of activity (Figure 2.1),
however it also allows for simple classification of several selections of candidate
enhancers in a binary score as functional or not. These additional ChIP-seq mea-
surements can be used individually or in combination with chromatin signatures
to determine their predictive qualities of enhancer function to provide a first tier
functional expectation.
In order accurately assess the predictive nature for enhancer activity of TF occu-
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pancy, we had to randomly select elements from the genomewhich covered both low,
medium and high signal from the myogenin ChIP-Seq measurement. (Figure 2.2)
This set of candidate elements allowed us to answer outstanding questions on the
functional contribution of each class of ChIP-seq signal in an unbiased way, instead
of relying on the 80% functional top signals for drawing expectations. (Visel A,
2009; Visel A, 2007)
We also selected elements from several genes key to myogenesis to provide a bridge
to the well characterized literature on muscle enhancers (Reviewed and contrasted
in Chapters 1 and 5). These loci are clearly special compared to the "run of the mill"
loci in the genome because of the number of elements they contain and connect to
but not in terms of biochemical strength (which ranges similarly to the genome-wide
distribution). (Fisher K, 2017 thesis) We sampled a small set of additional genes
from complex loci with matching RNA expression trajectories to our MRF genes, in
the hopes to gain the numbers necessary to contrast these elements to their randomly
selected counterparts in the genome. This locus based selection is separate from the
candidate Enhancers used in this chapter and are discussed in chapter 4.
All the candidate elements from both selections were cloned by Switchgear Ge-
nomics upstream of a commonly used basal TK promoter driving a high turnover
luciferase reporter gene (h-PEST). (McKnight SL, 1982) Figure 2.3 is a conceptual
representation of the selection process of candidate Enhancer elements from the
genome at relatively low, medium and high signal myogenin occupancy sites. The
actual experimental sampling in each signal class is illustrated in Figure 2.2 (right
panel) together with the genome wide distribution (left panel).
I transfected each element in four cell types representing a mesodermal precur-
sor (to provide a system without either MyoD or myogenin), mock differentiated
mesodermal precursor (to control for serum and insulin sensitive enhancers), undif-
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ferentiated myoblast and a set of myoblasts that undergo a differentiation stimulus
bringing them to an early myocyte state. (Figure 2.4)
My assay partially draws strength from this differentiable multi-cell type design to
isolate distinct expression patterns of genes and study the modulatory function of
specific elements under these separate conditions. This assay design also allows
us to set functional expectations for the large numbers of myoblast MyoD occupied
elements, many of which go on to be co-occupied at the myocyte state by both
MyoD and myogenin compared to the counterparts that are selectively occupied
only in the myocyte. (Chapter 5; Figure 5.1) This design also allowed us to draw
a contrast and set functional expectations for the relatively smaller, but potentially
functionally important set of elements which are highly occupied in the myoblast
by MyoD but are excluded from occupancy in the myocyte. (discussed later in this
Chapter) Unfortunately, a design spanning so many questions quickly led to a design
with several hundred elements to be tested across 4 cell types.
This type of nowmedium-throughput enhancer assays generally relies on a liposomal
reagents (electroporation was expensive and not available in 96 well format when I
stated these experiments) which require the cells to be dividing in order for the DNA
to be delivered to the nucleus. This created a logistical issue because myocytes,
where myogenin is expressed, do not divide and are fusing together to form the
multiple nucleus containing myocytes, meaning that even if electroporation was
possible each cell (assuming similar external surface area) might have different
proportions of transfected DNA going to each nucleus (depending on n of nuclei).
I opted to transfect the DNA at the myoblast state at a relatively low density and
assay at a later time-point for the myocyte to allow the cells to differentiate. This
also should have allowed me the benefit of matching the established “seed and
transfect” single step protocol suggested by Switchgear and successfully used by
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our collaborators at HudsonAlpha in K562 cells.
Unfortunately when I tested this process on C2C12 myoblasts it resulted in ball-like
structures rather than our cells settling in a mono-layer on the bottom of the well.
This created an issue because the onset of differentiation occurs spontaneously in
C2C12s myoblasts when they reach confluence (such as in a ball-like structure)
making a controlled progression to the onset of differentiation that matched our
biochemical measurements impossible.
These transient assays are also known to begin loosing their reproducible signal
after approximately 60 hours post-transfection (which I confirmed in a test using a
small set of test elements) creating a narrow window of opportunity.
This combination of these technical limitations created a non-trivial challenge as the
differentiation stimulus requires up to 16 hours after the cells become confluent to
reach significant levels of myogenin transcript meaning one does not want to assay
prior to the 24 hour time-point. (Unpublished Wold Lab data)
In order to work around these constraints I had to plate cells at a set density, let
them adhere, transfect and (where applicable) wait for them to achieve confluence,
then differentiate. I also had to adjust serum conditions to be higher (20% FBS
- something also known to affect the efficiency of these reagents) so that the cells
grow faster and allow me to create an assay that barely fit within these parameters.
Unfortunately working by hand also is a slow process, especially to test what when
counting technical and biological replicates across cell lines is in the order of 50,000
wells being plated, transfected and media changed to induce differentiation. These
timing differences which span in the order of many hours alone created a logistical
nightmare.
In order to reproducibly test this many enhancers I devised a robotic transfection
assay, which closely mimics the manual assay I developed in 96 well plates. (Figure
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2.5) The use of robotics resulted in reproducible timing, fast handling of plates
(mere minutes instead of hours), and lower loss of cells when changing media for
the differentiation, as the robot can remove and dispense reagents to plates in a way
and speed that a human simply cannot. These many advantages; along with allowing
for a large set of negative controls resulted in a well controlled, reliable assay with
low technical error. 2.6
2.3 Enhancer Thresholding
High confidence (IDR=0.02)myogenin datawhich has been processed by themodern
Encode 3 pipeline yields a distribution of signal sites (Figure 2.2 Left Panel) across
the genome where the majority of signal is contained in the medium to low signal
ranges similar to our original ChIP measurement for this factor. (Figure 1.3) We had
used this original ChIP measurement to select our candidates, and the IDR filtering
(and 1PCR libraries) excluded a surprisingly large set of elements. (discussed later
in Chapter) Even with these exclusions, our sampling was still deep enough to allow
us to predict activity for the full signal range of myogenin occupancy. (Figure 2.2
Right Panel)
In order to ensure specificity of activity I had to devise a set of controls. I used the
set of literature derived t-cell and neural enhancers as a specificity control. (Figure
1.2 - Purple) These regions provide an identical occupancy motif, and are centered
on the CAGSTG motif(s) contained, testing whether assay function is specific for
occupied regions. In addition I selected a small set of unoccupied muscle class
Eboxes (RRCAGSTG) from each key muscle loci to further establish a reliable
baseline of activity the assay.
2.4 Additional Results
The results of the transfection assay for the myocyte state are summarized in Figure
2.6 (Top Panel). The negative control elements are in gray on the left, showing no
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function across the entire set of tested elements, whether they were selected from
characterized enhancers or non occupied sites in key loci (where the chromatin
should be accessible). This indicates that our assay is specific for function in
elements that show occupancy by TFs. It is important to note that two of the
originally selected negative control elements were actually functional, and stood out
from the distribution of the negatives. These were later found to have significant
DHS sites which indicate the presence of another TF that was not yet measured in
our cells driving their function. As a result these were excluded from the negative
control set.
The experimental elements are ranked based on their corresponding ChIP-Seq signal
within the region. Enhancer function is present throughout the range of signal and
that while strong enhancers are enriched in the top 200 as expected, that the ratio of
activity is stable across the higher 2000 sites, all the way down into the low signal
range of ChIP-Seq. (Figure 2.6 Bottom Panel) Overall 40% of sites are found to be
active in the myocyte. This can be extrapolated to predict that ~5500 of the 15000
myogenin occupied sites are expected to be active genome-wide.
Overall this data tracks well with the activity found in the comparable portions of
signal used in other studies since published in the literature. The original EP300
study found ~80% enhancer function among the top ChIP-Seq peaks, whereas we
found ~75% function. (Visel A, 2007; Visel A, 2009) In the top 2000 signal
occupancy sites we found a comparable function at ~53% to our companion study
which derived candidate Enhancers fromTal1 andGata1 co-occupancy (54%active).
(Dogan N, 2015) While we found many inactive elements in high and medium
signal elements these may function as poised enhancer sites, or simply sites that
function when brought into physical proximity with other sites in the genome.
(Further discussed in Chapter 5) Overall we find 40% of candidate Enhancers to be
functional compared to <25% as measured by Starr-Seq, which may be suffering
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from sensitivity or cross-talk issues. (Arnold CD, 2013; Muerdter F, 2018)
Figure 2.7 presents the overall contribution to the number of genome wide enhancer
by signal class in a ChIP-Seq experiment. This means that while the strength
and proportion of enhancers in the lowest signal class may be lower, this class
of elements far outnumber their counterparts in the higher signal classes across the
genome. Even just the lowest signal class accounts for approximately approximately
half of active myogenin occupancy sites in the genome!
2.5 Activity of MyoD sites occupied exclusively undifferentiated C2C12
MyoD is a transcription factor that is expressed in both myoblast and in myocyte
cells. (Figure 1.1) I selected a set of sites which are exclusively occupied by MyoD
in the myoblast state in the hopes that these sites are a class of myoblast enhancers
that are then actively repressed to prevent their function in the myocyte (n=16). The
results of the myoblast assay in Figure 2.8 (blue) are unambiguous, most of these
do not function in the myoblast. One enhancer did function when cloned upstream
of a TK promoter but only significantly in the differentiated myocyte state (red).
These results, along with those of the entire population of myoblast MyoD occupied
elements indicates that little function if present at these sites, with the exception of
a few validated enhancers from known loci. (further discussed in Chapter 5)
2.6 Enhancer function analyzed against EP300 signal
The Histone Acetyl Transferase (HAT) EP300 has been associated with functional
elements in several enhancer studies. (Visel A, 2007; Vockley CM, 2016; Dogan N,
2015) Ranking our elements by EP300 signal classes results in a similar fraction of
activity as reported by Visel A, 2009 where an identical 80% of active enhancers
are found in the top200 sites. (Figure 2.9)
In myogenesis the study of the relationship between EP300 occupancy and enhancer
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function is complicated as otherHATs are present and expressed at levels comparable
or greater than EP300. (Further discussed in Chapter 5) (Albini S, 2010; He J, 2011)
This means that while no EP300 signal is found within several active enhancers
assayed in this study (Figure 2.9), these sites may simply pair to with different HAT
other than EP300 (eg CBP/pcaf). Unfortunately we do not have a significant number
of these active but non EP300 marked elements, which makes their analysis at the
motif level impossible without greater numbers. Attempts to ChIP these other HATs
unfortunately failed repeatedly.
2.7 Enhancer function analyzed ChIA-PET connectivity
Our randomly selected elements that have been tested can be separated by their
ChIA-PET connectivity status. (Fisher K, 2017 Thesis, Lajoie RR, 2015) Figure
2.10 shows the lack statistical significance at the p=0.05 level for difference of mean
activity between elements which are connected vs not connected. (t-test p=0.16)
This is contrasted to the expectations of many that connected elements might be
enriched for function. These sites may only work as an enhancer when brought into
physical contact with their cross-connected locations or may be working as poised
enhancer where the 3D chromatin structure is laid out prior to enhancer activation.
(Vockley CM, 2016) (Further discussed in Chapter 5)
2.8 Comparing IDR vs Pre-IDR peak calls; 1PCR vs 2PCR libraries
The original selection of elements was done using data processed with the ERANGE
peak caller from a 2PCR library. Of the randomly selected 131 elements 31 of
the tested candidate elements were discarded by the modern processing by the
ENCODE3 pipeline using SPP for peak-calling and processed for IDR=0.2 on
biological replicate 1PCR myogenin ChIP-Seq libraries. (Mortazavi A, 2008; Li Q,
2011; Moore J, 2018; ENCODE, 2012) Of these 31 sites, only 2 marginal enhancers
are detected in the MRF negative elements. (Figure 2.11)
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This indicates that either the 2PCR amplifications of the libraries included several
artifactual sites that looked like real signal when processed in a heuristic model
based peak caller such as ERANGE. (Mortazavi A, 2008) Unfortunately we do not
have two matching 2PCR ChIP-Seq for myogenin that we could run through IDR, to
determine if IDR is responsible for the exclusion of this class of sites from that data.
Knowing for certain whether these irreproducible sites are largely void of enhancer
activity would be helpful in guiding future efforts.
There is however a significant contribution by the combination of 1PCR libraries and
IDR to remove a large set of unstable sites across the two biological replicates, which
results in enrichment in significant function overall in the population of ChIP-Seq
sites (depending on where the IDR cutoff is set).
2.9 Conclusions
1) The transfection assay that I developed is sensitive for function within sites that
occupied by myogenin. This is proven by a large set of negative control elements
which do not function even though they provide comparable motifs. (Figure 2.6)
2) Elements in all signal classes (Figure 2.2), including top signals, did not function
as enhancers. (Figure 2.6) Thesemay be poised enhancers or simply require physical
connectivity to other elements (or their native promoter in the correct orientation
to function. Overall 40% of myogenin occupancy sites are expected to function,
indicating thatmyogenin is a permissive condition for function but not a determinant.
(Figure 2.6)
3) The vast majority of these enhancers are specific for function in the myocyte state.
(Figure 5.1) Only a few elements are marginally active in the myoblast state, the
mesodermal precursor cells (control for specific TF function) nor result of ectopic
activation from the differentiation stimulus (serum change and insulin exposure)
indicating that these Enhancers depend on TFs expressed or signaling only present
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in myocytes for their function. (Further discussed in Chapter 5)
4) MyoD occupancy which is exclusive in the myoblast failed to capture active
enhancers (Figure 2.8), although there is indication the MyoD may function at
several important sites as an enhancer when recruited by Pbx1/meis. (Further
discussed in Chapter 5)
5) While EP300 has been noted as a requirement for enhancer function, we find
several elements that function in our assay without the or with weak presence of
EP300, indicating that other HATs may perform redundant functions (Figure 2.9).
6) Physical connectivity, as measured by ChIA-PET, fails to capture exclusively
active enhancers. Several of these connected elements are not functional in my
assay suggesting a possible requirement for several of these sites to come together
physically be biologically active. (Figure 2.10)
7) Modern data processing using IDR on 1PCR biologically replicated ChIP-Seq
experiments appears to selectively remove candidate Enhancers that are largely
nonfunctional. (Figure 2.11)
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2.10 Figures (Chapter 2)
Figure 2.1: (Caption on next page.)
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Figure 2.1: 4AData from Sharp Lab at CSU-LA for a skeletal muscle actin construct
(blue) and a series of mutant elements (red-Ebox mutant, green – Mef2 mutant).
4B data produced in one of our initial transfection tests using the same constructs
as panel 4A. 4C 2PCR occupancy of MyoD, Myogenin (MyoG), Mef2A and CTCT
in the region over and upstream of the Acta1 gene. Red arrows indicate the Eboxes
that were mutated, while green arrows point to the mutated Mef2 motif. 4D Ini-
tial transfection test using Switchgear Genomics human promoter constructs and
comparison with the RNA trajectory of the associated gene.
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Figure 2.2: LEFT genome-wide distribution of myogenin occupancy sites in each
signal class (SPP-IDR p=0.02 peak calls). RIGHT number of candidate Enhancers
that were randomly selected in each signal class.
72
Figure 2.3: This figure shows the sampling and cloning of a representative low,
medium and high signal element into the same basal TK promoter construct driving a
high-turnover (h-PEST) Luciferase reporter gene. This process done for comparable
numbers in each class. (Figure 2.2)
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Figure 2.4: Top Left Panel: C2C12 undifferentiatedmyoblast expressingMyoD. Top
Right Panel: C2C12 differentiated myocyte expressing both MyoD and myogenin.
Bottom left Panel: 10T1/2 mesodermal precursor which acts as a specificity control
since neither MyoD or myogenin are expressed. Bottom Right Panel: 10T1/2 mock
differentiated mesodermal precursor cells which act as a control for serum and
insulin used to differentiated the C2C12 cells. MyoD and myogenin are also not
expressed in mock differentiated 10T1/2 cells.
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Figure 2.5: Flowchart for the transfection assay. Each cell line is plated indepen-
dently in triplicate technical plates. For the undifferentiated myoblast and mesoder-
mal precursor a simple 24 hour wait post transfection is followed by a readout on a
plate luminometer. For the differentiated C2C12 myocyte and mock differentiated
10T1/2 mesodermal precursor there is a wait for the cell density to increase to ~80%
confluence, the differentiation stimulus is then added, and the luminescent is read
after 24 hours post transfection.
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Figure 2.6: TOP Randomly selected elements sorted by their underlying myogenin
ChIP-seq signal (SPP-IDR peak calls). Negative control elements are represented in
gray and are used to set the activity threshold. BOTTOMLEFT Proportion of active
enhancers in each signal class, active enhancers represented in color, inactive portion
represented in gray. The number of elements tested that fall active and inactive in
each bin is represented at the top and bottom of each bin. BOTTOM RIGHT
Pie chart showing the overall expected number of enhancers using the transfection
assay as a base for genome-wide extrapolation. Overall, 40% of ChIP-Seq sites for
myogenin are expected to be active enhancers.
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Figure 2.7: A Expected number of genome wide enhancers using the transfection
assay as a base for prediction. 40% of ChIP-Seq sites for myogenin (SPP-IDR peak
calls) are expected to be active enhancers totaling over 5500 sites. B Shows the
contribution of predicted enhancers from each signal class, where low signal sites
contribute almost 45% of active enhancers genome-wide.
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Figure 2.8: Transfection assay activity for elements that are exclusively occupied in
the myoblast state by MyoD (no MRF MC signal). Myoblast (blue) and myocyte
(red) transfection assay activity for elements ranked low to high by myoblast MyoD
signal. These elements turned out generally void of EP300 occupancy, but element
11 is an exception which shows high EP300 signal present within the tested region
in myocyte indicating that it likely is a non myogenic enhancer.
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Figure 2.9: Proportion of active enhancer elements (blue) vs inactive (gray) among
myogenic candidate Enhancers scored by signal class of EP300 occupancy. Number
of cEnhancers active/inactive in each class are in white.
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Figure 2.10: Myocyte transfection activity for randomly selected elements are not
statistically different at the p=0.05 level for proportion, mean, and distribution of
activity between populations that are ChiA-pet connected (Blue) vs not connected
(red). T test p=0.16, Fisher’s Exact p=0.28, KS test p=0.15. Negative control
elements are shown in gray on the left.
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Figure 2.11: 2PCR ERANGE elements that failed to reproduce in 1PCR IDR called
replicate experiments. Additional elements that met a previousmyogenin occupancy
criteria (based on a 2PCR ERANGE ChIP-seq run), but failed to meet the modern
selection standards (IDR on true biological replicate data sets and 1PCR libraries)
used elsewhere in this chapter. The removal of the data not conforming to IDR
based on 1PCR biological replicate libraries appears to discard mainly inactive
cEnhancers.
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C h a p t e r 3
DRAFT MANUSCRIPT: PURSUING FUNCTION IN
CANDIDATE ENHANCER SIGNATURES
The introductory section to the draft manuscript was merged within Chapter 1
(introduction). I append an abstract of the results presented in this chapter.
Genome-wide DNAse hypersensitivity, histone modifications and transcription fac-
tor occupancymeasurements from the ENCODE andNIHRoadmap consortiae have
been used to identify candidate regulatory elements (cREs) and profile them as can-
didate enhancers, promoters and insulators based on their characteristic biochemical
signatures. However, accurately predicting the regulatory activity of cREs from the
biochemical maps alone has turned out to be difficult, and it is not yet clear to what
extent regulatory elements active in vivo can be identified from these biochemical
signatures. To assay the predictivity of the biochemical signatures characteristic of
enhancers we carried out tests for transcriptional enhancer activity for hundreds of
candidate elements from five human or mouse cell types, including immortalized
cells and cell lines modeling the early developmental differentiation to muscle or
red blood cells. Our candidate Enhancer (cEnh) collections were selected using bio-
chemical signature criteria ranging from from individual transcription factor (TF)
occupancy to tissue differential integrative machine learning models.
We find that in general ∼50% of both TF-selected and TF-agnostic cEnhs demon-
strated significant enhancer activity in transfection assays, observing similar pro-
portions across all cell lines and conditions examined. We observe that the presence
or number of TF recognition motifs in cEnhs displays no correlation with enhancer
activity. Most of the active enhancers detected displayed relatively modest bio-
chemical signatures in their genomic context, some of which scored among the
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most powerful on our assay. However, the relative activities of the cEnhs measured
reveal that the majority likely only exhibit modest regulatory activity on their own.
Conversely genomic regions that lacked the biochemical marks, even while contain-
ing the motifs necessary for the relevant TFs, generally did not sustain enhancer
function.
We demonstrated that as expected from the redundancy of biochemical measure-
ments that DHS and H3K27ac are equally predictive of enhancer activity compared
to TF occupancy alone. We also observe a positive but weak correlation between
biochemical signal strength and predictivity of enhancer activity, with even the most
biochemically outstanding group displaying a significant fraction of cEnhs displays
no discernible enhancer activity.
We corroborated these findings by using the STARR-seqMPRA to assay the activity
of thousands of genomic regions occupied by the glucocorticoid receptor (GR) in
stimulated A549 cells.
Finally, we discuss these results in the context of current models of the regulatory
effect of enhancers on their cognate genes. We expect our findings to help guide
future efforts towards cataloging the functional repertoire of mammalian genomes.
3.1 Results: Large-scale activity test of full-length cEnhancers
While powerful approaches now enable measuring the regulatory activity of thou-
sands of elements simultaneously, the diminutive size of the elements assayed is
a common concession. (Patwardhan RP, 2009; Kinney JB, 2010; Kwasnieski JC,
2012; Melnikov A, 2012; Patwardhan RP, 2012; Arnold CD, 2013; Murtha M,
2014; Kheradpour P, 2013; Kwasnieski JC, 2014; Ernst J, 2016). If the fragments
tested (typically 80-250bp) are significantly shorter than the size of many full-length
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candidate functional regulatory elements found in mammalian genomes they may
lead to significant numbers of false negatives being scored.
In order to assess the ability of MPRAs to assay the activity for complete, full-
length cREs one requires a large collection of likely candidate regulatory elements
to estimate their representative size, preferably across many tissues.
Unfortunately the boundaries of distal elements defined by the current biochemical
measurements are often unclear, especially when regions are merged from several
partially redundant measurements. This creates boundaries that will extend much
further than any likely regulatory element. However the distribution of the lengths
of conserved noncoding segments (e.g. excluding the sequences overlapping with
or in the vicinity of annotated exons) in the human genome (Supplementary Figure
3.1) provides a representative library of candidate functional elements. While this
collection excludes the representation of tissues known to depend heavily on recently
evolved enhancers (such has heart), it provides a core library of elements with well
defined boundaries that stood the test of time.
From this library, we found that tens to hundreds of thousands (depending on the
definition) of such blocks fall outside the range of testing supported byMPRAs. The
additional concern with MPRAs is the possibility of cross-talk between different
REs, the effects of which may vary and self-compound depending on the nature of
the input library.
To address these issues, and accurately asses the functional predictivity of biochem-
ical marks, we carried out our tests of cEnhs identified on the basis of biochemical
signatures in a variety of mammalian systems using single plasmid transient lu-
ciferase reported enhancer activity assays, which allow for much larger segments of
DNA to be tested for enhancer activity (Supplemental Figure 3.2).
While the full catalog of REs in the genome includes promoters, insulators, en-
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hancers, silencers, and elements with other function; for the purposes of this study
we focused primarily on distal candidate transcriptional enhancers (cEnhs).
A major reason for this choice is that distal cEnhancers can readily be identified
using TF occupancy, by the overlap of DNAse hypersensitive sites (DHS) and
regions marked by H3K27ac, or by all three at genomic locations that do not exhibit
the biochemical signatures characteristic of promoter function or a GENCODE TSS
annotation.
These historically underrepresented distal cEnhs also constitute the bulk of cREs
distinguishing different cell types from each other, in contrast to TSS proximal
enhancers the majority of which are biochemically occupied in multiple tissues that
make predictions for cell type specific active enhancers difficult because of the often
overlapping promoter function. (Figure 3.1D and supplemental figure 3.4).
Because these distal candidate enhancers are largely tissue specific we focused on
testing their ability to individually support active biological function in the tissue
where they are annotated. We also selected regions that contain DNAmotifs relevant
to each individual cell context
Immortalized cell lines were targeted for our enhancer assay tests as they have
been extensively studied by the ENCODE consortium(ENCODE, 2011; ENCODE,
2012) and they are the source of a significant portion of ENCODE data. We aimed at
comparing the predictivity of multiple approaches for identifying functional cEnhs,
and at incorporating a diversity of biological systems in our analysis (Figure 1E).
We targeted model systems for major developmental transitions (myogenesis and
erythropoiesis), immortalized cell lines (the humanK562 andHepG2 cell lines), and
amodel system for cellular response to exogenous signaling stimuli (activation of the
glucocorticoid receptor in the human alveolar epithelium cell line A549). We also
aimed to represent the full spectrum of cEnh biochemical signatures (Figure 3.1D
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and Supplementary Figure 3.3), as multiple studies have shown that the landscape
of transcription factor occupancy, DNAse hypersensitivity and histone modification
maps includes many more weaker sites than very strong peaks (Landt SG, 2012;
Kellis M, 2014).
3.2 Results: Tissue specific enhancers from muscle and red blood cell differ-
entiation
In the context ofmuscle differentiation, we selected TSS distal cEnh regions based on
myogenin ChIP-seq data in differentiated C2C12 myocytes. We randomly selected a
set of regions (n = 89) spanning the full range of myogenin occupancy levels, most
of which contain a CAGSTG (n = 88) and the extended RRCASGTG (n = 84) E-
box. We also used myogenin to select additional cEnh elements (n = 88) associated
with genes playing a well characterized role in muscle development; to test whether
they exhibit higher levels of functionality than the genome-wide average.
We selected a group of negative controls to test the specificity of biochemical
signatures for prediction of functional activity in a given cell type. To this end, we
selected elements (n = 23) from a set of well characterized enhancer elements that
are active in T cells and in neurons but that are not occupied by myogenin in C2C12
cells; 21 of these elements contain the CAGSTG motifs. We specifically selected
the majority of the regions to contain and be centered on a muscle class E-box as
we wanted to allow for the potential binding of myogenin in an exogenous plasmid
system. A second set of negative control elements were selected in order to assess
the baseline functional activity of biochemically and functionally neutral regions.
We selected candidate regions (n = 11), 6 of which contain E-box motifs from areas
void of enhancer signatures. No significant difference in activity was found between
the two sets which were merged for the purposes of this paper.
Erythroid cEnhancers were selected to provide a cross tissue comparison to our
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mouse elements from GATA1 or Tal1 ChIP occupied regions (n = 113) of the
mouse genome and tested in the easily transfectable human K562 cells. GATA1
ChIP-chip data in the cell line G1E-ER4 was used to select GATA1 cREs. Elements
were subjected to independent validation by ChIP-qPCR, with validated comprising
candidate Enhancers (n = 53). TAL1 ChIP-seq data was used to select ChIP-
seq positive regions (n = 60) that were tested for enhancer activity after transient
transfection inK562 cells. Genomic elements thatwere not significantly occupied by
GATA1 were selected as occupancy negative controls for the assay (n = 74)Taylor J,
2006; Cheng Y, 2008. Of these, GATA1 ChIP-chip that failed ChIP-qpcr validation
comprised 63 of the negative control elements. Another set of 11 DNA segments
were not called as peaks in the ChIP-chip analysis, these are labeled GHN for
GATA1 hit negative. Although they are not biochemically occupied, 45 of the
control elements contain a GATA1 motif (WGATAA); while 40 contain a Tal1
occupancy motif (CAGMTG) providing a baseline functional activity.
Figure 3.2 shows the measured enhancer activities for TF-centric cEnh selections
and negative controls in myogenesis (Figure 3.2A) and erythropoiesis (Figure 3.2B).
We provide a summary of the enhancer assay results from each of these two systems
where we selected candidates based on TF occupancy in Figure 3.2; together with
the biochemical signal measured and statistically significant peak calls (IDR≥ 0.05)
for the key TF; DNAse-seq and H3K27ac ChIP-Seq. We also provide the number of
DNA motifs present within each cEnhancer tested. We found 39 out of 89 or 44%
of muscle cEnhs to pass the threshold of activity in contrast to 3 out of 34, or 9%
of muscle negative controls. Similarly, 50 out of 112, or 45% erythropoetic cEnhs
and 2 out of 73, or 3% of negative controls, were found to be active. We note that
even though in both cases the occupancy is highly selective for a tiny fraction of
the available motifs genome-wide, only ∼ 50% of candidate Enhancers are active in
each system and that both the strength or presence of the biochemical signals or the
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number of motifs appears to be non-deterministic of enhancer function. Many of the
active elements are contributed by fairly modest signals, with related biochemical
measurements such as DNAse and TF occupancy often differing widely in signal
strength compared within each individual element.
3.3 Results: The compendium of elements within the closest CTCF bound-
aries near genes mirrors that behavior of the genome wide population.
We also used myogenin to select additional cEnh elements (n=88) associated with
genes playing a well characterized role in muscle development; to test whether they
exhibit higher levels of functionality than the genome-wide average. We found 49 out
of 88 or 56% of muscle cEnhs to pass the threshold of activity in contrast to 2 out of
34, or 5% of muscle negative controls. Although the locus selected elements appear
slightly more predictive of enhancer activity, we found no measurable difference
in muscle development between the distribution of active elements (KS p=0.167)
selected for TF occupancy between elements randomly selected (figure 3.2) and
the specific locus affiliated cEnhancers (supplementary figure 3.7). As such these
elements were merged for the further analysis done in this manuscript.
3.4 Results: The occupancy ofmultiple TFs are equally predictive of enhancer
activity as their individual tissue specific counterparts.
While C2C12s and G1E-ER4s provided a low hanging fruit for selecting tissue
specific candidate enhancers; K562 andHepG2 comprised the primary immortalized
cell lines selected by the ENCODE consortium for extensive annotationENCODE,
2011; ENCODE, 2012.
We aimed at comparing the predictivy of cEnhancers selected from a cell-type
specific factors (myogenin and GATA1/Tal1) to that of a collection of overlapping
occupancy peak calls by non cell-type specific positive acting factors (such as JUND,
MAX, TEAD4 and USF1) mapped by ENCODE in K562s. One might expect that
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by requiring the occupancy of multiple factors, one would improve the predictivity
of active enhancer function.
To this end we used the vast trove of biochemical annotations in K562 cells to
generate cEnhancers (n = 28) occupied by several generic activating TFs, to contrast
the predictivity of cell type specific TFs used to select cEnhs in our differentiation
models. A set of regions similarly TF occupied exclusively in HepG2 (n = 32)
were used as negative controls. In K562 cells, we found 14 out of 28, or 50%,TF-
centric cEnhs to be active, in contrast to 2 out of 32, or 6%) in the corresponding
sets of negative controls. The individual results for K562 cEnhancers, including
the number of TFs occupying each element, are available in Supplementary Figure
3.14.
We find no significant difference in the predictivity of cEnhancers selected by using
cell-lineage specific contrasted with selection of cEnhancers based on generic trans-
activator TFs. The results of these enhancer assays based on TF-centric cEnhancers
and occupancy negative control elements are summarized in Figure 3.3A.
3.5 Results: Biochemical marks and TF occupancy are similarly predictive
of active enhancers in multiple cell types
Next, we aimed at comparing the predictivity of multiple approaches for identifying
functional cEnhs, and at incorporating in our analysis a diversity of biological
systems (Figure 3.1E). As such, we applied several different strategies for compiling
lists of cEnhs to be tested, broadly contrasting the TF-centric with TF-agnostic
picks based primarily on chromatin state signatures and evolutionary conservation
in order to compare their predictivity for active enhancers.
We relied on multiple computational approaches for integrating high-dimensional
collections of functional genomic datasets into a small set of chromatin states that
have been devised over the last few years and applied to the problem in ENCODE
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cell lines, including the Hidden Markov Model-based SegwayHoffman MM, 2012
and chromHMM(Ernst J, 2012), as well as Self-Organizing Maps(Mortazavi A,
2013) (SOMs). We selected cEnhs in K562 cells based on Segway and chromHMM
chromatin state assignments and the presence ofDNAse andH3K27ac (n = 30), with
elements lacking both marks used as negative controls (n = 21). We also selected
cEnhs based on SOMs trained DNAse and histone mark ChIP-seq data over multiple
ENCODE cell types; these cEnhs were picked so that they were specifically in an
open chromatin state and marked by histone modifications associated with enhancer
activity in HepG2 cells (n = 32). The negative control elements were also derived
from other SOM regions that lacked both marks in HepG2 (n = 18). The individual
enhancer assay results are summarized in the supplemental figure 3.15 with the
correlations to the biochemical data (supplemental figure 3.16) being comparable
to those found in C2C12 and G1E-ER4.
In the context of hematopoiesis, a TF-agnostic cEnhancer selection was based on
evolutionary conservation. A total of 46 cREs were selected from regions conserved
in alignments of multiple mammalian species characteristic of regulatory regions
but containing a GATA1 motif. Six additional DNA segments highly conserved to
outside of mammals that also contain a GATA1 binding motif were also included.
These elements were annotated for DHS and H3K27ac in G1E-ER4 cells; with 28
elements scored positive for both biochemical marks and were used as “cEnhancers”
while the 24 elements lacked both of the modern marks were used to score as
a negative control set.(Wang H, 2006; Taylor J, 2006) The individual results for
cEnhancers are presented in supplemental figure 3.11.
The same analysis for TF-agnostic cEnh selections showed that 18 out of 32 (56%) of
SOM picks were active in HepG2 cells, 14 out of 42 (33%) of chromHMM/Segway
picks were active in K562 cells (Supplemental Figure 15), and 13 out of 28 (46%)
of GATA1 conservation selections exhibited significant activity contrasted to 2 out
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of 24 negative controls (8%) supplemental figure 3.11.
However, as expected from previous studies that sampled candidate elements solely
on conservation Visel A, 2007, the GATA1 motif containing and evolutionarily
conserved cEnhs scored blind to the biochemistry yield a reduced fraction of func-
tionally active elements.
3.6 Results:DNAse and H3K27ac predictivity.
In order to contrast and extrapolate to genome-wide “gold standard” cEhancers
we applied the current criteria proposed by ENCODE. We required the elements
for this comparison to be DNAse hypersensitive and ChIP-seq H3K27ac occupied.
This enabled us to compare these regions to their TF agnostic counterparts that
were selected almost exclusively from regions that contain these two biochemical
annotations. Because no measurable differences were found between the two sets
(random and locus) in muscle; both were merged and used. The results of these
enhancer assays and occupancy negative control elements are summarized in Fig-
ure 3.3B. We extrapolate genome-wide predictions for each system based on the
proportion of active enhancers. Overall, we find no difference in the predictivity
of enhancer activity for either TF-centric or TF-agnostic selections across multiple
tissues, and estimate that approximately half of the population of biochemically
DNAse/H3K27ac co-marked cEnhancers are biologically active.
However, as expected from previous studies that sampled candidate elements solely
on conservation Visel A, 2007, the GATA1 motif containing and evolutionarily
conserved cEnhs scored blind to the biochemistry yield a reduced fraction of func-
tionally active elements.
We find no significant difference in the predictivity of enhancer function for can-
didates selected by using cell-lineage specific TFs contrasted with selection of
cEnhancers based on generic trans-activator TFs. The results of these enhancer
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assays based on TF-centric cEnhancers and occupancy negative control elements
are summarized in Figure 3.3A. We extrapolate genome-wide predictions for each
system based on the proportion of active enhancers. We note that while G1E-ER4
appears to have significantly less enhancers, this is simply attributable to a weaker
DNAse hypersensitivity measurement.
We then examined the subsets of cEnhs in each system bearing the simultaneous bio-
chemical signature of TF ChIP-seq occupancy, H3K27ac demarcation and DNAse
hypersensitivity, which would represent the most likely to be functional cEnhs. We
observed 55.6% active such cEnhs in myogenic cEnhs, 50% among erythroid ones,
and 49.5% in the set of cEnhs selected from human immortalized cell lines (Figure
3.3A). The same analysis for TF-agnostic cEnh selections showed that 18 out of
32 (56.2%) of SOM picks were active in HepG2 cells, 14 out of 30 (46.6%) of
chromHMM/Segway picks were active in K562 cells (Supplemental Figure 15), and
12 out of 26 (46.2%) of GATA1 conservation selections exhibited significant activity
contrasted to 2 out of 24 negative controls (8%) (Supplemental Figure 3.11). We note
that HepG2 SOM selections were biased towards more strongly H3K27ac/DNAse
positive regions (Supplementary Figure 3.3), which might explain the higher levels
of observed activity within that set.
Overall we find similar levels of activity in both the TF-centric and TF-agnostic
sets of cEnhs predictions, around 50%. Using the total number of cEnhs in each
cell type and the observed proportions of cEnhs active in functional assays, we
estimate that there are 8421 active myogenin+/H3K27ac+/DNAse+ enhancers in
C2C12 cells, 3789 GATA1 + /H3K27ac + /DNAse + ones in erythroid cells, 13255
TF + /H3K27ac + /DNAse + ones in K562 cells. Self Organizing Maps com-
bined with functional testing predict 13464 active enhancers in K562 cells while
chromHMM/Segway predict 12460 ones. The combination of GATA1 conservation
and the H3K27ac/DNAse biochemical signature predicts 5253 active enhancers in
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erythroid cells. We note that the low prediction in G1E-ER4 cells is likely due to
weaker measurement which thresholds the available number of sites to be lower in
the genome.
We also note that in all functional tests we carried out using luciferase assays, we
find a skewed distribution of activity, similar what is observed for biochemical signal
strength in ChIP-seq and other functional genomic experiments. A small number of
cEnhs appear to be highly active, while the majority of even active cEnhs exhibits
only modest activity (Figure 3.2, Supplementary Figure 3.3 and Supplementary
Figure 3.15).
3.7 Results: The bulk of enhancers in a given cell type are marked by modest
biochemical signatures
Although we presented evidence that the overall predictivity for biochemical signa-
tures are equivalent across multiple systems, the biochemical signals measured by
a ChIP-seq experiment vary widely within statistically significant regions (Figure
3.1D).
As mentioned, we found no significant difference in the predictivity or relative
activity between the subpopulation of cEnhancers culled from a random selection
of TF occupied sites compared to ones affiliated with transcriptionally outstanding
genes. The genomic region surrounding theBTG2-MYBPH-myogenin genes (figure
3.4A) shows that, like functional activity, the general range of myogenin ChIP-Seq
signals is well represented even near outstandingly transcribed genes. However,
overall smaller biochemical signals make up the vast majority of the catalog of
myogenin occupancy based cEnhancers in the genome (Figure 3.4B). One key
unresolved question is whether biological activity is significantly present within this
lower spectrum of the biochemical measurement.
In order to asses the relationship between occupancy strength and functional activity,
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we split the cEnhs we tested in C2C12s into four bins (“low”, “medium”, “high”,
and “top”) according to the level of myogenin ChIP-seq signal observed (Figure
3.4C). We find that the fraction of active cEnhs increases steadily with the strength
of myogenin signal, with only ~20% of low-myogenin cEnhs exhibiting significant
activity in contrast to ~65% of the most strongly occupied ones. These observations
superficially imply a close relationship between biochemical signal strength and
functional activity, however, we note that even in the latter group a large fraction
(nearly half) of cEnhs is inactive when directly functionally tested.
We then asked howmany active enhancers genome-wide are likely to be found among
each portion of the signal strength distribution. Figure 3.4D shows the extrapolated
numbers of active enhancers in each bin of myogenin occupancy strength. However,
this function is specific for the biochemically marked regions as demonstrated by
the negative control elements. While the strongest myogenin sites are mostly likely
to be functionally active, the much greater numbers of weaker sites mean that the
75% of active enhancers in muscle cells are expected to be found among the sites
belonging to the “low” and “medium” bins.
Similar observations apply to the combinations of biochemical marks used by the
ENCODE encyclopedia within myogenin occupied sites. (Supplementary Figure
3.17). It should be noted that while the proportion of active enhancers remains
the same, when using multiple overlapping measurements the predicted numbers of
enhancers is affected; especially in the range of medium to low signal. While these
elements that “drop out” are within a lower biochemical marks range, their relative
activity on the assay is sometimes significant. This indicates that while utilizing
multiple overlapping marks one will sometimes miss weaker marked sites that can
nonetheless be functionally important. This results in thousands less sites being
predicted; which make up a significant portion of the genome. It is important to
note that we only tested elements as individuals and many more of these weakly
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marked sites may worked when paired with other elements included in the region
proximal to their natural promoter target.
Finally, we sought to contrast the contribution of enhancers from regions biochemi-
cally marked and occupied by a TF necessary for differentiation with that of regions
occupied as the result of an external signaling stimulation. We chose these two main
types of dynamic transition of cellular states associated with regulatory alterations
of chromatin states to represent both the slower and typically irreversible differ-
entiation of one cell type into another, and the much faster and reversible cellular
response to signaling molecules.
The transcriptional response to glucocorticoids, on the other hand, is characterized
by amore rapid kinetics of gene expression activation, and by its general reversibility.
The A549s are a human lung epithelial cell line which has been used to study the
genomic response to the stimulation of the glucocorticoid receptor (GR), normally
involved in the suppression of inflammatory responses. We used the response
of A549 cells to activation of the GR transcription factor by the cortisol analog
dexamethasone (Dex) as a model system for our study. Upon activation by Dex GR
rapidly associates with thousands of sites along the genome, both directly through
its cognate motif and indirectly through association with cofactors such as AP-1
(Reddy TE, 2009; So AY, 2007; Gertz J, 2013), leading to changes in the expression
of hundreds of genes. The epigenomic landscape of A549 cells during GR activation
is illustrated for reference in Supplementary Figure 3.18. Using an IP for GR against
the DNA of A549 cells induced by exposure to dexamethasone; we created a library
to be used in a self-reporting enhancer assay (STARR-seq) (supplemental figure
3.19) (Vockley CM, 2016).
As such, we corroborated these finding by examining our A549 GR ChIP-STARR-
seq data. Comparing STARR-seq reads to their input DNA libraries, and only
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including cEnhs with sufficiently deep representation in sequencing libraries (see
the Methods section for details), we identified ~5% of GR cEnhs to be significantly
active in Dex-stimulated A549 cells and ~10% to be active in untreated cells (Sup-
plementary Figure 3.12A). This fraction is considerably lower than what is observed
for cEnhs with luciferase assays, an observation that is explained by a combination
of the generally lower sensitivity of MPRAs and the shorter fragments being rep-
resented in STARR-seq libraries, which likely do not capture complete regulatory
elements (although we note that we also carried out an activity analysis at the level
of individual DNA fragments and did not observe longer DNA fragments to be pref-
erentially active compared to shorter ones; Supplementary Figure 3.12C). We also
note that, similar to luciferase functional assays, the majority of active enhancers in
ChIP-STARR-seq datasets exhibit moderate levels of activity, with only a small mi-
nority of very highly active functional enhancers (Supplementary Figure 3.14). The
distribution of GR ChIP-seq signal strength in cEnhs tested by ChIP-STARR-seq is
not as skewed in favor of low-occupancy sites as it is in other contexts (Figure 3.4E),
which is due to the fact that representation in the ChIP-STARR-seq input libraries is
biased towards stronger sites and that we excluded cEnhs with insufficient number
of reads to evaluate their activity. Nevertheless, we do see more weaker sites than
stronger ones, and we also observe much higher levels of activity (~40%) in the
“top” bin (Figure 3.4F) than within the “low” and “medium” ones (~10%). Thus
we can conclude that even though the most visible biochemical signatures are most
likely to correspond to active regulatory elements, in most biological contexts most
functional enhancers in fact reside among the population of cEnhs characterized
by only modest biochemical signatures, underscoring the complexity of the task of
identifying active cEnhs from biochemical measurements alone.
Unlike our previous selections, whichwere heavily biased for TSS distal regions, this
provided an assay that tested both TSS proximal and distal cEnhancers in reporter
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vector that positioned the regions 3’ relative to the contained promoter element.
We selected the genomic regions which were significantly represented in the library
and mapped the corresponding GR ChIP-seq signal (figure 3.4E). While the assay
biased for the overall presence of relatively strong biochemical signals the overall
proportion of enhancers found active in each signal class remains remarkably similar
figure 3.4F.
3.8 Results: Biochemical signature signal is not correlated with measured
enhancer strength
A most prominent misconception is that the top biochemical signals measured will
invariably contain the strongest enhancers in the genome.
The signature combination of H3K27ac and DNAse hypersensitivity outside of
promoter regions has been used by ENCODE to characterize cREs with the potential
for enhancer function.
The overlap of H3K27ac and DNAse hypersensitivity signal is significant for either
C2C12 and G1E-ER4 in terms of numbers, but the two measurements are only
marginally correlated even where they overlap (supplementary figures 3.6 and 3.10).
The human HepG2 and K562 display a similar relationship between DNAse hy-
persensitivity and H3K27 acetylation to that found in mouse C2C12 cells with
comparable numbers of candidate enhancers found in both TSS proximal and distal
portions(supplemental figure 3.13).
Even the TSS distal genome-wide TF occupancy andDNAse hypersensitivity, which
have almost identical genome-wide profiles (Figure 3.1B) have a signal strength
correlation that is mediocre at best.
This lack of correlation between even the partially redundant biochemical measure-
ments made it unlikely to find any correlation to activity on the assay.
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Finally, we examined the quantitative correlation between biochemical signal and
functional activity. Figure 3.5 shows the distribution of active and inactive muscle
(Figure 3.5A) and erythroid (Figure 3.5B) cEnhs relative to the spectrum of DNAse
and H3K27ac signal genome-wide.
While highly active enhancers are more often found among the most strongly
H3K27ac+/DNAse+ regions in muscle cells, overall there is only modest corre-
lation between biochemical marking and functional activity, and it is even less
apparent in the erythroid context. We calculated the correlation between TF occu-
pancy and biochemical marks on one hand, and functional activity on the other and
found only a small positive quantitative correlation (Pearson r 2 ≤ 0.10 ; Spearman
rank correlation r ≤ 0.40 ) between each of these signatures and enhancer activity
(Figure 3.5C), observations that also hold in the other contexts we examined (Sup-
plementary Figures 3.5A-B, 3.8A-B, 3.12A-B, and 3.16B). We also evaluated the
predictivity of biochemical signatures using a receiver operating characteristic curve
analysis (Supplementary Figures 3.4C-F, 3.7C-D, and 3.10C-F). With the exception
of erythroid cEnhs, where the combination of GATA1 and TAL1 was most predic-
tive of functional activity, we find that DNAse and H3K27ac are most often the best
predictors of functional enhancers. Their predictivity, however, is not incredibly
strong, with AUROC values only exceeding 0.8 in K562 and HepG2 cells. Overall,
the combination of H3K27ac and DNAse hypersensitivity appears to be as reliable
a predictor of functional activity as any other biochemical signature, however, even
it is in no way absolutely predictive of function, with only approximately half of
H3K27ac+/DNAse+ actually exhibiting significant enhancer activity.
3.9 Discussion
In this study we examined the degree to which the biochemical signatures of a
candidate enhancer infer active biological function.
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Even though candidate enhancer signatures are selective for a remarkably small
fraction of the genome, we found that only ∼50% are able to individually activate
transcription of a reporter gene. We found that predictivity remained constant across
cell types and different signal-unbiased methods for candidate selection centered on
DNase hypersensitivity sites flanked by H3K27ac modified histones.
We showed that the vast majority of distal candidate enhancer regions are biochem-
ically marked in a tissue specific manner. However, many contain DNA motifs
recognized by TFs specific to other tissue types; potentially allowing them to oper-
ate in a transient plasmid based transfection assay where the DNA likely remains
outside of its native chromatin context. To address this criticism we demonstrated
that the presence of multiple motifs in a region that is biochemically void are not
sufficient to drive function in our assay, even when the region is an enhancer in other
tissue types.
Finally, by studying cEnhs sampled across the full spectrum of ChIP occupancy for
multiple transcription factors, we have demonstrated that themost strongly biochem-
ically marked cEnhs are highly enriched for functionality. However, active elements,
including some of the most powerful, are detected throughout the whole biochem-
ical signal spectrum; with the bulk genome-wide residing in the vast population of
modest biochemical signatures.
A possible explanation for this result can be gleaned from an enhancer located
proximal to the muscle creatine kinase gene. This enhancer, studied over the last
three decades for its outstanding function, displays only a modest myogenin ChIP
signal that does not correlate with the ≥ 95% physical occupancy measured in vivo
on the chromosome (Mueller PR, 1989; Garrity PA, 1992).
We did not observe a particularly strong correlation between the magnitude of
enhancer activity in functional assays and strength of biochemicalmarks, as expected
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if the decoupling of the biochemical measurements from the true physical occupancy
is a genome-wide phenomenon.
These findings are in contrast to earlier studies, which reported over 80-90% activity
for cEnhs defined using, for example EP300 ChIP-seq(Visel A, 2009). This is most
likely due to the fact the these studies only focused on elements selected among
the most strongly enriched and likely to be functional cEnhs rather than the full
spectrum of ChIP-seq signal.
We find a smaller fraction (15-25%) of active cEnhs using a high-throughput ChIP-
STARR-seqMPRA, but similar qualitative patterns across the spectrum of biochem-
ical signatures defining cEnhs. The reasons for the lower activity rates returned by
MPRAs are manifold, and include (but are likely not limited to) the fact that the
DNA fragments used as input to the MPRA are shorter than the length of fully func-
tional regions, and that ChIP-STARR-seq libraries do not provide deep and complex
representation of the original pools of ChIP-seq fragments, leaving many modestly
active enhancers with insufficiently many reads to cross the thresholds of statistical
significance; both of these factors are expected to lead to high false negative rate.
We observe that biochemical marks can be decoupled from each other temporally,
which can impact cEnh predictions based on their co-occurrence. For example,
during muscle differentiation thousands of TF occupancy sites also exhibit DNAse
hypersensitivity and EP300 localization but are not yet robustly acetylated at H3K27,
and conversely, in differentiated cells H3K27ac can remain for some time associated
with sites previously TF-occupied DNAse hypersensitive sites even though they are
no longer open.
A possible mechanism of action for these orphaned H3K27Ac sites is demonstrated
by GR stimulated A549 cells; where a significant subset of biologically active en-
hancers are fromGRoccupancy at these formerly orphanedH3K27ac locations from
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unstimulated A549 cells. These orphaned sites may thus function as a guide for dif-
ferent responses to external stimuli; or lack thereof in different tissues (Supplemental
figure 3.20).
The ENCODE consortium recently compiled a comprehensive list of candidate reg-
ulatory elements (cREs) based on DNAse-seq maps, CTCF occupancy and histone
marks profiles resulting with 1.31M and 0.53M cREs in humans and mouse respec-
tively. (ENCODE, 2012; Moore J, 2018) Elements within the registry were classed
as “Promoter Like State” (PLS), “Enhancer Like State” (ELS) and CTCF.
In order to survey the coverage of the new encyclopedia we annotated our collec-
tion of tested candidate Enhancers which spans several tissues represented in the
encyclopedia either directly, or indirectly (through similar tissues types). Figure 6A
provides an example of our C2C12 tested elements in a 300kb region together with
any ENCODE cRE annotation type (Figure 6B) found within our tested regions.
The full collection of ENCODE Element Registry within this genomic region can
be observed in Figure 6C (Agnostic) together with the biochemical annotations for
two tissues. Embryonic limb (E14.5) was used as the closest match to muscle devel-
opment, whereas liver from the same stage of development was included to provide
an exogenous comparison.
The overall encyclopedia cRE coverage of our combined tested constructs is almost
total (Figure 7A), including a remarkable 83% coverage for Mouse C2C12s (which
had no direct representative). In the negative controls similar coverage was observed
for elements that are expected to work in other tissues based on biochemical occu-
pancy, whereas control elements picked from random regions which were negative
for ChIP-seq signals generally did not register on the encyclopedia.
We also scored all of our elements again split into ones that score as enhances and
ones that do not for cEnhancer (ELS) and cPromoter (CLS). (Figure 7B) We find
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that the majority of elements that we tested score as expected in a cEnhancer (ELS)
state. However we found a surprising number of PLS candidates within our tested
elements, which were preferentially picked to be promoter distal (>2kb). These PLS
elements are often found in intronic regions of genes (for example Figure 6 – R3)
and appear to be an artifact of the high levels of H3K4me3 often found in gene
bodies.
It is unclear if the many elements found inactive in this study, including some
which have been shown to be physically connected to a gene, may not function as
individuals, or they may require a specific enhancer-enhancer or promoter-enhancer
pairing indicated by the physical interaction maps (Zabidi MA, 2015). Indeed
local examples of elements found to function more strongly when paired with a
neighboring cEnhancer can be observed in R2, R3, R4 and R5 of Figure 6A.
Interestingly, R1 shows the opposite behavior indicating that cryptic repressor sites
may be involved in either tuning or suppressing the function of some of these
individual enhancers.
Some of these elements found to be inactive may only able to function in specific cell
contexts. For example, the formation of muscle across different compartments of
the embryo commonly uses myogenin, but involves both different temporal domains
and the exposure to different cofactors. This would impart for an additional level of
control to activate only a subset of the programming.
We expect these findings from the ENCODE functional tests, paired with the col-
lection of higher throughput enhancer assays, to help guide future efforts towards
annotating and further testing the other possible functions of elements inmammalian
genomes. Taken as a combination these elements provide a high quality repertoire
of tested elements and indicate that further testing will likely be needed to fully
catalog the genome in future efforts that expand beyond the high quality DNAse and
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H3K27ac occupancy.
3.10 Methods
Except where otherwise stated, all analyses were performed using custom-written
python scripts. The GENCODE
Cell culture
C2C12 cells
C2C12 myoblasts were maintained and seeded for transfection in 20% FBS sup-
plemented DMEM medium. Upon reaching >80% confluence, the cells were were
differentiated using 2% horse serum and 1 µM insulin in DMEM medium.
G1E cells
G1E cells were grown according to previously published protocolsWang H, 2006;
Cheng Y, 2008; Dogan N, 2015.
K562, HepG2 and A549 cells
K562; HepG2 and A549 cells were grown according to the approved ENCODE cell
culture protocols publicly available through theENCODEportal (https://www.encodeproject.org/).
Functional assays
Cloning and DNA purification
The specifics of each selection set, the promoters used for each cell line, and other de-
tails are publicly available through theENCODEportal (https://www.encodeproject.org/).
Functional assay testing of cEnhs in C2C12 cells
Candidate REs and negative control regions were either PCR-amplified from female
BALB/C purified mouse genomic DNA (Switchgear Genomics) or synthesized de
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novo (Genscript). The resultingDNAwas cloned into a reporter vector 5′ of a custom
TK promoter (SwitchGear Genomics) driving a high-turnover sequence-optimized
luciferase reporter gene. Plasmids were purified using Miniprep kits (Qiagen) and
standardized to 30 ng/µL using the Qubit® dsDNAHS (High Sensitivity) Assay Kit.
For the purpose of testing elements in the myoblast state, undifferentiated C2C12
cells were seeded in 96-well delta surface plates (NUNC) quadruplicates 12 hours
before transfection at a concentration of 2500 cells/well. For the purpose of testing
elements in the myocyte state, undifferentiated C2C12 cells were seeded at a density
of 3500 cells/well. Transfections were carried out with 50 ng of DNA per construct
in each replicate using Lipofectamine LTX, after a 5 minute incubation with a 1:16
dilution with the PLUS reagent (Thermo Fisher). Myoblast plates were lysed using a
Steady-Glo® kit, and luminescence was measured on a plate luminometer 24 hours
post-transfection. Myocyte plates had their media exchanged with differentiation
12-16 hours post transfection and measured following the same procedure 24 hours
later.
Aside from the plate reading step, the entirety of the transfection process was
automated and carried out on a Tecan Freedom EVO 200 robot.
Functional assay testing of cEnhs in K562 and HepG2 cells
The set of K562 and HepG2 cEnh regions was PCR-amplified and cloned 5′ of
the promoter of enhancer assay plasmids containing luciferase and Renilla reporter
genes; cloning was performed by SwitchGear Genomics. Each construct was quan-
tified (using Qubit) and standardized to 30ng/µL before use in transfection assays.
Chris Partridge please review this
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Functional assay testing of erythropoetic cEnhs
G1E candidate enhancer regions were tested in K562 cells according to protocols
publicly available through the ENCODE portal (https://www.encodeproject.org/.
Functional Assay Data processing
For each cEnh or negative control measurement, the ratio between its value and the
corresponding basal promoter vector (relative assay activity) was calculated. Active
cREs were discriminated from inactive using a z-score analysis, comparing the
population of test element technical replicate values to the set of negative controls.
ChIP-seq experiments
Chromatin immunoprecipitation in A549 cells was performed as previously de-
scribed (Reddy et al. 2009) using 2 × 107 A549 cells per replicate. Cells were
sonicated using a Bioruptor XL (Diagenode) on the high setting until the resulting
chromatin was fragmented to a median fragment size of 250 nt as assayed by agarose
gel electrophoresis. GR ChIP was performed using 5 µg of a rabbit polyclonal α-
GR antibody (Santa Cruz Biotechnology sc-1003), and 200 µl of magnetic sheep
anti-rabbit beads (Life Technologies M-280). H3K27ac ChIP was performed using
XXXAb source XXX. After reversal of formaldehyde crosslinks at 65 ◦C overnight,
DNA was purified using MinElute DNA purification columns (QIAGEN). Illumina
sequencing libraries were then generated using the Apollo 324 liquid handling plat-
form according to manufacturer’s specifications (Wafergen).
ChIP-seq in C2C12 cells was performed using chromatin from 2× 107 nuclei, which
was fragmented using aMisonix probe tip sonicator and subjected to immunoprecip-
itation using a robotic ChIP pipeline described before. The resulting purified DNA
was then converted into sequencing libraries and sequenced on an HiSeq 2500 (Il-
lumina) as described previouslyGasper WC, 2014. The following antibodies were
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used: α-myogenin (Santa Cruz Biotechnology SC-12732, lot K2311), α-MyoD
(Santa Cruz Biotechnology SC-32758, lot J3115), α-MEF2 (Santa Cruz Biotech-
nology SC-17785, lot H1913), α-p300 (Santa Cruz Biotechnology SC-585, lot
H3115), α-E2A (Santa Cruz Biotechnology SC-349X, lot B1207), α-H2B (Santa
Cruz Biotechnology SC-357, F2305), and α-H3K27ac (Active Motif 39133, lot
34849).
In addition, publicly availableDellOrso S, 2016 Pbx1 ChIP-seq and Control datasets
were downloaded from GEO accession GSE76010.
For G1E, K562 andHepG2 cells, previously publicly availableENCODE, 2011; EN-
CODE, 2012; Yue F, 2014 ChIP-seq datasets were downloaded from the ENCODE
portal (https://www.encodeproject.org/).
DNAse-seq experiments
In C2C12 cells, DNAse-seq was carried out as follows: XXXXX DETAILS XXX
In A549 cells, DNAse-seq was carried out as follows: XXXXX DETAILS XXX.
For G1E, K562 and HepG2 cells, previously publicly availableENCODE, 2011;
ENCODE, 2012; Yue F, 2014 DNAse-seq datasets were downloaded from the
ENCODE portal (https://www.encodeproject.org/).
STARR-seq experiments
The STARR-seq experiments previously published by Vockley et al.Vockley CM,
2016 were used in this study.
Genomic coordinate conversion
The regions to be tested using functional assays were designed based on the mm8
and mm9 verions of the mouse genome and the hg19 version of the human genomes.
Conversion of the original coordinates to mm10 and hg20 coordinates was performed
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using the liftOver tool from the UCSC Genome Browser UtilitiesTyner C, 2017.
Conservation analysis
Sequence conservation analysis were carried out using the phastCons60way and
phastCons100way conservation tracks, which were downloaded from the UCSC
Genome BrowserTyner C, 2017.
ChIP-seq data processing and analysis
ChIP-seq reads were trimmed down to 36 bp in length and mapped against the
hg20 (for human samples; the male or female version depending on the sex of the
cell line the sample originated from) and mm10 (for mouse samples) using Bowtie
Langmead B, 2009 (version 1.0.1) with the following settings: -v 2 -k 2 -m 1
--best --strata. DNAse-seq reads were processed similarly except that they
were trimmed down to 20bp for A549 samples and 36bp for C2C12 cells (due to
differences in the experimental protocol used to generate the data).
Peak calling was carried out as follows. For DNAse and H3K27ac datasets, MACS2
Feng J, 2012 (version 2.1.0) was run on individual replicates and on pseudoreplicates
(generated by randomly splitting the pooled set of reads for both replicates into two)
with relaxed settings (--to-large -p 1e-1). For H3K27ac control datasets were
subjected to the same treatment (no background/control is available for DNAse
data) The top 100,000 peaks from each replicate or pseudoreplicate (ranked by
q-value) were then used as input into IDR Li Q, 2011. The number of peaks
above a given IDR threshold called as reproducible between true replicates (Nt) and
between pseudoreplicates (Np) were recorded. Peak calling was then carried out
on the pooled set of reads and the top max(Nt, Np) peaks were chosen as the final
set of reproducible peaks. For point-source Pepke S, 2009 datasets (transcription
factors), peak calling was carried out following the same procedure but using SPP
Kharchenko PV, 2008 (version 1.10.1), using the top 300,000 peaks as input to IDR.
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The pooled sets of reads were also used to calculate RPM (reads per million)
enrichment values over elements tested in functional assays.
STARR-seq data processing and analysis
STARR-seq and STARR-seq control/input reads (2×25mers) were mapped as paired
ends to the hg20 version of the human genome using Bowtie with the same settings
as described above. Post-IDR peaks obtained from GR ChIP-seq were used as the
list of candidate cEnhs to be scored using the STARR-seq data. For each STARR-seq
and STARR-seq control/input replicate, raw fragment counts were obtained from
every GR ChIP-seq peak; in addition, the rest of the genome (i.e. the regions that
fall between the post-IDR GR ChIP-seq peaks) was split into bins of at most 50 kb
length, and read counts were calculated for all such regions. The fragment counts for
GRChIP-seq peaks and for the intervening regions were combined together and used
as input to DESeq2Love MI, 2014 for estimating differentially represented regions
between STARR-seq and control/input libraries (at FDR-adjusted p ≤ 0.05). The
lowest average fragment counts value which was scored as significantly significant
by DESeq2 was identified for each comparison, and all GR ChIP-seq regions with
average fragment counts lower than this value were excluded from subsequent anal-
ysis, as such regions were not sufficiently represented in the available sequencing
data to be reliably scored as active or inactive. We also carried out a fragment-level
analysis, in which read counts were calculated for each individual sequencing frag-
ment (defined as the pair of positions {i, j}, where i and j are respectively the 5′
and 3′ ends of the first and the second sequencing reads in a pair), using the same
DESeq2 framework.
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3.12 Figures (Chapter 3)
Figure 3.1: (Caption on next page.)
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Figure 3.1: Biochemical signatures and functional testing of candidate enhancer
elements (cEnhs) in mammalian genomes. (A) Biochemical signatures of cEnhs
and promoters. Active enhancers are characterized by DNAse hypersensitivity due
to nucleosome depletion, by p300 occupancy and by H3K27ac, as well H3K4me1
(not shown). Promoter elements share some of these features, but also associate
with components of the transcription and transcription initiation machineries, and
are marked by H3K4me3 (not shown); (B) Genome-wide commonalities and dif-
ferences between the biochemical signatures of enhancers and promoters. Shown
is the average signal profile around TSS distal (right; defined as regions more than
1kb away from an annotated TSS) and TSS proximal (left) cEnhs (defined as sta-
tistically significant peaks in the respective datasets; see the Methods section for
further detail) in mouse and human cells for TFs (myogenin in differentiating mouse
muscle cell, GATA1 in erythroid mouse cells, and the glucocorticoid receptor upon
Dexamethasone stimulation of human A549 cells), DNAse hypersensitivity and
H3K27ac; (C) The distribution of biochemical signal strength varies over a large
continuum. Shown are the signal distribution for myogenin, p300, DNAse-seq, and
H3K27ac relative to the summits of the top 500, middle 500 and bottom 500 repro-
ducible myogenin ChIP-seq sites (total n = 32, 278) in differentiated C2C12 muscle
cells, as well as the distribution of the cognate myogenin TF binding motif. (D)
Different cell types share a small fraction of their distal cEnh elements, in contrast
to promoter elements. Shown are the common and cell-type specific TSS proximal
(within 1kb of an annotated TSS) and TSS distal DHSs between the human erythroid
K562 and hepatocyte HepG2 immortalized cell lines; E) Outline of cENH selection
approaches, biological systems, experimental design and functional assays used in
this study. Sets of cEnhs for functional testing were compiled based on: TF ChIP-
Seq occupancy measurements (of the master regulators of muscle differentiation,
MyoD and myogenin) in differentiating mouse C2C12 cells; phylogenetic conserva-
tion patterns and TF occupancy measurements (of the regulators of erythropoiesis
GATA1 and TAL1) in differentiating mouse G1E-ER4 cells; TF occupancy (multi-
ple TFs) in immortalized K562 cells; machine learning methods (Self-Organizing
Maps, chromHMM and Segway) defining integrated chromatin states over multiple
histone modification, DNAse and TF occupancy measurements. These cEnhs were
tested using luciferase assays. In addition, DNA fragments from GR ChIP-seq ex-
periments in Dex-stimulated A549 cells were cloned and assayed for activity using
the STARR-seq assay. Active elements identified using these methods were then
evaluated for the presence and distribution of various biochemical signatures.
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Figure 3.2: (Caption on next page.)
114
Figure 3.2: Functional testing of cEnh regulatory activity in mammalian cells. (A)
Functional assay testing of cEnh regulatory activity in the context of muscle differ-
entiation. Shown is luciferase assay fold activity in differentiated C2C12 myocytes
across technical replicates (n = 4). The red arrow corresponds to the mean fold
activity threshold above which elements are considered active. In addition, for each
cEnhDNAse hypersensitivity, H3K27ac status, andmyogenin occupancy are shown,
both as RPM (Read Per Million) signal intensity values and as binary peak calls,
as well as the number of myogenin motif (RRCAGSTG, derived from myogenin
ChIP-seq data) occurrences. Tested cEnhs are sorted by mean fold activity. (B)
Functional assay testing of cEnh regulatory activity in the context of erythropoiesis.
Shown is luciferase assay fold activity in K562 cells across biological (n ∈ [1 : 9])
and technical replicates (n = 4 for each biological replicate). The red arrow cor-
responds to the mean fold activity threshold above which elements are considered
active. In addition, for each cEnh DNAse hypersensitivity, H3K27ac status, and
GATA1/TAL1 occupancy are shown, both as RPM (Read Per Million) signal inten-
sity values and as binary peak calls, as well as the number of TAL1 (CAGMTG)
and GATA1 (WGATAA) motif occurrences. Tested cEnhs are sorted by mean fold
activity.
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Figure 3.3: (Caption on next page.)
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Figure 3.3: Summary of cEnh activity predictions by different selection criteria.
(A) TF occupancy-centered selections. Tested eEnhs selected on the basis of TF
occupancy in the context of mouse muscle differentiation and erythropoiesis and
in human K562 cells were further subselected with the additional requirement of
exhibiting DNAse hypersensitivity and the H3K27ac histone mark. The fraction
of active constructs in negative controls and cEnhs are shown on the left. The
expected number of active cEnhs genome-wide is extrapolated on the left based on
the number of TF+/DNAse+/H3K27ac+ regions in the genome; (B) TF-occupancy
agnostic selections. Tested eEnhs selected using Self-Organizing Maps in HepG2
cells, chromHMM in K562 cells, and evolutionary conservation of GATA1 motifs
in G1E cells were further subselected with the additional requirement of exhibiting
DNAse hypersensitivity and the H3K27ac histone mark. The fraction of active
constructs in negative controls and cEnhs are shown on the left. The expected
number of active cEnhs genome-wide is extrapolated on the left based on the num-
ber of DNAse+/H3K27ac+ (for HepG2 SOM and K562 chromHMM selections)
DNAse+/H3K27ac+ regions with a conserved GATA1 motif (for GATA1 conserva-
tion selections) in the genome.
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Figure 3.4: (Caption on next page.)
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Figure 3.4: Enrichment of active cEnhs in different classes of cEnhs defined by
the strength of their biochemical signatures. (A) cEnhs (rectangle boxes) belonging
to different signal classes (based on ChIP-seq data for myogenin in C2C12 my-
ocytes; “top”: RPM ≥ 10; “high”: RPM∈ [5, 10]; “medium”: RPM∈ [2.5, 5];
“low” RPM≤ 2.5) in the neighborhood of the mouseMyog gene; (B) Genome-wide
distribution of cEnhs in different signal classes based on ChIP-seq data for myo-
genin in C2C12 myocytes; (C) Fraction of active enhancers in different cEnh signal
classes (based on ChIP-seq data for myogenin in C2C12 myocytes; “top”: n = 66;
“high”: n = 49; “medium”: n = 45; “low” n = 27) as well as in negative con-
trols (with not myogenin occupancy; n = 34). Only cEnhs positive for myogenin,
DNAse and H3K27ac were included; (D) Extrapolated number of active enhancers
in C2C12 belonging to each signal strength class based on the genome-wide num-
ber of myogenin+/DNAse+/H3K27ac+ regions. (E) Genome-wide distribution of
cEnhs in different signal classes based on the set of GR ChIP-STARR-seq cEnhs
in A549 cells (“top”: A549 Dex GR ChIP-seq RPM ≥ 10; “high”: RPM∈ [5, 10];
“medium”: RPM∈ [2.5, 5]; “low” RPM≤ 2.5). Only GR ChIP-seq regions signif-
icantly represented within STARR-seq libraries (i.e. with sufficiently many reads
to score as active if they were in fact active) are shown for each signal class. (F)
Fraction of cEnhs exhibiting significant activity in the GR ChIP-STARR-Seq assay
in stimulated A549 cells for each signal strength class.
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Figure 3.5: Absence of general strong correlation between biochemical signal
strength and enhancer activity of cEnhs. (A) Distribution of tested cEnhs relative
to the genome-wide DNAse and H3K27ac signal distribution in C2C12 myocytes.
Shown are DNAse and H3K27ac RPM values for all DNAse+/H3K27ac+ regions
as well as for cEns tested for activity in C2C12 myocytes (outlined circles) and
for occupancy negative control (outlined squares), with tested cEnhs separated into
four classes based on their measured enhancer activity, from dark red (most active)
to yellow (inactive). (B) Distribution of tested cEnhs relative to the genome-wide
DNAse and H3K27ac signal distribution in G1E-ER4 cells. Shown are DNAse and
H3K27ac RPM values for all DNAse+/H3K27ac+ regions as well as for cEnhs tested
for activity (outlined circles) and for occupancy negative control (outlined squares),
with tested cEnhs separated into four classes based on their measured enhancer
activity, from dark red (most active) to yellow (inactive). (C) Correlation between
biochemical signals and measured enhancer activity in C2C12 and G1E cells. See
also Supplementary Figures 3.4, 3.8, and 3.12 for more details.
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Figure 3.6: Summary of activity for cEnhs (A) in the genomic span between the
BTG2 and myogenin loci with the corresponding ENCODE cRE types annotations
from the ENCODE encyclopedia (B), PhyloP conservation track, coupled with the
underlying biochemical annotations from “agnostic”; Embryo Limb and Liver at
E14.5 (C). Candidate Enhancer elements (A) of identical size that appear twice
represent both possible orientations relative to the promoter being tested.
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Figure 3.7: (Caption on next page.)
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Figure 3.7: Summary of cEnhs from our experiments compared to ENCODE cRE
annotations. Elements tested in our selections from bothmouse and human genomes
were classed by whether they are scored as a biologically active/inactive element
and scored for presence (A) and type (B) of ENCODE cREs in each class. Negative
control elements from each study were included for comparison.
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3.13 Supplementary Figures
Supplementary Figure 3.1: The length of thousands of conserved noncoding ele-
ments in mammalian genomes greatly exceeds the size range of MPRA constructs.
(A) The length distribution of conserved noncoding regions in the human genome.
The phastCons100way conservation track for the hg20 version of the human
genome was downloaded from the UCSC Genome Browser. Blocks of conserva-
tion, in which all nucleotides have phastCons scores higher than the indicated
minimum (phCons), were identified, and then merged into larger regions if the
length of the gaps between them was smaller than the indicated maxGap parameter.
The distribution of the lengths of the resulting sets of regions was plotted. This
approach captures the properties of enhancer elements observed in the genome,
which often consist of multiple blocks of highly conserved sequences separated by
gaps of less conserved sequences, resulting in an enhancer element of up to a few
hundred base pairs in length or more. (B) Such an example is shown for the Acta1
gene in mouse.
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Supplementary Figure 3.2: Length distribution of functional assays constructs used
to test cREs in this study. (A) Distribution of functional assay construct lengths
tested in this study in C2C12 cells. (B) Distribution of functional assay construct
lengths tested in this study in G1E cells. (C) Distribution of functional assay
construct lengths tested in this study in K562 and HepG2 cells.
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Supplementary Figure 3.3: Distribution of biochemical signal in tested cEnhs and
genome-wide. Shown is the distribution of ChIP-seq or DNAse-seq RPM values for
the set of cEnhs tested and for the genome-wide set of cEnhwith similar biochemical
signatures shown in Figure 3.3.
126
Supplementary Figure 3.4: Differential marking of proximal and distal cREs by
DNAse and H3K27ac between different cell types and cell states. (A) Promoter-
proximal (within ≤1 kb of an annotated TSS) sites in K562 and HepG2 cells;
(A) Distal (≥1 kb from an annotated TSS) sites in K562 and HepG2 cells; (C)
Promoter-proximal (within ≤1 kb of an annotated TSS) sites in differentiated and
undifferentiated C2C12 and G1E cells; (D) Distal (≥1 kb from an annotated TSS)
sites in differentiated and undifferentiated C2C12 and G1E cells. The overlap score
(Oxy) shown in each cell (x, y) indicates the fraction of peaks in the dataset on the
y-axis that are also found in the dataset on the x-axis, i.e. Oxy = |X ∩ Y |/|Y |.
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Supplementary Figure 3.5: (Caption on next page.)
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Supplementary Figure 3.5: Regulatory landscape ofmuscle differentiation. DNAse-
seq and ChIP-seq experiments against H3K27ac, p300, the MRFs MyoD and myo-
genin, and cofactors (MEF2, E2A/TCF3, HEB/TCF12, and Pbx1) in undifferen-
tiated (myoblast, or “MB”) and differentiated (myocyte, or “MC”) C2C12 cells
were analyzed. Sites were split into multiple subgroups depending on regulatory
factor occupancy (at IDR=0.05) – MyoD-positive (in either condition) sites (A),
myogenin-only sites (B), and MEF2-only sites (C) – then sorted by MRF ChIP-seq
signal (in the following order of priority: myoblast MyoD, myocyte MyoD, myocyte
myogenin, myoblast MEF2, myocyte MEF2); the signal in the 500bp-radius region
around the ChIP-seq peak position is shown.
(Full size files available here:
http://woldlab.caltech.edu/~gdesalvo/eLifeFigApp3a-C2C12-heatmaps-MyoD-
V2.png
http://woldlab.caltech.edu/~gdesalvo/eLifeFigApp3b-C2C12-heatmaps-myogenin-
only-V2.png
http://woldlab.caltech.edu/~gdesalvo/eLifeFigApp3c-C2C12-heatmaps-MEF2-
only-V2.png)
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Supplementary Figure 3.6: Relationship between DNAse hypersensitivity and
H3K27 acetylation during muscle differentiation. (A) Overlap between DNAse hy-
persensitive and H3K27ac-positive promoter-proximal regions in C2C12myoblasts;
(B) Overlap between DNAse hypersensitive and H3K27ac-positive promoter-
proximal regions in C2C12 myocytes; (C) Overlap between DNAse hypersensitive
and H3K27ac-positive distal regions in C2C12 myoblasts; (D) Overlap between
DNAse hypersensitive and H3K27ac-positive distal regions in C2C12 myocytes;
the kernel density of the ChIP-seq/DNAse-seq signal distribution for each class of
sites is overlaid over the scatter plots, and the distribution of tested cREs is shown
in black; (E) Dynamic changes in DNAse hypersensitivity and H3K27 acetylation
upon differentiation for promoter-proximal and distal sites.
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Supplementary Figure 3.7: Functional assay testing of cRE regulatory activity
in C2C12 cells. Fold activity in myocytes (top) and myoblasts (bottom) across
biological replicates (n = 4) and technical replicates (n = 4 for each biological
replicate) is shown. Candidate REs were sorted first by their DNAse status and then
by their mean fold activity. The horizontal dotted line corresponds to the mean fold
activity threshold above which elements are considered active. In addition, DNAse
hypersensitivity, H3K27ac status, p300, MyoD and myogenin occupancy are shown
for each cRE, both as binary (IDR=0.05) calls (red coloring indicates occupancy),
and as RPM scores. (A) cREs selected for their physical proximity to loci known for
their importance tomuscle development (“locus picks”); (B) randomly selected from
the genome-wide set of MyoD/myogenin-occupied regions; (C) negative controls.
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Supplementary Figure 3.8: (Caption on next page.)
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Supplementary Figure 3.8: Correlation between regulatory activity and biochemi-
cal marks in C2C12 cells. Correlation between regulatory activity and biochemical
marks in C2C12 cells. (A and B) Correlation between fold activity and DNAse
hypersensitivity, H3K27ac, p300, myogenin, MyoD and MEF2 occupancy in my-
oblasts and myocytes; (C) ROC curves showing biochemical mark predictivity of
cRE fold activity in myocytes; (D) AUROC (area under ROC curve) values for
different biochemical marks in myocytes; (E) ROC curves showing biochemical
mark predictivity of cRE fold activity in myoblasts; (F) AUROC values for different
biochemical marks in myoblasts.
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Supplementary Figure 3.9: (Caption on next page.)
136
Supplementary Figure 3.9: Regulatory landscape of erythroid differentiation.
DNAse-seq and ChIP-seq experiments against H3K27ac, GATA1, TAL1 and
GATA2 G1E and G1E-ER4 were analyzed. Sites were split into subgroups de-
pending on GATA1 and TAL1 occupancy (IDR=0.05), then sorted by ChIP-seq
signal (in the following order of priority: G1E-ER4 GATA1, G1E-ER4 TAL1); the
signal in the 500bp-radius region around the ChIP-seq peak position is shown.
(Full size file available here: http://woldlab.caltech.edu/~gdesalvo/eLifeFigApp5-
G1E-TAL1-GATA-heatmaps-V2.png)
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Supplementary Figure 3.10: Relationship between DNAse hypersensitivity and
H3K27 acetylation during erythroid differentiation. (A) Overlap between DNAse
hypersensitive and H3K27ac-positive promoter-proximal regions in G1E cells;
(B) Overlap between DNAse hypersensitive and H3K27ac-positive promoter-
proximal regions in G1E-ER4 cells; (C) Overlap between DNAse hypersensitive
and H3K27ac-positive distal regions in G1E cells; (D) Overlap between DNAse
hypersensitive and H3K27ac-positive distal regions in G1E-ER4 cells; the kernel
density of the ChIP-seq/DNAse-seq signal distribution for each class of sites is
overlaid over the scatter plots, and the distribution of tested cREs is shown in black;
(E) Dynamic changes in DNAse hypersensitivity and H3K27 acetylation upon dif-
ferentiation for promoter-proximal and distal sites.
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Supplementary Figure 3.11: Functional assay testing of the regulatory activity of
erythroid cREs. Fold activity in K562 cells across biological replicates (n ∈ [1, 9])
and technical replicates (n = 4 for each biological replicate) is shown. Candidate
REs were sorted first by their DNAse status and then by their mean fold activity. The
horizontal dotted line corresponds to the mean fold activity threshold above which
elements are considered active. In addition, DNAse hypersensitivity, H3K27ac
status, GATA1, and TAL1 occupancy are shown for each cRE, both as binary
(IDR=0.05) calls (red coloring indicates occupancy), and as RPM scores. (A) cREs
randomly selected from the genome-wide set of GATA1/TAL1-occupied regions;
(B) cREs selected among the set of highly evolutionarily constrained non-coding
elements that contain a GATA1 motif (“regulatory potential selections”).
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Supplementary Figure 3.12: Correlation between regulatory activity and biochem-
ical marks in erythroid cells. (A and B) Correlation between fold activity in K562
cells and DNAse hypersensitivity, H3K27ac, TAL1, and GATA1 occupancy in G1E
and G1E-ER4 cells; (C) ROC curves showing biochemical mark predictivity of cRE
fold activity; (D) AUROC (area under ROC curve) values for different biochemical
marks.
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Supplementary Figure 3.13: Relationship between DNAse hypersensitivity and
H3K27 acetylation in immortalized human cell lines. (A) Overlap between DNAse
hypersensitive and H3K27ac-positive promoter-proximal regions in K562 cells;
(B) Overlap between DNAse hypersensitive and H3K27ac-positive distal regions
in K562 cells; (C) Overlap between DNAse hypersensitive and H3K27ac-positive
promoter-proximal regions in HepG2 cells; (D) Overlap between DNAse hypersen-
sitive and H3K27ac-positive distal regions in HepG2 cells; the kernel density of the
ChIP-seq/DNAse-seq signal distribution for each class of sites is overlaid over the
scatter plots, and the distribution of tested cREs is shown in black.
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Supplementary Figure 3.14: Functional assay testing of TF selected cEnhs in human
immortalized cell lines. Fold activity across biological replicates (n =?? ???) and
technical replicates (n =?? ???) for each biological replicate) is shown. Candidate
REs were sorted first by their DNAse status and then by their mean fold activity.
The horizontal dotted line corresponds to the mean fold activity threshold above
which elements are considered active. In addition, DNAse hypersensitivity and
H3K27ac status are shown for each cRE, both as binary (IDR=0.05) calls (red
coloring indicates occupancy), and as RPM scores. (A) cREs tested in K562 cells
(B) cREs tested in HepG2 cells.
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Supplementary Figure 3.15: Functional assay testing of machine learning selected
cEnhs in human immortalized cell lines. Fold activity across biological replicates
(n =? ???) and technical replicates (n =?? ??? for each biological replicate) is shown.
Candidate REs were sorted first by their DNAse status and then by their mean fold
activity. The horizontal dotted line corresponds to the mean fold activity threshold
above which elements are considered active. In addition, DNAse hypersensitivity
and H3K27ac status are shown for each cRE, both as binary (IDR=0.05) calls (red
coloring indicates occupancy), and as RPM scores. (A) cREs tested in K562 cells
(B) cREs tested in HepG2 cells.
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Supplementary Figure 3.16: (Caption on next page.)
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Supplementary Figure 3.16: Correlation between regulatory activity and biochem-
ical marks in human immortalized cell lines. (A and B) Correlation between fold
activity in K562 cells and DNAse hypersensitivity, and transcription factor oc-
cupancy in K562 and HepG2 cells; (C) ROC curves showing biochemical mark
predictivity of cRE fold activity in K562 cells; (D) AUROC (area under ROC curve)
values for different biochemical marks in K562 cells; (E) ROC curves showing
biochemical mark predictivity of cRE fold activity in K562 cells; (F) AUROC (area
under ROC curve) values for different biochemical marks in K562 cells.
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Supplementary Figure 3.17: Enrichment of active cEnhs in different classes of
cEnhs defined by the strength of their biochemical signatures. (A) Fraction of active
enhancers in different cEnh signal classes based on ChIP-seq data for H3K27ac
in C2C12 myocytes. Genome-wide distribution and extrapolated number of active
enhancers in C2C12 belonging to each signal strength class. (B) Fraction of active
enhancers in different cEnh signal classes based on DNAse hypersensitivity data for
H3K27ac in C2C12 myocytes. Genome-wide distribution and extrapolated number
of active enhancers in C2C12 belonging to each signal strength class.
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Supplementary Figure 3.18: Regulatory landscape of GR response in A549 cells.
DNAse-seq and ChIP-seq experiments against H3K27ac across a 12 hour A549
dex response time course were analyzed within GR occupancy (IDR=0.05). Sites
were split using GENCODE annotations into promoter proximal and distal sub-
groups then sorted by ChIP-seq signal for GR; the signal in the 500bp-radius re-
gion around the ChIP-seq peak position is shown. (Full size file available here:
http://woldlab.caltech.edu/~gdesalvo/eLifeFigApp6-A549-heatmaps-V2.png)
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Supplementary Figure 3.19: Testing of cEnhs for activity using ChIP-STARR-seq
for GR in A549 cells with and without Dexamethasone stimulation. (A) Fraction
of active cEnhs detected in each condition. Shown is the number of cEnhs that
passed the minimum representation threshold (see the Methods section for more
details) and were identified as active using DESeq2. (B) Fraction of significantly
active (FDR-corrected p-value ≤ 0.05) biochemically marked individually on in
combinations by H3K27ac, DNAse, p300. (C) Length distribution of active and
inactive STARR-seq fragments as defined by DESeq2.
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Supplementary Figure 3.20: Marking of common and cell state-specific active
cEnhs by H32K7ac, DNAse and p300. (A) STARR-seq data in A549 cells with and
without Dexamethasone treatment (epigenomic datasets from the 3 hour time point
were used); (B) Luciferase assay data in differentiated and undifferentiated C2C12
cells.
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Supplementary Figure 3.21: Distribution of STARR-seq activity in A549 cells.
Shown is the distribution of log2(FoldChange) values (defined by DESeq2) for
STARR-seq experiments in resting EtOH-treated (A) and Dexamethasone-treated
(B) A549 cells.
150
References
Arnold CD Gerlach D, et al. (2013). “Genome-wide quantitative enhancer activ-
ity maps identified by STARR-seq.” In: Molecular and Cellular Biology. 339,
pp. 1074–1077.
ChengYKingDC, et al. (2008). “Transcriptional enhancement byGATA1-occupied
DNA segments is strongly associated with evolutionary constraint on the binding
site motif.” In: Genome Res 18, pp. 1896–1905.
DellOrso SWangAH, et al. (2016). “TheHistoneVariantMacroH2A12 IsNecessary
for the Activation of Muscle Enhancers and Recruitment of the Transcription
Factor Pbx1.” In: Cell Rep. 14, pp. 1156–1168.
Dogan N Wu W, et al. (2015). “Occupancy by key transcription factors is a more
accurate predictor of enhancer activity than histone modifications or chromatin
accessibility.” In: Epigenetics Chromatin. 8, p. 16.
ENCODE, Project Consortium (2011). “A user’s guide to the encyclopedia of DNA
elements (ENCODE).” In: PLoS Biol. 9, e1001046.
– (2012). “An integrated encyclopedia of DNA elements in the human genome.”
In: Nature. 489, pp. 57–74.
Ernst J Kellis M, et al. (2012). “ChromHMM: automating chromatin-state discovery
and characterization.” In: Nat Methods. 9, pp. 215–216.
Ernst J Melnikov A, et al. (2016). “Genome-scale high-resolution mapping of ac-
tivating and repressive nucleotides in regulatory regions.” In: Genome Res. 34,
pp. 1180–1190.
Feng J Liu T, et al. (2012). “Identifying ChIP-seq enrichment using MACS.” In: Nat
Protoc. 7, pp. 1728–1740.
Garrity PAWold BJ, et al. (1992). “Effects of different DNApolymerases in ligation-
mediated PCR enhanced genomic sequencing and in vivo footprinting.” In:PNAS.
89, pp. 1021–1025.
GasperWCMarinovGK, et al. (2014). “Fully automated high-throughput chromatin
immunoprecipitation for ChIP-seq: identifying ChIP-quality p300 monoclonal
antibodies.” In: Sci Rep. 4, p. 5152.
Gertz J Savic D, et al. (2013). “Distinct properties of cell type-specific and shared
transcription factor binding sites.” In: Mol Cell. 52, pp. 1–2.
Hoffman MM Buske OJ, et al. (2012). “Unsupervised pattern discovery in human
chromatin structure through genomic segmentation.” In:NatMethods. 9, pp. 473–
476.
Kellis M Hardison RC, et al (2014). “Defining functional DNA elements in the
human genome.” In: Proc Natl Acad Sci U S A 111, pp. 6131–6138.
151
Kharchenko PV Tolstorukov MY, et al. (2008). “Design and analysis of ChIP-seq
experiments for DNA-binding proteins.” In: Nat Biotechnol. 26, pp. 1351–1359.
Kheradpour P Ernst J, et al. (2013). “Systematic dissection of regulatory motifs in
2000 predicted human enhancers using a massively parallel reporter assay.” In:
Genome Res. 23, pp. 800–811.
Kinney JB Murugan A, et al. (2010). “Using deep sequencing to characterize the
biophysical mechanism of a transcriptional regulatory sequence.” In: Proc Natl
Acad Sci U S A. 107, pp. 9158–9163.
Kwasnieski JC Fiore C, et al. (2014). “High-throughput functional testing of EN-
CODE segmentation predictions.” In: Genome Res. 24, pp. 1595–1602.
Kwasnieski JC Mogno I, et al. (2012). “Complex effects of nucleotide variants
in a mammalian cis-regulatory element.” In: Proc Natl Acad Sci U S A. 109,
pp. 19498–19503.
Landt SG Marinov GK, et al. (2012). “ChIP-seq guidelines and practices of the
ENCODE and modENCODE consortia.” In: Genome Res. 22, pp. 1813–1831.
Langmead B Trapnell C, et al. (2009). “Ultrafast and memory-efficient alignment
of short DNA sequences to the human genome.” In: Genome Biol. 10, R25.
Li Q Brown J, et al. (2011). “Measuring reproducibility of high-throughput experi-
ments.” In: Ann Appl Stat. 5, pp. 1752–1779.
LoveMIHuberW, et al. (2014). “Moderated estimation of fold change and dispersion
for RNA-seq data with DESeq2.” In: Genome Biol. 15, p. 550.
Melnikov A Murugan A, et al. (2012). “Systematic dissection and optimization of
inducible enhancers in human cells using a massively parallel reporter assay.” In:
Nat Biotechnol. 30, pp. 271–277.
Moore J Purcaro MJ, et al. (2018). “ENCODE Phase III Building an Encyclopaedia
of candidate Regulatory Elements for Human andMouse.” In: Submitted. Pp. 1–2.
Mortazavi A Pepke S, et al. (2013). “Integrating and mining the chromatin land-
scape of cell-type specificity using self-organizing maps.” In: Genome Res. 23,
pp. 2136–2148.
Mueller PR Wold BJ, et al. (1989). “In vivo footprinting of a muscle specific
enhancer by ligation mediated PCR.” In: Science. 246, pp. 780–786.
MurthaMTokcaer-KeskinZ, et al. (2014). “FIREWACh: high-throughput functional
detection of transcriptional regulatory modules in mammalian cells.” In: Nat
Methods. 11, pp. 559–565.
Patwardhan RP Hiatt JB, et al. (2012). “Massively parallel functional dissection of
mammalian enhancers in vivo.” In: Nat Biotechnol. 30, pp. 265–270.
Patwardhan RP Lee C, et al. (2009). “High-resolution analysis of DNA regulatory
elements by synthetic saturation mutagenesis.” In: Nature. 27, pp. 1173–1175.
152
Pepke S Wold BJ, et al. (2009). “Computation for ChIP-seq and RNA-seq studies.”
In: Nat Methods. 11, pp. 22–32.
Reddy TE Pauli F, et al. (2009). “Genomic determination of the glucocorticoid
response reveals unexpected mechanisms of gene regulation.” In: Genome Res.
19, pp. 2163–2171.
So AY Chaivorapol C, et al. (2007). “Determinants of cell- and gene-specific tran-
scriptional regulation by the glucocorticoid.” In: PLoS Genet. 3, pp. 94–95.
Taylor J Tyekucheva S, et al. (2006). “ESPERR learning strong and weak signals in
genomic sequence alignments to identify functional elements.” In: Genome Res
16, pp. 1596–1604.
Tyner C Barber GP, et al. (2017). “The UCSC Genome Browser database: 2017
update.” In: Nucleic Acids Res 45, pp. D626–D634.
Visel A BlowMJ, et al. (2009). “ChIP-seq accurately predicts tissue-specific activity
of enhancers.” In: Nature. 457, pp. 854–858.
Visel AMinovitsky S, et al. (2007). “VISTA Enhancer Browser-a database of tissue-
specific human enhancers.” In: Nucleic Acids Res 35, pp. D88–92.
Vockley CM DIppolito AM, et al. (2016). “Direct GR Binding Sites Potentiate
Clusters of TF Binding across the Human Genome.” In: Cell. 166, pp. 1269–
1281.
Wang H Zhang Y, et al. (2006). “Experimental validation of predicted mammalian
erythroid.” In: Genome Res 16, pp. 1480–1492.
Yue F Cheng Y, et al. (2014). “A comparative encyclopedia of DNA elements in the
mouse genome.” In: Nature. 515, pp. 355–364.
Zabidi MA Arnold CD, et al. (2015). “Enhancer core promoter specificity separates
developmental and housekeeping gene regulation.” In: Nature. 518, pp. 556–559.
153
C h a p t e r 4
DISSECTING THE CONTRIBUTION OF INDIVIDUAL
ELEMENTS IN COMPLEX LOCI
4.1 Testing the of entire set of candidate Enhancers affiliated with individual
genes
I set out to test the functional contribution of individual candidate regulatory element
found within loci of a set of genes that are either important to or have been histori-
cally studied in the context of myogenesis. Even though these loci are biochemically
complex and score as connected to a large number of candidate Enhancers com-
pared to the run of the mill gene, the mean functional contribution (and overall
distribution) of these individually tested elements (Figure 2.10) are not found sta-
tistically significantly different at the p=0.05 level (t-test p=0.16; ks test p=0.15)
from randomly selected myogenic occupancy in the genome. These landmark loci,
dissected by years of studies thus provide a reliable platform on which to extrapolate
key mechanistic components on the larger genome.
To this end I tested all of the myogenin occupied and myocyte DNAse hypersensitive
regions, using connectivity as a guide from theMYBPH,myogenin, andMyoD1 loci
in order to sample all detectable candidate Enhancer elements. I also sampled the
myogenin occupancy associated within the connectivity boundaries for ID2, BTG2,
TMSB4X, Desmin and the Troponin loci; all genes either important or selected
because they closely follow the RNA modulation of these well studied genes across
early myogenesis.
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4.2 Proportion of enhancer activity predicted bymyogenin occupancy is iden-
tical irrespective of affiliated gene transcriptional trajectory
Assigning enhancers to a promoter is a difficult task for an algorithm to reliably
perform due to the partial redundancy of some signals which are necessary and/or
beneficial to a biological system. Although when working with a limited number of
genes such as the ones picked above it is possible for a human, based on observation,
to assign nearby candidate enhancers with a possible target gene either by the nearest
expressed gene (cEnhswithin 10kb), or viaChia-pet connectivity (cEnhs >10kb from
TSSes)withinCTCFboundaries. (OtiM, 2016)Becausewework in a differentiation
model, which offers a transition between two states, we can sort genes based on their
transcriptional trajectory across this stage change. (Figure 1.1) For example, genes
that are upregulated more than 3 fold between myoblast and myocytes, genes that
“flat” or in between the two other classes, and genes that are downregulated more
than 3 fold allowing to contrast the enhancers near genes that have large differences
in transcriptional regulation across differentiation of C2C12s. (Kirilusha A, 2014
thesis,Mortazavi A, 2008)
Because genes in the loci we tested tend to fall within stretches of chromosome
segmented by repeating CTCF peaks, and within these regions either behave in a
manner that is similar following the RNA trajectory or remain silent I was able
to assign a gene trajectory to two of our sets of candidate Enhancers. Although
the proportion of elements active is significantly different at the p=0.01 level be-
tween upregulated and flat genes affiliated enhancers (Figure 4.1- Fisher’s Exact
test p=0.0034) the statistically insignificant difference at the p=0.05 level in means
(t-test p=0.11) can also be attributed both the low sample number and to the large
numbers of inactive elements from the MyoD locus (Figure 4.4). In order to obtain
a better sampling for this comparison one would want to ideally select a population
of candidate Enhancers from a larger number of flat expressed genes. Although
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a very small sample (n=11), the activity of enhancers affiliated to downregulated
genes observed suggests an important biological role for repression and silencers
in order to negatively modulate the transcript level of these genes. (Yokoyama S,
2009)
4.3 Myogenin POLII connected occupied candidate enhancers provide identi-
cal proportion and distributions of activity as nonmyogenicDHS elements
similarly selected by POLII connectivity
The myogenin, MyoD and Desmin candidate loci were sampled for myogenin occu-
pancy, and DHS within the boundaries set by the furthest POLII physical connec-
tivity. (Fisher K, 2016 thesis,Li Q, 2011) From these candidates one can compare
the functional contribution of myogenin occupied (n=77) vs physically connected
non-myogenic (DHS) elements (n=51). (With the caveat that some of these sites
might be ChIP-seq non-accessible)
I found that 51% of elements are active in Myogenin based selections contrasted
to 47% being active in the DHS candidate Enhancers. There is no statistically
significant difference at the p=0.05 level in proportion (Fisher’s exact test p=0.72) of
active enhancers and a t-test (p=0.13) of means or KS test (p=0.40) of distribution
of signal also fail to detect a statistically significant at the p=0.05 level between
these two distributions of activity. (Figure 4.2) These regions were tested against an
exogenous TK promoter and it is possible that this observation might be different if
the candidate Enhancers were paired with a promoter that normally responds (and
contains the motifs relevant) in the context of myocytes. (McKnight SL, 1982)
4.4 Individual candidate Enhancer elements and their putative relative locus
contributions
The BTG2, MYBPH, Myogenin and TMEM183A loci are located physically prox-
imal to each other in a 300kb span centered near bp 136M of chromosome 1 in the
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mouseMM10 assembly. (Figure 4.3) Each sub-locus boundary I assigned is marked
by red bars connecting the name box of the locus to the biochemical signal trace
of the CTCF ChIP-seq measurement in C2C12 myocytes. The name of the gene
represents the trajectory of the RNA expression between myoblasts and myocytes.
Genes names are marked as downregulated (blue), flat (purple) and upregulated
(red). The top 6 tracks represent specified myoblast (S) while the bottom 7 represent
differentiated myocytes (D). The additional track in myocytes is myogenin itself,
which is not transcribed in myoblasts, and was therefore not ChIPed in myoblasts.
Tested candidate Enhancer elements are represented by small black boxes below the
biochemical tracks, and numbered for each locus with a similar color scheme to rep-
resent their enhancer function in myoblasts (blue), myocytes (red) or both (purple).
The measured enhancer activity for each element tested, including dissections of
larger elements, are included below. A simplified version of this locus — lacking
the C2C12 biochemical measurements — was used to compare our tested elements
with the ENCODE encyclopedia cRE annotations from agnostic, E14.5 liver and
E14.5 limb. (Figure 3.6)
Although there are other genes in the locus, they behave in a manner that is either
consistent, albeit at much reduced level, with the transcriptional behavior of target
gene, or remain silent entirely. This implies a strong promoter selectivity to target
these enhancers correctly. One notable exception being Chit1, which provides ma-
ture macrophages with the ability to hydrolyze chitin in response to fungal diseases.
(Kanneganti M, 2012) Expression of this gene is associated with Gaucher’s disease
and atherosclerosis, and is likely under tight regulation at the promoter. (Grace
ME, 2007) I Include descriptions of each sublocus individually for the three most
prominent genes in the subsections below.
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BTG2 locus
BTG2 is a gene known to function as a co-activator in transcriptional regulation,
and is broadly expressed across many tissues. (Passeri D, 2006) It is expressed
moderately in both myoblasts and myocytes. The measured enhancer activity (70%
active - n=10) within this locus domain includes primarily enhancers that function
in both cell states. This locus based scoring includes any partially overlapping
elements tested in combinatorics and may appear higher than the non overlapping
selections. The exceptions are the two S-MyoD occupied enhancers (Figure 4.3
- BTG Locus cEnhs 3 and 4) which only score as enhancers upon activation of
the myogenin expression. Interestingly, this genes has been linked to ERalpha-
mediated activation, whichmakes the Tal1/Gata1 ChIP-sites detected near it difficult
to interpret in G1E-ER cells. (Prevot D, 2001)
MYBPH locus
MYBPH, binds to filaments of striatedmuscle cells, it’s function is currently unclear.
(GruenM, 1999) It might helps provide function by locking muscle fibers in place or
providing strength, as it is found strongly downregulated in patients with prolapsed
pelvic organs. (Hundley AF, 2006) This muscle associated gene is driven by
surprisingly strong myocyte specific enhancers (100% active - n=5) within its CTCF
domain region. Three of these enhancers are stronger than the ones found between
the myogenin locus boundaries, although ChiA-PET data indicates that they are
brought into physical contactwith the promoter region ofmyogenin andmay function
to control both genes. Both of these genes have surprisingly weak promoters
(Figure 4.9) and likely rely on the combined effect of these enhancers to achieve
their stratospheric transcriptional levels activated during the differentiation between
myoblasts and myocytes.
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myogenin locus
The myogenin locus includes 6 enhancers that function as individual elements
(46% active - n=13), all exclusively in myocytes. Based on their relatively modest
enhancer function measured, it is likely that these enhancers in the myogenin locus
work best when brought together, or require proximal elements found within their
native promoter in order to truly shine. Based on connectivity data, it is likely that
myogenin recruits one or more enhancers from the MYBPH locus. The candidate
Enhancers affiliated with TMEM183A were only partially sampled but are reported
as tested. (20%active - n=5)
4.5 MyoD1 locus
In the MyoD1 locus again promoter contribution is only modest (Figure 4.9) when
compared to other promoters tested. All biochemical data for this and all following
loci is organized as described in section 4.4 and in the individual figure legends. The
activity detected in this locus indicates that a similar mode of enhancer regulation to
myogenin that requires combinatorics is likely to be in play (Figure 4.4) especially
since the majority of the enhancers tested do not function (16% active - n=19).
4.6 Desmin/Speg locus
The Desmin locus was selected because this gene is similarly transcriptionally
regulated to MyoD but not important to the development of muscle. Both the
promoter of Desmin, and enhancers 1 and 5 within the Desmin locus behave as one
might expect based on the strong transcriptional output of this gene. (29% active -
n=7) (Figure 4.5)
The Speg locus enhancers also behave as one might expect based on the weak
transcriptional output of this gene including 3 modest enhancers in the region.
(75% active - n=4)
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4.7 ID2 locus enhancers suggest that combinatorics are key.
Surprisingly several of the moderately biochemically marked elements in this locus,
including strongEP300marked sites, do not function on their own. Similar candidate
Enhancers are observed in the myogenin, which when tested combination to their
proximal neighbor were able to exert enhancer function. (Figure 3.7)
The findings in this locus show that both biochemically marked regions score as
active enhancers when locally combined underlying the necessity of a synergistic
model of control for these elements, where multiple factors need to be brought
together in order to activate transcription to a high level. (Figure 4.6 - where only
the merged enhancers #2 and #5 function on the assay)
These findings, together with the limited observation in Starr-Seq that larger regions
tend to score on average as more active, implies that even within our tests we may
be too limited to score the context of hundreds of relatively closely spaced regions
on a genomic scale. (Vockley CM, 2016) These findings call for testing enhancer
pairs; and due to vast differences in relative promoter activity observed, one should
also test these enhancers paired with their native promoters. (further discussed in
Chapter 5)
4.8 Troponin neighborhood
I designed an experiment in the Troponin loci where I sampled every large enhancer-
like signature within approximately amegabase of the locus. (Figure 4.7) I made this
collection of high signal myogenin or DHS regions that looked like gold standard
enhancers because of their high H3K27ac signal and included a small set of test
enhancers that fell within first or second intron enhancers similar to the ones found
in CKM (#3,10,12,15,16). Interestingly, 70% (n=17) of these high signal candidate
elements worked as expected (Visel A, 2007), except ones found in the first and
second introns (#10,12,15,16) or within intronic regions of genes (#3).
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An initial key experiment to dissect this finding be to test these cases of first or second
intron enhancers that did not function on their own, positioned 3’ of a promoter, as
the CKM intronic enhancer was found to function irrespective of their orientation.
(Tai PWL, 2011)
4.9 TMSB4X locus
The TMSB4X locus was sampled for enhancers at connected regions at the request
and to support the work of a fellow graduate student in the lab. (Figure 4.8)
Say-Tar Goh aims to show the physical interaction of some of these elements using
fluorescent probes for the promoter and distal enhancer (FISH). Although this region
spans a gene sparse megabase of the genome, in clear contrast to the gene dense
Troponin neighborhood, this gene neighborhood is similarly marked by clear CTCF
boundaries as expected and contains similar proportions of active enhancers (67%
n=9). The elements found to interact with the promoter by ChIA-pet are for the most
part moderately active on their own, in contrast to a gene that is similarly expressed
to myogenin. It is possible that these elements will provide much more powerful
enhancement if brought together physically, however this gene indicates that these
enhancers can act over distances of hundreds of kb, and that our expected locus
structure is largely reflected even in this immense locus. (Ghirlando R, 2016; Oti M,
2016)
4.10 Promoter contribution for MRF genes is modest compared to their an-
tagonists (IDs) and similar trajectory genes
After this saturation test of individual candidate enhancers within key loci we tested
their target promoter proximal regions in order to compare their contributions. These
genes are found to have widely varying degrees of relative promoter contribution.
(Figure 4.9) This small set of promoters, while not enough to lay a statistical claim,
does provide insights that could be further studied. For example promoters of differ-
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entiation specific genes appear to be regulated by the combination of distal elements
paired with a relatively weak promoter proximal region. Flat expressed genes have
promoters proximal regions that confer comparable transcriptional control in both
C2C12s and 10T1/2 fibroblasts. The one striking exception is Desmin which has
likely a myogenic responsive element in the promoter region. (Figure 4.9) This
proximal enhancer, which likely contributes the up-tick in transcriptional output by
the Desmin promoter proximal region detected in the myocytes, shows weak MyoD
occupancy in the myoblast, whereas strong occupancy of both MyoD and myogenin
in the differentiated myocytes.
4.11 Myogenin promoter function
We tested a dissection of the myogenin promoter, which had been studied in several
high profile papers over the last decade. The 1092bp upstream of myogenin pro-
moter in C2C12s roughly matches the function of the elements tested in transgenics
showing a specific activation in the myocyte cells. Their GZ133 and GZ188 and
GZ1092 constructs match up well in function with our reporter assay (Figure 4.9;
MYOG132, MYOG187, MYOG1097) which show modestly increasing amounts
of luciferase reporter. (Yee SP, 1993) Removing just a few basepairs (Figure 4.9;
MYOG125) of the PBX site occupancy site to 125BP, prevents meis binding and
coupling with MyoD to promote myocyte function of the myogenin promoter also
behaved as expected killing all activity. (Berkes CA, 2005) Their study also in-
cluded a second mutant which similarly killed the enhancer function when an Ebox
is deleted which makes up the right side of a combined MSY3 motif later identified
to act as a competitive repressor for myogenic transcription in late stage differenti-
ation. (Berghella L, 2008) This further supported as the 1092-133 fragment which
when tested against an HSP68 promoter loses its muscle specificity instead showing
strong ectopic expression. (Yee SP, 1993)
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4.12 Effect of a repressive Ebox on the Atoh8 promoter activity
We set out to contrast two different but overlapping Atoh8 promoter proximal re-
gions. The smaller region, which excludes an E-box theorized by a fellow lab
member to be a repressive E-box, whereas the second larger construct includes this
potentially repressive E-box. (Kirilusha A, 2014 thesis) At least in this particular
case it appears that the E-box functions as theorized, resulting in a dampening of
the transfection output across all conditions tested. (Figure 4.9)
4.13 Downregulated genes
The downregulated gene affiliated promoters register expression in the myocyte
stronger than in the myoblast. This is surprising but may be the result of the cells
being transfected and then grown to confluence prior to differentiation stimulus,
which possibly gave these constructs more time to accumulate signal. This signal
may be great enough in the case of promoters that it is not atoned even by the faster
turnover (h-pest) luciferase reporter that we chose for our assay. It is also possible
that these constructs rely on distal elements not present on the construct to bring
in repressor elements, which would be partly supported by the DNAse patterns
remaining unchanged at these promoters of downregulated genes.
4.14 Different genes, different regulatory structures?
These findings support a model where regulation of genes is gated by binding very
proximal to the promoter but where distal enhancers, which when acting against the
correct promoter can impart a much higher level of expression. (Longabaugh WJ,
2005) This makes physical connectivity maps important in order to be able to in the
future test enhancer pairings which are likely to be functional. (Further discussed
in chapter 5)
It is also important to note that we selected an heterologous promoter (HSV-TK)
which does not contain any myogenic (or known cofactor) occupancy motifs, unlike
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several promoters that are myocyte specific. Considering different promoters and
pairing sets of enhancers may be important, especially as models are emerging for
promoter elements, where a promoter can be a tight compact region, or a more lax
promoter where elements are sprawled over a larger region (much like enhancers
themselves). (Mikhaylichenko O, 2018) This creates a situation which may be
difficult or even impossible to model in bulk, and might be best resolved on a case
by case basis as needed for further studies into individual gene functions; although
a few potential experiments are proposed in Chapter 5.
4.15 Conclusions
1) Elements affiliated with loci important to myogenesis appear equally predictive
as their randomly selected counterparts (Figure 2.10). Similarly, myogenin and
DHS connected (no myogenin) elements elements appear to not have statistically
significant differences at the p=0.05 level for both the test of proportions (Fisher’s
exact test p=0.72) and means (t-test p=0.13) of enhancer activity.
2) The proportion of active enhancers is significantly enriched for regions affiliated
to upregulated genes (Fisher’s Exact test p=0.0034) compared to flat ones, however
the means of enhancer activity predicted by myogenin occupancy is statistically
insignificant at the p=0.05 level irrespective of affiliated gene transcriptional trajec-
tory. (t-test p=0.11 between upregulated and flat gene affiliated cEnhancers; p=0.36
between upregulated and and downregulated; and p=1 between flat and downreg-
ulated gene affiliated). This difference observed is likely due to the large numbers
of individually inactive elements found within the MyoD locus, which may not be
representative of other flat expressed genes.
3) The function observed when combining our small set of individually inactive
regions in these loci suggests (albeit in numbers too low to test statistically) that
enhancers likely work in combinations of elements either through short range pairs,
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long range pairings or even through recruitment of individually bound (but both
necessary) and separate factors such as shown for AP1 and GR upon stimulation by
dexamethasone. (Vockley CM, 2016)
4) Although a numerically small set, some of our promoter elements are extremely
powerful, whereas the promoters of developmental genes tested in this chapter appear
to be relatively weak, possibly relying on the contribution of combinations of distal
elements. Further testing could eventually resolve this question, although evidence
in drosophila seems to indicate key differences for developmental enhancers which
they report as able to act as "weak" promoters. (Mikhaylichenko O, 2018) The
observed weak promoter function paired with the significant promoter to promoter
connectivity observed in our muscle data raises interesting questions as to the
motifs required to support some of these functions, including both stimulation and
localization.
5) The overall lack of myoblast exclusive enhancer elements being detected from
the occupancy is surprising. (further discussed in Chapter 5) Although exclusively
myoblast active elements are not detected, even near downregulated genes, one
major pitfall is that our selection did not sample for strong myoblast DHS regions
but instead relied onChia-PET connectivity andmyocyteDHSmeasurements, which
are relatively weaker in myoblasts.
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4.16 Figures (Chapter 4)
Figure 4.1: Comparing the enhancers of upregulated (n=44), flat (n=22) and down-
regulated (n=11) genes across differentiation of C2C12 myoblasts to myocytes.
Although the proportion of elements active is significantly different between up-
regulated and flat loci (Fisher’s Exact test p=0.0034); the means of signals is not
statistically significant at the p=0.05 level (t-test p=0.11 between upregulated and
flat gene affiliated cEnhancers; p=0.36 between upregulated and and downregulated;
and p=1 between flat and downregulated gene affiliated.)
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Figure 4.2: Functional comparison of myogenin occupied candidate Enhancers
(n=77) and DHS elements (non myogenic candidate Enhancers - n=51) that are
connected to a TSS. Fisher’s exact test p=0.72 is statistically insignificant at the
p=0.05 level for both proportion of active enhancers while the t-test (p=0.13) and
KS test (p=0.40) are statistically insignificant at the p=0.05 level for the difference
in mean and distribution of signal for both conditions.
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Figure 4.3: BTG2, MYBPH and myogenin locus enhancer activity. Biochemical
data and enhancer assay activity provided for specified myoblasts (blue - S) and
differentiated myocytes (red - D). The top 6 biochemical signal tracks represent data
including ChIP-Seq andRNA-Seq for specifiedmyoblast (blue - S); while the bottom
7 represent corresponding data for differentiatedmyocytes (red -D). Tested candidate
Enhancer elements are represented by small black boxes below the biochemical
tracks, and numbered for each locus with a similar color scheme to represent their
enhancer function in myoblasts (blue), myocytes (red) or both (purple). Genes
loci are outlined by the black box border, with red lines linking to the observed
CTCF boundaries with names encoded to denote the gene as downregulated (blue),
flat (purple) and upregulated (red). The measured enhancer activity in myoblast
(blue) and in myocyte (red) for each element tested is presented below above its
corresponding number. The black bar represents the threshold at which elements
are considered an active enhancer.
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Figure 4.4: MyoD1 Locus enhancer assay activity and Biochemical data provided
for specified myoblasts (blue - S) and differentiated myocytes (red - D). The top
6 biochemical signal tracks represent data including ChIP-Seq and RNA-Seq for
specified myoblast (blue - S); while the bottom 7 represent corresponding data for
differentiated myocytes (red - D). Tested candidate Enhancer elements are repre-
sented by small black boxes below the biochemical tracks, and numbered for each
locus with a similar color scheme to represent their enhancer function in myoblasts
(blue), myocytes (red) or both (purple). Genes loci are outlined by the black box
border, with red lines linking to the observed CTCF boundaries with names encoded
to denote the gene as downregulated (blue), flat (purple) and upregulated (red). The
measured enhancer activity in myoblast (blue) and in myocyte (red) for each element
tested is presented below above its corresponding number. The black bar represents
the threshold at which elements are considered an active enhancer.
170
Scale
chr1:
10333 Myod Exp
C2Undif_Pval10
16506-C2C12-exp-p300-37oC-5271-5406_IP_4C.50mers.3x.2RPM
10480 Myod 60h
16495-C2C12-60h-myogenin-RT-5199-5406_IP_2C.50mers.3x.2RPM
C2Dif_pval10
16507-C2C12-60h-p300-37oC-5404-5406_IP_4D.50mers.3x.2RPM
20 kb
75345000 75350000 75355000 75360000 75365000 75370000 75375000 75380000 75385000 75390000 75395000 75400000 75405000 75410000
Des Speg
Speg
Speg
Speg
NML_13
NML_14
NML_15
WOLD2014JAN_010
NML_16
WOLD2014JAN_084
NML_18
NML_17
NML_19 NML_20 NML_21 NML_22 NML_23
NML_24
NML_25
10333 Myod Exp
3.0597 -
0.0397 _
C2_CTCF_myotube_BROAD
3.1561 -
0.0117 _
myoblast_r2
4.91525 -
0.056497 _
C2_H3K27ac_myoblast_BROAD
5.1478 -
0.0224 _
16506-C2C12-exp-p300-37oC-5271-5406_IP_4C.50mers.unique.RPM
0.8521 -
0.071 _
10636 Signal
50 -
0 _
10638 Signal
50 -
0 _
10480 Myod 60h
9.7958 -
0.1306 _
16495-C2C12-60h-myogenin-RT-5199-5406_IP_2C.50mers.unique.RPM
2.7271 -
0.0619 _
C2_CTCF_myoblast_BROAD
3.5697 -
0.0115 _
myocyte_r2
4.62963 -
0.092593 _
C2_H3K27ac_myotube_BROAD
6 -
0 _
16507-C2C12-60h-p300-37oC-5404-5406_IP_4D.36mers.unique.RPM
0.455 -
0.0758 _
S-CTCF
S-RNA
D-EP300 
DESMIN
SPEG LOCUS
BIOCHEMICAL MARKS AT THE DESMIN-SPEG LOCI 
SPECIFIED MYOBLAST (S) AND DIFFERENTIATED MYOCYTE (D)
BIOLOGICAL ACTIVITY AT THE DESMIN-SPEG LOCI
SPECIFIED MYOBLAST (S) AND DIFFERENTIATED MYOCYTE (D)
S-MyoD
D-RNA
D-MyoD
344 -> 838 13 -> 13 FPKM
S-EP300
S-H3K27ac
S-DHS
GENES
D-myog
D-CTCF
D-DHS
D-H3K27ac
SPEG
45
!"
#"
$!"
$#"
%!"
%#"
&!"
$" %" &" '" #" (" )"
!"
#"
$!"
$#"
%!"
%#"
&!"
$" %" &" '"
!"
#"
$!"
$#"
%!"
%#"
&!"
'()$" '()%" '()&"
MYOBLAST ACTIVITY
MYOCYTE ACTIVITY
EN
H
 A
SS
AY
 A
C
TI
VI
TY
EN
H
 A
SS
AY
 A
C
TI
VI
TY
EN
H
 A
SS
AY
 A
C
TI
VI
TY
cREs cREs
NEGATIVE 
CONTROLSPEG LOCUS
candidate Regulatory Elements
N3N1 N231 2 41 52 3 4 6 7
DESMIN LOCUS
100KB
DESMIN LOCUS
1 1 4 N33N12 673 2 N2
p=0.01 p=0.01 p=0.01
Figure 4.5: (Caption on next page.)
171
Figure 4.5: Desmin Locus enhancer assay activity and Biochemical data provided
for specified myoblasts (blue - S) and differentiated myocytes (red - D). The top
6 biochemical signal tracks represent data including ChIP-Seq and RNA-Seq for
specified myoblast (blue - S); while the bottom 7 represent corresponding data for
differentiated myocytes (red - D). Tested candidate Enhancer elements are repre-
sented by small black boxes below the biochemical tracks, and numbered for each
locus with a similar color scheme to represent their enhancer function in myoblasts
(blue), myocytes (red) or both (purple). Genes loci are outlined by the black box
border, with red lines linking to the observed CTCF boundaries with names encoded
to denote the gene as downregulated (blue), flat (purple) and upregulated (red). The
measured enhancer activity in myoblast (blue) and in myocyte (red) for each element
tested is presented below above its corresponding number. The black bar represents
the threshold at which elements are considered an active enhancer.
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Figure 4.6: LOCUS. Biochemical data and enhancer assay activity provided for
specified myoblasts (blue - S) and differentiated myocytes (red - D). The top 6 bio-
chemical signal tracks represent data including ChIP-Seq and RNA-Seq for specified
myoblast (blue - S); while the bottom 7 represent corresponding data for differen-
tiated myocytes (red - D). Tested candidate Enhancer elements are represented by
small black boxes below the biochemical tracks, and numbered for each locus with
a similar color scheme to represent their enhancer function in myoblasts (blue), my-
ocytes (red) or both (purple). Genes loci are outlined by the black box border, with
red lines linking to the observed CTCF boundaries with names encoded to denote
the gene as downregulated (blue), flat (purple) and upregulated (red). The measured
enhancer activity in myoblast (blue) and in myocyte (red) for each element tested
is presented below above its corresponding number. The black bar represents the
threshold at which elements are considered an active enhancer.
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Figure 4.7: 750mb regions around the Tnni1 gene. Biochemical data and enhancer
assay activity provided for specifiedmyoblasts (blue - S) and differentiatedmyocytes
(red - D). The top 6 biochemical signal tracks represent data including ChIP-Seq and
RNA-Seq for specifiedmyoblast (blue - S); while the bottom 7 represent correspond-
ing data for differentiated myocytes (red - D). Tested candidate Enhancer elements
are represented by small black boxes below the biochemical tracks, and numbered
for each locus with a similar color scheme to represent their enhancer function in
myoblasts (blue), myocytes (red) or both (purple). Genes loci are outlined by the
black box border, with red lines linking to the observed CTCF boundaries with
names encoded to denote the gene as downregulated (blue), flat (purple) and up-
regulated (red). The measured enhancer activity in myoblast (blue) and in myocyte
(red) for each element tested is presented below above its corresponding number.
The black bar represents the threshold at which elements are considered an active
enhancer.
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Figure 4.8: TMSB4X Locus. Biochemical data and enhancer assay activity pro-
vided for specified myoblasts (blue - S) and differentiated myocytes (red - D). The
top 6 biochemical signal tracks represent data including ChIP-Seq and RNA-Seq
for specified myoblast (blue - S); while the bottom 7 represent corresponding data
for differentiated myocytes (red - D). Tested candidate Enhancer elements are rep-
resented by small black boxes below the biochemical tracks, and numbered for each
locus with a similar color scheme to represent their enhancer function in myoblasts
(blue), myocytes (red) or both (purple). Genes loci are outlined by the black box
border, with red lines linking to the observed CTCF boundaries with names encoded
to denote the gene as downregulated (blue), flat (purple) and upregulated (red). The
measured enhancer activity in myoblast (blue) and in myocyte (red) for each element
tested is presented below above its corresponding number. The black bar represents
the threshold at which elements are considered an active enhancer.
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Figure 4.9: Activity of promoter elements for genes upregulated (UP GENES); Flat
expressed genes (FLAT GENES) and for genes that are downregulated (DOWN
GENES) across the differentiation of C2C12 cells from myoblast to myocyte. No
activity threshold is set for these elements as we did not have a distribution of
inactive promoters to test against, however the values are normalized to the activity
of the TK basal promoter vector.
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C h a p t e r 5
DISCUSSION AND POSSIBLE FUTURE DIRECTIONS OF
STUDY
5.1 Are biochemical signatures predictive of enhancer activity?
In order to function as an enhancer, a given stretch ofDNAmust contain the sequence
necessary to recruit the TFs that result in biological function (stimulation) plus those
that physically target (localization) an element to one or more promoter(s). These
localization and stimulation functions need not require separate DNA sequences and
might be guided or modified through interactions with non-DNA binding cofactors.
(Nakada Y, 2004) It is pertinent in thinking about results and developing future
assays thatwemeasured stimulation activity by positioning the test elements adjacent
to the reporter gene basal promoter, which renders the measurement indifferent to
the localization function, if it exists.
Across all transfection tests in muscle, erythroid and hepatic systems, roughly half
of the tested regions functioned significantly while the other half did not. Our
muscle and erythroid studies produced hundreds of active elements, allowing a
search for underlying distinctions between the groups: for example in sequence
motif frequency, biochemical signature, or evolutionary conservation. However,
no significant distinction emerged including across biochemical signatures (Figure
3.5); and TF occupied evolutionary conserved regions had similar predictivity rates
as randomly selected occupied regions (Figure 3.3, Supplementary Figure 3.11).
(Dogan N, 2015) Motif frequency was also not distinguishable between active and
inactive elements.
Further, we found that among the significantly active elements, some are quanti-
tatively much stronger than others. Analysis of these top active enhancers in both
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muscle and erythroid lineages yielded de novo derived motifs but these mapped to
both moderately active and inactive regions indicating that they are not a discrim-
inative feature of top enhancers (Appendix B). The enrichment analysis of these
expanded motifs relative to their presence in the genome would require isolating a
larger set of top enhancers, which are currently numerically limited.
Of course the idea that specific combinations of enhancer elements, including ones
that are individually marginal, weak or strong, offers another layer for future testing
and integration. Our own initial studies of individual loci, including some results
reported in chapter 4, point that this is an important direction to understand the
compendium of different functional elements in the genome. Similar conceptual
examples have been modeled on the basis of functional data for individual GR and
AP1 binding sites coming together - but through looping over greater distances - to
form a functional pair by recruiting proximal AP1 sites after GR binding. (Vockley
CM, 2016)
In this concluding chapter, I draw on my data and analyses, together with other work
in the field, to highlight the questions I currently think are most important together
with newly possible approaches to answer them. Overall, my transfection results
and comparative analyses across systems raised and consolidated general questions
about the relationship of contemporary biochemical andDNAsequence signatures of
enhancer capacity and activity state. (Catarino RR, 2018) A second set of questions
are more specifically raised in the muscle differentiation system concerning the
roles TFs, co-activators, and repressors in establishing and/or maintaining poised
and active states.
5.2 Co-factor recruitment and poised elements
EP300, a major co-activating HAT, is required for normal development and has
been shown in muscle to recruit the SWI/SNF complex to activate transcription
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by acetylating the MyoD TF itself, as well as acetylating histone components of
local chromatin conferring modifications associated with opening of chromatin and
activity of enhancers. (Albini S, 2010) The presence and magnitude of p300/CBP
occupancy, as measured by ChIP, is widely regarded as a superior predictor of
an active enhancer in a given cell type or tissue. (Visel A, 2007) As expected
from current models, we detect relatively strong EP300 signal at cEnhancers which
are only activated after the onset of differentiation, whereas H3k27ac signal is
predominant in sites that already measured as (albeit at a lower level) functional in
the myoblast. (Appendix Figure B.2 and Appendix B)
The myogenesis field does not yet know if this recruitment is selective for a specific
HAT. The lower EP300 signal observed these pan active enhancers (Appendix Figure
B.2) is puzzling when both populations are functionally equal in the myocyte and
suggests that either some of these elements are only functional in very early steps of
differentiation (as the biochemical measurement is temporally decoupled from our
enhancer assay by about 36 hours) or that selective HAT recruitment might be an
possible mechanism for selecting temporal activity of enhancers.
We also currently do not understand how the enhancer/promoter occupancy, once
established, is related to acetylation of its known histone targets and specific TF
targets that include MyoD. Some of the experiments presented in the next section
aim to dissect some of these functions through mutations. (Albini S, 2010)
Factors that can recognize and bind DNA in previously closed chromatin are opera-
tionally known as pioneers. In muscle, PBX1 has been shown to work as a pioneer to
help tether MyoD at a specific compound motif in the myogenin promoter just prior
to differentiation that requires myogenin expression (Berkes CA, 2004). Supported
by my ChIP data, combined with the function assay results, a working model is that
PBX1 contributes across the genome to MyoD/E2 mediated pioneering at a subset
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of the muscle-class Eboxes (RRCAGGTG). (Nakada Y, 2004; Casey BH, 2018;
Fong AP, 2015; Yao Z, 2013)
An attractive idea is that sites in the genome that are pioneered (TF bound but
lacking active enhancer-like biochemical signatures) or poised (containing the bio-
chemical signature of an enhancer, but not scoring as functional), are elements
that will act elsewhere in development in related cell types/states. In muscle these
might include enhancers specific for mature fast-twitch or slow-twitch fiber types, or
enhancers specific for different body locations (head versus axial versus limb loca-
tions), responsiveness to different signaling pathways, or reserved for adult muscle
regeneration. It has also been uncertain if a given bound TF can act simultaneously
as both pioneer and activator.
The portion of our functionally tested elements “pioneered” in myoblast (76 of 142
tested - Figure 5.1A,MyoD occupied inmyoblast); of these, 80% are “poised”mean-
ing they are either H3K27ac marked or EP300-occupied, scored as either inactive
or marginal or the myoblast state. This was a surprise, since the conventional wis-
dom would be that p300+/H3K27Ac+ is a strong predictor of concurrent enhancer
function. These pioneered and (almost entirely) poised elements seen in myoblasts
do continue to be marked in myocytes where they can be compared with a second
set of elements that are only biochemically occupied by MRFs later, at the onset
of muscle differentiation in myocytes (n=66 – Figure 5.1B). Despite their different
biochemical occupancy in myoblasts, in the myocyte state the two sets of candidate
enhancers were not statistically significant at the p=0.05 for both proportion of active
enhancers (Fisher’s Exact test p=1) and for the mean and distribution of enhancer
activity over each population (ks test p=0.21, t-test p=0.26).
Neither population was strongly active in my transfection assays in the myoblast
(though control enhancers were), indicating that while MyoD can pioneer a large
182
group of sites that will later be active enhancers, MyoD occupancy, evenwith EP300,
is not a powerful activator of transcription until the onset of differentiation. It is
worth noting, though some known myoblast enhancers (Figure 4.7 cEnh 11; 4.6
cEnh2, 4.4 cEnh10) and novel (4.3 cEnh 5) that bind MyoD are active in myoblasts
and can be used for a first tier stratification analysis against their myocyte exclusive
counterparts (Appendix B.2) to inform further experiments.
Among the vast majority that are active only in the myocyte state, the switch could
be achieved by a change of heteromeric partner for MyoD; occupancy by a repressor
being released (MSY3) or by post-translational activating modification(s), including
for example acetylation of the MyoD protein itself or phosphorylations on Mef2.
(Albini S, 2010; Molkentin JD, 1996; Black BL, 1998; Berghella L, 2008)
5.3 EP300 interactions with the indirect DNA binding factor MEF2 influence
locus activation
A possible model for this EP300 recruitment observed in myocyte can be made from
the combination of structural studies and our biochemical observations. Structural
studies indicate that EP300 forms up to a potential trimer with the MADS box
TFs of the MEF2 group, as each p300 presents 3 pockets for MEF2 binding in
its Taz2 domain. (Figure 5.2) (He J, 2011) In differentiated Myocytes MEF2
can occupy DNA directly at canonical MEF2 motifs, but when we examined such
class of sites, we found that in myogenesis the vast majority do not recruit EP300
significantly or mediate H3K27ac unless there are also occupying MRF family
factors within a given element. (Supplementary Figure 3.5A and C) The occupancy
heat maps, paired with analysis of myMef2 ChIP-seq data (Kirilusha A, manuscript
in preparation), show that themajority ofMef2 occupancy inmyogenesis ismediated
by off-DNA interactions, with directly-bound MRF/E2 at their RRCAGCTGmotifs.
In striking contrast to DNA-bound MEF2 at its canonical CTAWWWWTAG motif,
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these indirectMEF2/MRF co-occupancies avidly recruit EP300 inmyocytes, and the
regions occupied in this way display the acetylation associated on nearby histones.
(Andres V, 1995)
These observations lead me to propose a model in which off-DNA MEF2 is critical
for EP300 recruitment and activity at a majority of myocyte enhancer elements.
(Figure 5.3). This model covers about 1500 high signal sites, genome-wide, that
differ from the numerically minor set of known myocyte enhancers that contain
functionally critical MEF2 DNA motifs, such as CKM and myogenin. (Molkentin
JD, 1996; Black BL, 1998) These known and well-studied examples are very few in
number and happen to be located within a few kilobases of a TSS, qualifying for my
definition as “promoter proximal” enhancers. Too few of these MEF2-DNAmotif-
requiring elements have been found to clarify if they are a distinct class of element
with respect to EP300.
In the myoblast state, the binding profile analysis shows that MEF2 is also recruited
to non-MEF2 DNAmotif elements, but that this occupancy is independent of active
MyoD binding, possibly acting instead through PBX1 occupancy (see MB only
section, purple arrows Figure 5.6), where it recruits HATs that acetylate the nearby
histones. Note that almost no MEF2 DNA motifs are found in the set of Mef2-
only myoblast (MB) genomic sites; whereas the canonical MEF2 sequence motif
is present at the center of most myocyte (MC) Mef2A exclusive (no MRF) sites.
(Figure 5.6) (Andres V, 1995)
Indeed some of these elements might require promoter proximal regions to facilitate
or pioneer in order to allow for occupancy by Mef2 directly on the DNA. It could be
informative to translocate some of these promoter proximal elements to a location
distal of the TSS and observe their functional output. The opposite, bringing
distal elements to a relatively promoter proximal region may prove informative of
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cryptic enhancers or repressors if the flanking sequences are made accessible by
the translocation. Further, a CRISPR/Cas9 mediated knock-in of a Mef2 DNA
motif in a promoter region of a weakly transcribed gene located near function-
validated muscle enhancers could be highly informative if controlled by knock-in of
a similarly mutated promoter in a known CTCF bounded region generally void of
such enhancers (ie globin locus). (Ghirlando R, 2016)
5.4 A mechanistic model for myogenic locus activation
While this explains occupancy, the finding that MEF2 high signal sites are pref-
erentially physically connected in Pol2 Chia-PET data to promoters (Chi Squared
p=0.0001; irrespective of their transfection function result or their myogenin occu-
pancy signal), suggests that MRF/MEF2/EP300 interactions may also be explicitly
required for bridging distal myogenic elements to other enhancers including pro-
moter proximal ones. (Figure 5.4)
A similar mode of connectivity recruitment to that detected in muscle for regions
occupied byMef2 (Figure 5.3 and 5.4) has been observed in the context of ERwhere
clusters of regions with co-binding by FoxA1 and ER result in a measurable increase
of connectivity compared to clusters of regions that only bind ER. Although the
combinations of factors in ER detects only 60% of sites as connected, we primarily
tested sites that are TSS distal in muscle, also indicated by our 50% baseline of
connectivity within tested regions. Because short connections are stripped from
such analysis due to technical limits of the connectivity assays the proximal sites
may be biased against detecting a connection accounting for the differences noted.
(Vockley CM, 2016)
Interestingly, multiple genes in the btg2 - myogenin locus (Figure 4.3) are similarly
differentially expressed (albeit at vastly different levels) and in both mouse and hu-
man species, even where structural variations have substantially altered the distances
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supporting models that the promoter targeting tolerates changes in absolute distance
and likely even changes in enhancer order relative to the TSS. (Song G, 2012)
The observation that virtually all myocyte specific gene promoters have at least one
MRF proximal occupancy, while 56% of all expressed genes in muscle have aMyoD
binding site near the promoter suggests a possible mechanism for promoter targeting
through MRF binding. (Figures 5.2 and 5.4) (Cao Y, 2010) A candidate mechanism
is that the local chromatin acetylation and basal functional levels require just one
Mef2 pocket on EP300 being occupied; as local pioneering opens the chromatin
to allow for subsequent factor occupancy (Figure 5.3). Instead, supported by the
physical connectivity observed between multiple enhancers, in order to transition
to strong enhancement activity in this model, together with long distance physical
connectivity with other enhancer and/or promoter elements, multiple pockets of
EP300 need to be filled by multiple MEF2 proteins which could each be anchored
in a different cis-element. (Figures 5.2 and 5.3) This creates an appealingly flexible
model, with the potential to integrate a variable combination of distal and proximal
contributions for synergistic activation observed when we combined a few individ-
ual regions. It could also explain why biochemical signals from a multi-element
complex could be poor predictors of what each individual element can do on its
own. (Mikhaylichenko O, 2018; Weintraub H, 1991; Weintraub H, 1990)
A CRISPR-driven point mutation (homozygous) in two of the three EP300 Mef2
pocket(s), assayed with transcriptome and H3K27ac measurements, could test
whether chromatin modification and/or transcription can be maintained with just
a single pairing possible. Since we have the crystal structure of the interacting
domains, we should be able to design disruption of this interaction with relatively
minimal effect on overall protein folding. (Figure 5.2)
This proposed model, requiring multiple occupancy of Ep300 pockets, is consistent
186
with prior observations that 2XMef2 sites can function moderately well to activate
the muscle specific promoter of MYH3 in 10T1/2 cells where the p38 MAPK is
unlikely to be activated. (Molkentin JD, 1996) In the context of muscle, P38MAPK
and Casein Kinase are involved in the early differentiation of myocytes by targeting
Mef2A at its dimerization and DNA binding domains, respectively. ChIP for Mef2,
in the presence and absence of P38MAPK and Casein Kinase inhibitors individually
and jointly, could be used to probe the roles of these kinases.
The discussion above focused on EP300 partly because it is the HAT for which
I successfully identified and validated a strong ChIP antibody and generated the
occupancy data. In addition to EP300, CBP is a paralogous co-activating HAT
expressed in myogenic, erythroid, T-cell and Hepatic lineages, while the myogenic
system also uses a thirdHAT, PCAF,which can acetylateMyoD andTCF3 (Sartorelli
V, 1999), though it remains unresolved whether the TF-modifying activity is distinct
from EP300’s, or is always accomplished in association with it. The presence of the
other two related activities, reportedly having many targets that overlap, and some
that are thought to be specific or biased, means that the as yet unmapped HATs
might complicate genetic experiment and may contribute to discrepancies between
EP300 occupancy levels at a given target enhancer, the nearby histone acetylation
levels and the corresponding enhancer assay output. Large-scale data projects will
likely take on the task of making and testing reagents for PCAF and CBP that could
then be applied in myogenesis.
5.5 The BTG-Mybph-myogenin locus as a test case for promoter targeting by
enhancers
Biochemical signatures were measured in the context of the entire chromosome,
but each element was tested for activity in isolation for all of my transfection
experiments. Random interactions of these transfected elements with non-native
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elements on the chromosomes cannot however be excluded for elements which can
provide localization function. Local combinations of individual elements, including
ones that partner inactive elements with stronger elements to test for synergy, offer
a second layer of organization to probe. There is already precedent in other systems
for synergy among elements (Vockley CM, 2016; Zaret KS, 2016), as well as in
some of my results (Chapter 4), and it is attractive to think that a more exhaustive
test of compound constructs with combinations of elements will better recapitulate
overall locus regulatory activity and correlate better with observed biochemical
signatures. In particular, larger protein complexes, including perhaps more off-
DNA interactions – may be giving substantial TF signatures to elements lacking
individual activity but contributing in the context of larger complexes.
In addition, the differential modulation of individual genes in the BTG2-Mybph-
myogenin locus (Figure 4.3) suggests that enhancers I have identified likely interact
differently on different target promoters. As discussed, the majority (56%) of
myocyte specific promoters contain both an Ebox and MyoD binding within them.
A simple model is that paired MRF/MEF2 motif content in a promoter elevates the
frequency of interactions with distal enhancer elements that contain MRF-only or
other combination in which MEF2 is an off-DNA co-factor or linker protein. The
promoter paired motif structure could then account for preferential targeting of distal
enhancers in myocytes. One of the questions that remains unanswered, is whether
the distal enhancers can provide a similar fold modulation when paired with the
nearby muscle (MyoD-occupied M-class Ebox) and non muscle (no Ebox or MyoD
occupancy) promoters found in the BTG-Mybph-myogenin locus where CTCF sites
in the locus and long distances ranging from up to 100kb have been eliminated by
the assay construct. A direct test by cloning a modest set of strong enhancers in
front of each promoter type would provide insight into whether the enhancers that
we identified do interact differently on each specific promoter type.
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These data, together with a modest set of native single cell RNA-seq can be interro-
gated to tell us if these low, but correlated measurements of secondary genes in the
locus are the result of jack-potting where a few connections with the strong muscle
enhancers to the wrong genes are giving an overall low, but correlated signal. The
indication of a strongly preferential, distance guided system (as ChiaPET connec-
tion strength appears to largely be when observed in the local context of CTCF
connectivity) indicates that the targeting is a somewhat random process. Indeed
modifying CTCF boundaries may only matter in instances when they are necessary
for retargeting enhancers to different promoters in the locus and appears to be a
common function in multiple systems. (Tang Z, 2015; Oti M, 2016; Vockley CM,
2016) Although CTCF knockout in Zebrafish is lethal, and knockdown of this pro-
tein results in significant developmental defects. These findings suggests that it is
necessary to maintain order across developmental transitions, but whether this fac-
tor is required once the correct connections are already established remains unclear.
(CarmonaAldana F, 2018)
5.6 Minimal motif presence and spacing required for biological function
A series of experiments from the early 90s remain relevant. They determined the
minimum number of Eboxes required for detectable function in a reporter assay,
using multiple copies of the right-side E-box (R-sequence) from the CKM enhancer
coupled to a Thymidine Kinase reporter linked with a chloramphenicol acetyltrans-
ferase reporter (R-TK-CAT). While a construct containing 2 Ebox motifs (2R) was
minimally functional, a dose of 4 was required to recapitulate the native level of
activity observed for the CKM TSS proximal enhancer (which natively contains 2
Eboxes (R+L) and a Mef2 motif). (Figure 5.5) (Weintraub H, 1990; Weintraub H,
1991) The proposed model calling for multiple Mef2 proteins being recruited, either
directly to the DNA or indirectly through MRFs to interact with EP300 to strongly
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activate transcription is consistent with these experiments. My own assay results
are consistent with the requirement of multiple occupied E-boxes within a construct
being required for function. (Figures 5.3 and 5.2)
The 4R-CAT experiment, when compared to the function observed for 3R, sug-
gestion that a minimum spacing might be preferable for E-box sites to function
effectively. This is a suggestion rather than a strong conclusion, due to limitations
of the early study: thus the 3R-CAT construct included 4NT spacers in between
each RRCAGCTGYY Ebox whereas the 2R and 4R cats included 6NT spacers in
between the motifs. (Weintraub H, 1990; Weintraub H, 1991) The spacing bias is
consistent with much more contemporary observations that bHLH dimer binding
can affect the shape of the DNA flanking the RR nucleotides. (Gordan R, 2013) The
impact of DNA shape of the wings might affect the Kd of TFs occupying imme-
diately proximal motifs (in a cofactor- and DNA methylation- dependent manner).
(Zuo Z, 2017; Jin J, 2016) Similar spacing is also observed in the context of GR
between GRE and JunD motifs and a similar model was proposed by our collab-
orators where pairs of motifs must either come together locally, or through distal
interactions recruited once the primary factor binds. They also demonstrated in a
small scale test that the distance between motifs impacts the magnitude of enhancer
signal observed on assays similar to my own. (Vockley CM, 2016) However relative
orientation (as suggested below), numbers and motif types might all prove to have
individual effects on this distance effect that are summed to the enhancer activity
observed of each candidate element.
The in vivo spacing between Eboxes in MRF-occupied native functional enhancer
regions I tested was typically >15 base pairs apart with few exceptions. In cases
where Eboxes were more tightly spaced than 15bp, there was always a separate third
more distantly spaced Eboxe(s) present. This argues that, at least in muscle, natural
enhancers have evolved to use multiple E-boxes with relaxed spacing, although
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modern experiments that vary spacing overall large numbers of bar-coded constructs
are needed to establish real optima and thresholds. At the observational level, very
high quality DHS of chemical footprinting will be useful to confirm which motifs
are being accessed most frequently.
In contrast to the general conclusion about MRF-MRF spacing above in the muscle
system, motifs spacing in some other systems appear to be tightly spaced possibly
by evolutionary constraint, such as the GATA1/TAL1 joint motif in erythropoiesis.
(Han GC, 2016) There, two different factor types demonstrate very close spacing
between motifs. I was able to derive this paired spaced GATA1/TAL1 motif de
novo from top erythropoietic enhancers, but it also mapped to several less active,
and even inactive elements indicating that it is not deterministic for top enhancer
function (Appendix B). This indicates that in this system, like ours, additional
epigenetic factors or cryptic repressors are likely at play to control the activity of
select elements. Although they are technically challenging, re-ChIP experiments,
if successful, could clarify which enhancers have true co-occupancy on the same
chromosome at the same time for known factors, versus mutually exclusive patterns
that would have quite different mechanistic implications. And stronger evidence
for occupancy by unknown or unChIPpable factors (including various repressors)
could come from high quality footprinting. These data would also drivemutagenesis
studies within elements to better understand the functional capacity of in vivo Ebox,
MEF and other sites. (Gordan R, 2013)
5.7 The combinatorial control role of paired regions
Physical connectivity data (Pol2 ChIA-PET) shows that some enhancers affiliate
with promoters and with other distal elements, although it is not clear that these
events are simultaneous in the cell. Such pairing of motifs, whether classical muscle
(Ebox+Mef2) or the pairing of 2 Eboxes with Mef2 recruited off DNA, might be
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required in order to generate strong biological function and can be used to regulate
specific effects. (Liu ML, 1994; Weintraub H, 1990) The simplest model uses the
binding of MyoD at the promoter region paired with a singular distal element to
provide regulation of which genes are being preferentially activated. More complex
modeling can involve multiple distal or potentially multiple promoter regions. My
locus-level surveys provide some clues, though in depth dissection will be needed
to develop the story. For example, the ID2 locus contains candidate Enhancer
2 (Figure 5.7) which is MyoD-occupied and appears inactive on its own. This
element only showed discernible enhancer activity when paired with cRE3, which
lacks MyoD binding. A second instance in the ID2 locus is illustrated by cRE4+5,
where individually non-functional myogenic cREs become an active enhancer when
paired. (Figure 5.7) Combining several relatively closely spaced individual modest
enhancers located 3’ of Acta1 also results in a very powerful enhancer (not shown).
Although physical connectivity measurements are unable to detect connections
between such closely spaced elements, there are many distal candidate enhancers
from complex loci that are Pol2 or myogenin ChiA-PET connected between them
that are either marginal or sub-threshold on their own. These elements can be
tested for enhancer function when brought into a plasmid system together with
their connected but distal pairs. Testing combinations of marginal elements, and
combinations of moderate enhancers with some of these nonfunctional elements,
might also improve our understanding of the combinatoric power of these elements.
The relative orientation of individual element pairs is also highly relevant and the
possible combinations should be tested.
However, as mentioned above, the vast majority of muscle promoters, and those of
a large fraction of active genes include an Ebox motif occupied by MyoD. A paired
synergistic activity with MyoD occupied promoters might explain selective strong
activation of individual genes within a locus where multiple promoter to promoter
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connections are also observed. Several studies have shown that these promoter
proximal motifs are necessary to retain the proper developmental patterns of gene
expression. Reviewed in (Molkentin JD, 1996) The vast majority of genes also only
present either none or a modest 1-2 connected distal regions. Elements of this type
that are nonfunctional or marginal on their own, should now be tested against the
context of native promoter(s) proximal elements.
5.8 Possible roles for cellular context
The specificity of occupancy patterns could be imparted by the primary pio-
neering factors, as indicated by the modest 20% overlap between Ascl1/MASH
(RRCAGCTG) and myogenin (RRCAGSTG) occupancy, despite a much higher
overlap in the motif instances across the genome. (Cao Y, 2010; Casey BH, 2018)
Similar numbers were found between B-cell and muscle regions in (Kirilusha A,
2014 thesis). This specificity suggests that some sub-threshold elements might be
poised for higher activity later in the differentiation time-course or under alternate
metabolic or environmental cues. As noted above, this suggests that, in our sys-
tem they are actively repressed or are awaiting an additional positive acting factor
or activating modification - or both. For these reasons, it is possible that some
(maybe a majority of) factor-occupied candidate enhancers that score below thresh-
old in the transfection assay, actually function at higher levels in other muscles
and developmental stages (e.g. of the head, face, limb or diaphragm, or during
regeneration after injury or in response to exercise). In such cases, the biochemical
mark identifies regulatory potential that is not realized in the C2C12 cell line used
by us and the broader field to represent “skeletal muscle”. Testing this possibility
for putative myogenic elements across the life cycle and anatomy of the mouse,
either genome-comprehensively, or even for smaller, yet statistically powered sets of
30-100 elements, is conceptually desirable but not yet technically or economically
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feasible using current methods of germ line genome engineering and whole body
assays.
In mammalian myogenesis, an initial sense of the answer could come from testing a
modest group of connected elements that proved inactive in C2C12 cells, in mouse
transgenesis coveringmostmuscle systems up throughmid gestation in collaboration
with the LBLMouse resource lab. This small set of threshold elements can bemined
for candidates affiliatedwith genes that are strongly expressed in non-skeletal muscle
tissues. (Visel A, 2009) For the broader field, the better answer might be to address
this issue in a different system – organism and possibly tissue type – to gain better
life-cycle access and transgenesis technology. For example, in Zebrafish, automated
high throughput screening platforms have been adapted to track the whole organism
in real time. (Walker SL, 2012)
5.9 Does orientation of aDNAelement affect its potential for enhancer activity
and gene partner selection?
The classical definition of an enhancer element, unlike a promoter, is that it can
operate in an orientation independent manner. My enhancer assay, with a few ex-
ceptions, only tested TSS distal candidate Enhancers in one orientation. From initial
tests done by my collaborator Dr. Christopher Partridge at Hudson Alpha working
in the liver cell line system, it appears that the orientation of enhancers relative
to the promoter can affect relative activity significantly, but that both orientations
typically score as enhancers. I also tested a small set of elements from the myogenin
locus in both orientations, with similar results. Candidate elements that failed to
function in one orientation, also mainly failed when tested in either orientation. The
quantitative differentials for active elements might have improved the correlations
of activity level with biochemical marks, but they did not. The results overall did
not improve the correlation of measured activity with myogenin occupancy, p300 or
194
active histone mark levels. Our preliminary results showing significant directional
bias do suggest future clarification within constructs and especially at their native
locations through CRISPR mediated genome editing. This requires allele-marked
reporter genes to quantify impact within the same cell. Because the RR-Ebox is
directional, and might be preferentially be occupied on either the Watson or Crick
strand, depending on the MRF/E pairing, elements making connections to more
than one gene can be tested in a bi-directional promoter-reporter system, along with
internal RRCAGSTG orientation flips, to test if a single distal element is potentially
able to drive both genes simultaneously, or one preferentially depending on the motif
orientations. (Polson A, 2011).
A similar orientation selective mechanism can be gleaned from the bi-directional
promoters controlling 10% of all genes in the human genome. These genes share
a set of elements that have the potential to act to activate both genes or, depending
on context, selectively act on one gene specifically. (Trinklein ND, 2004) Similarly,
in ChIA-PET data, some of our tested enhancers are cross-connected or connected
to multiple genes over long distances. We noticed that many of our most notable
biochemical signals, and a portion of ourmost active enhancers contain sets ofmotifs
that appear directionally paired in opposing orientations. Although our numbers are
too small for any statistical claims, they raise an unresolved question as to whether
some of these more complex elements (called by some “super-enhancers”) are able
to cross-connect multiple genes and/or distal elements to act as a stabilizing bridge.
Indeed some of these sites may work to selectively create zones of outstanding
activity by creating localized enrichments of TFs. (Hnisz D, 2017)
Similar selectivity ofmotif orientationwas found to be necessary for CTCFmediated
to establish looping specificity. (Ghirlando R, 2016; Oti M, 2016) The pair of strong
enhancers upstream of myogenin, in the intronic region of MYBPH (Figure 3.6 -
R3), and between Adora1 and myogenin (Figure 3.6 - R4), could be inverted by
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CRISPR in vivo (avoiding the nearby CTCT sites) and may be helpful to further
our understanding of the orientation requirement of these key regulatory elements.
One could also test the most orientation-sensitive (in transfection) sites identified
by our collaborators at Hudson Alpha in their respective native locations. I noticed
that these elements were often proximal to mapped CTCF occupancy sites, so one
would want to test both an orientation flip of the enhancer alone, and later for both
the enhancer and nearest CTCF site together.
5.10 High-throughput methods for enhancer screening
When I began this project I hoped to gain insight into the source(s) of large quanti-
tative differences observed in the enhancer “strength” of different elements. These
quantitative differences were reproducible and significant in my survey, spanning
nearly two orders of magnitude.
Though the activity distinction is encoded in the transfected DNA sequence, my
assays did not include finer scale mapping to locate the source of the difference.
New methods now allow the field of cis-regulatory element functional analysis that
moves to higher scale numerical tests for both gain-of-function and loss-of-function.
While they hold promise for finding more examples, these systems are not a cure-
all. New methods that now allow the field of cis-regulatory element functional
analysis to move to higher scale numerical tests for both gain-of-function and loss-
of-function hold promise, yet these systems are not a cure-all. Scaled-up versions
of the assays reported here permit samplings on the order of 1E3-1E6 individual
elements. (Arnold CD, 2013; Murtha M, 2014)
While they provide increased diversity of sampling and improved statistical power,
their designs retain the effects of transient transfections, including unintended re-
porter construct issues. (Muerdter F, 2018) They also add some new technical
and background challenges. For example, in massively parallel reporter assays, the
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size of elements (~80-200bp) is currently smaller than the size range of observed,
conserved TF occupied regions of the genome (Supplemental Figure 3.1). These
multiplexed assays are also affected by technical issues stemming from competition
and or promoter crosstalk from the bacterial origin of replication that is present
on the transfection plasmid but this later can likely be resolved in the future by
PCR amplification or cleavage of part of the plasmid prior to transfection of DNA.
(Muerdter F, 2018) Specifically, Starr-Seq in Drosophila and FIREWACH in human
cells both report ~24 and 28% respectively of biochemically marked elements as
active enhancers. (Arnold CD, 2013; Murtha M, 2014)
This is in contrast to our assays, across different cell types and gene systems, tested
larger regions (~400-1kb+; Supplemental Figure 3.1), and reported that ~50% of
elements that have clear biochemical signatures associated with activity showed
detectable reporter function. This 50% is similar to the overall enhancer discovery
rate in the LANL ENCODE transgenic enhancer assay in which candidate elements
were selected for activity primarily from individual tissues, suggesting that this 50%
rate is likely accurate at least in the context limited to a single state of development.
(Visel A, 2007; Visel A, 2009) However, we also show that the majority of the
remaining 50% hover just below the activity threshold of statistical significance.
While this creates uncertainty for any one element in the population, the group as a
whole is detectably different from a group of known tissue-specific enhancers from
the immune and nervous systems.
The power of the higher throughput assays might yet be useful in the context of
testing "artificial enhancers" such as the experiment in muscle where a minimum of
two RR-Eboxes from the R site of the CKM enhancer were found to be a requirement
for basal level biological function. (Figure 5.5) (Weintraub H, 1990) These large
numbers of candidate elements permits for tests of relative functional output for all
RR-Ebox motif permutations individually (as an internal control) and combination
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pairings (with both distance and permutations of motifs) within variable relatively
short synthesized oligo sequences (~200bp). (Figure 5.8)
An initial test in the GR system showed that distance between AP1 and GR binding
can significantly alter the activity level detected, suggesting an expanded numerical
test. This same type of assay can be used to test distance requirements between
both pairs of functional Eboxes (for example expanding 2R-cat to the same relative
distance between Eboxes as 4R-cat) and distances between classical muscle E+Mef2.
(Vockley CM, 2016) Similar tests can be performed in the erythroid system for the
more closely paired Tal1/GATA1 motifs. (Han GC, 2016)
Insuring high complexity and proper sequencing of the plasmid pool transfected
would also allow for the resolution of preferred enhancer orientation, distance and
motif numbers. The results from this experiment could then guide further mutation
and orientation flip experiments in vivo.
5.11 Searching for active repression
The class of negative regulatory elements termed repressors might provide modula-
tory input for transcription, although their actual biological contribution remains to
be understood. In contrast, “silencers” are able to suppress expression of a gene and
have demonstrated biological function. For example, in other systems a silencer has
been shown to play a role in lineage selection and determination to CD8+ T cells by
suppression of the CD4 gene. (Donda A, 1996; Sawada S, 1994)
Region 1 (R1) figure 3.6 of the BTG2 locus points to repressor content in reg-
ulatory genomic regions. The experimental observation was that retaining a se-
quence located between the two independently active, biochemically marked re-
gions, flat-lined enhancer activity observed for either flanking element. A further
example might be the partial repression of activity observed in figure 4.10 for the
ATOH8 promoter when a larger region containing a ZNF238/RP-58 susceptible
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Ebox (CAGSTGT) is included in the construct. The interpretation of these partial
results is however confounded in whole population measurements and the effect in
individual cells remains unclear. For example, the transfection results obtained for
the ID2 enhancers 2+3 sites appear to be marginally downregulated at 24 hours post
differentiation with function in individual subpopulations of cells unknown. (Figure
5.7) In contrast, the function of this site measured over a population is further ablated
by RP58 by 60 hours. (Kirilusha A, 2014 thesis, Weintraub H, 1990; So KK, 2017;
Han GC, 2016; Blackwell TK, 1990; Yokoyama S, 2009)
Many of these candidate repressors are known to bind DNA at specific sequence
motifs. (Mortazavi A, 2006) Interestingly, over the years a variety of primarily acti-
vating factors have also been sometimes associated with repressor activity, including
MyoD itself. (Jayavelu ND, 2018; Chu C, 1997)
A recent study tested for repressor activity using a STARR-seq library containing
genomic regions that contain known repressor as well as putative candidate repres-
sive function for known activators including TCF12 and GATA1-4. (Jayavelu ND,
2018) Even though MyoD was not included, no repressive function was detected
for any of the activating TF motifs; although these might not be detectable over a
population of cells in an assay primarily designed as a first tier test for enhancer
activity. The candidate repressive elements successfully isolated a vast library of
validated repressor sites. They also scored for known repressive factor binding and
found an identical 50% activity rate to our own. (Jayavelu ND, 2018)
These findings however raise the important and thus far less-studied question of
repressor contributions, especially for genes where multiple distal elements are
brought into contact. The testing of MRF ChIP-seq sites together with point muta-
tions over the known repressor motifs, and conversely over the Ebox motifs in a high
throughput cis-repression element assay would increase our ability to understand
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the functional contribution of each of these types of candidate elements individually
at first, and later using CRISPR-mediated insertions or deletions, to test the ability
of some of these repressors by positioning them proximal to otherwise powerful
enhancers.
5.12 The possible role of epigenetic context
Although we have studied and measured the “regulatory potential” of a given DNA
segment, whether that regulatory potential is free of epigenetic input remains unclear.
Most of the regions that we tested span from 2-8 nucleosomes in vivo and could
be chromatinized after entering the nucleus. It is possible that some candidate
enhancers do not function simply because they lack sufficient histone context without
prior sequential pioneering of the given DNA region. (Zaret KS, 2016) Further, in
a transfection system DNA methylation might affect the naked DNA entering the
cell especially at RP58 susceptible Eboxes which are present in approximately half
of the tested elements (both active and inactive). (Pollack Y, 1980)
One unanswered question is whether chromatin, and coherent native histone marks,
are present in these transfected regions of DNA. Dr. Nergiz Dogan and Dr. Ross
Hardison tested mouse candidate enhancer elements against a human B-globin
promoter in K562 cells. Many of the tested candidate enhancers whether functional
or not come from in vivo highly acetylated locations. This “cross species hybrid”
assay presents an opportunity to test the chromatin context of transfected DNA. A
ChIP-seq against H3K27ac and H3K27me3 aligned to the mouse genome from a
population of transfected cells with a set of strong enhancers can be compared to a
second population of cells transfected with strongly acetylated regions that scored
inactive on the assay. This should answer, with a relatively modest investment,
whether the lack of function of these regions is tied to the native histone context not
being reflected selectively. This is especially important because naked DNA is being
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introduced, and the histone context may be set simply incorrectly over a secondary
site with higher affinity, which might not have been pioneered and accessible in
vivo. The same strategy applies to accessibility measurements (DHS/ATAC) to
confirm that similar sites are being accessed on the plasmid vs in vivo. The pairing
of these measurements should allow us to assay whether a set of elements are
being repressed by binding over unexpected motifs, modified of histone context (if
any), DNA methylation, or possible lack of ordered pioneering. (Zaret KS, 2016;
Catarino RR, 2018)
DNA methylation might play a large role on modifying the affinity of TFs to seem-
ingly identical DNA sites. (Jin J, 2016; Zuo Z, 2017) This is especially interesting
in the context of muscle because the cell line 10T1/2 treated with 5-Azacytidine re-
sults in the activation of several mesenchyme derivatives including myocytes. More
recently 5-Azacytidine has been shown to provoke the transdifferentiation of cardiac
cells to myocytes. In general myoblasts threated with 5-Azacytidine will progress
through differentiation more quickly. (Taylor SM, 1979; Kaur K, 2014; Pollack Y,
1980)
I looked through the ENCODE human WGBS data available for human myoblast
cells in order to ascertain the methylation status of enhancers which function specifi-
cally in the myocyte. Although myoblasts are the precursor state, all of the candidate
enhancer regions displayed sparse hypomethylation even when occupied differen-
tially in myocytes only. It is important to note that I could not find instances of
differentially methylated regions (DMRs) directly over the Eboxes but the effects of
5-Azacytidine on 10T1/2 cells indicates that hypomethylation might be necessary
to achieve differentiation into myocytes. Muscle tissue also has one of the highest
levels of non CG methylation (mCH) in adult tissues which likely further affects
occupancy patterns. (Schultz MD, 2015)
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In the case of the glucocorticoid regulatory element (GRE),methylation on the flanks
of the motif results in an improved equilibrium dissociation constant. (Jin J, 2016;
Zuo Z, 2017) This might explain why the glucocorticoid receptor (GR) might be
able to so effectively bind to “orphaned” H3K27ac sites that are currently excluded
from the population in use at the time of dexamethasone induction. (Supplemental
Figure 3.20A -Middle histogram; note the lowDNAse but relatively high H3K27Ac
coverage of these regions) In contrast the estrogen receptor is unaffected by flanking
methylation sites but core motif methylation prevents binding. (Jin J, 2016; Zuo Z,
2017) The Ebox of Clock/bmal1 (a bHLH heterodimer) instead is unaffected by
central methylation of the core EBOX, but is affected by methylation along the
immediate flanking nucleotides of the Ebox. (Jin J, 2016)
This result taken together with the above observations of 5-azacytidine, and the
distinct binding profiles of both native and overexpressed TFs such as ASCL2 and
MYOD (both ofwhich bind separate populations of an identical RR-CAGCTGEbox)
suggests that the pattern of DNA methylation over these sites is likely constant, and
that the pattern of binding is regulated by secondary co-factors developmentally
prior to the myoblast state. (Casey BH, 2018) This is likely tuned by co-factors,
including splice variants and relative phosphorylation state culminating in the highly
selective occupancy observed. However, a deep dissection of the methylation status
over the motifs may be necessary to fully understand the control of specific TFs.
5.13 Conclusion
These experiments aim to leverage currently available technology to address ques-
tions that remain yet to be answered, including the characteristics of the stimula-
tion functions of enhancers (combinatorics, orientation, cellular context and motif
requirements) together with their localization function (promoter targeting pref-
erences) all of which are necessary to maintain; and paired with silencers and
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repressors to regulate the correct levels of transcriptional products of genes.
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5.14 Figures (Chapter 5)
Figure 5.1: Comparison of myoblast and myocyte activity for cEnhancers that are
(A) myoblast MyoD occupied (MB+ and MC+) vs (B) cEnhancers only occupied
by MyoD upon the onset of differentiation (MB- and MC+).
204
Figure 5.2: Proposed mutation experiment in the Taz2 domain of EP300 affecting
the ability to bind multiple Mef2 molecules.
205
Figure 5.3: Proposed model for minimal requirements of TF occupancy for histone
modification and active enhancers in myocytes
206
Figure 5.4: POLII Chia-PET connectivity is highly enriched in high vs low Mef2
signal tested cEnhancers
207
Figure 5.5: Model of 1R vs 2R cat as a demonstration of possible minimal functional
requirements of DNA motifs.
208
Figure 5.6: Heatmap of ChIP-seq signals for Mef2 exclusively occupied sites of the
genome (MRF -)
209
Figure 5.7: Summary of combinatoric Enhancer activity in the ID2 locus.
210
Figure 5.8: High throughput Ebox motif flanks and combinatorics test.
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A p p e n d i x A
TRANSFECTION ASSAY DATA FOR ALL 371 REGIONS
TESTED IN MUSCLE
The table is available at:
http : //woldlab.caltech.edu/~gdesalvo/Woldtrans f ectiondata01152017.xlsx
The following is a description of the data available in the table: 1. Cell type
/ Cell line: C2C12 Myoblast C2C12 Myocyte 10T1/2 Fibroblast 10T1/2 Mock
Differentiated
2. Transfection protocol: transient transfectionElementswere cloned bySwitchGear
Genomics 5’ of a custom TK promoter driving a PEST containing synthetic lu-
ciferase reporter gene. 50ng of fluorometer measured single plasmid was transfected
for each technical replicate using the Lipofectamine® LTX with Plus™ reagent.
https : //tools.thermo f isher .com/content/s f s/manuals/
Lipo f ectamineLTXPLUSReagprotocol .pdf
3. Assay reagent: Steady-GloLuciferaseAssaySystem https : //www.promega.com/
products/reporter − assays − and − trans f ection/
reporter − assays/steadyglo − luci f erase − assay − system/
4. Element design/prediction A first set of candidate Regulatory Elements were
selected to sample occupancy signal in a Myogenin ChIP-Seq experiment.
A second set of candidate Regulatory elements were selected to sample Myogenin
occupancy affiliated with key genes that are modulated at the transcriptional level
during the differentiation of muscle.
216
A set of negative control elements were selected from previously characterized
T-cell and neuronal enhancer regions that contain a muscle class E-box motif.
5. Replication design: The candidate Regulatory Elements were assayed when
possible as biological replicate (transfections performed on different days), with 2-4
underlying technical replicates for each biological replicate.
6. Explanation of numerical assay value, including normalization performed: The
units for activity are “fold change relative to activity from parental vector”. Each
group of transfections included a transfection with the control parental firefly lu-
ciferase plasmid that lacked a test DNA insert.
7. Assignment of Activity bin for each tested DNA segment (also stated in primary
data) The rule for declaring a DNA segment an "Enhancer" is that its fold change is
at least two standard deviations above the mean of the negative control elements set
as a whole. All others are declared "NotEnhancer".
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A p p e n d i x B
DE NOVO MOTIF ANALYSIS
The vast majority of our candidate Enhancer regions (represented here by a random
sample of 77 elements) are only active in the myocyte state. (Figure B.1) Over the
entire population of over 300 elements tested a modest set of 24 also function at
significant levels in the myoblast state. (Figure B.2 Pan Active Enhancers)
These pan active enhancers are different and perhaps interesting; but end up invari-
ably upregulated in activity upon differentiation raising the possibility that most of
the signal is coming form early differentiating cells. These can however be com-
pared to elements which are strictly specific for enhancer function to the myocyte
state. (Figure B.2)
The population of pan active enhancers trends towards being more active than the
myocyte specific enhancers, but fails to meet statistical significance at the p=0.05
level (t-test p=0.18). This difference in activity observed can be explained because
we are assaying at 24 hour post differentiation, and the pan active elements had a
head-start in terms of activity in the myoblast which if subtracted would bring the
populations in line.
The means of signal of EP300 (Welch t-test p=0.018 - mean of 42.5 (specific) and
22.2 (pan)) and H3K27ac (Welch t-test p=0.013 - mean of 16.5 (specific) and 36.0
(pan)) appear selectively different at the p=0.05 level across these two classes of
elements, with EP300 signal being stronger in signal in elements recently accessed,
while H3K27ac appears to have on average stronger signal in elements that were
already active at the myoblast state. The DHS ratios for myoblast/myocyte across
both classes of enhancers are also presented in Figure B.2. Both of these findings
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are in accord with current models that EP300 is recruited to sites being activated
functions to deposit H3K27ac, which can also lag behind activity. (Zhang JA, 2012;
Catarino RR, 2018)
In order to investigate potential motifs selecting for activity in these myocyte specific
enhancers, I performed de novo motif finding on these two classes of elements. As
expected both derived an RRCAGCTG E-box but the elements specific for activity
in the myocyte also derived an Ebox-like (but expanded) motif. (Figure B.3)
Observation of ChIP-seq and histone mark data from the myoblast state within the
boundaries of the pan active enhancers show that half of these active elements are not
likely to be driven byMyoD. (Figure B.4) Interestingly strong H3K27ac is present in
some of these low level MyoD/EP300 sites indicating that they are either orphaned
H3K27ac locations (ie methylated on the chromosome?) or non MRF enhancers
which recruit H3K27ac through another HAT present in our system. If these sites
were numerically greater one could score for the presence of other TF motifs (ie
AP1) and relative presence or absence of EP300 occupancy compared to the MyoD
occupied half. (Figure B.4)
In the regions co-occupied by Tal1 and GATA1— two key Erythropoietic TFs — a
new paired recognition motif has been derived. This motif has a half E-box (CTG)
locked in orientation with a GATA motif (AGATAA) about 8 base pairs away. (Han
GC et al. 2016) After discovering a novel motif in muscle I used a similar strategy in
Erythropoiesis using different classes of active enhancers to derive de novo motifs.
(figure B.5) I was able derived both a CGT half E-box and a AGATAA motif from
average enhancers. In the top enhancers I also derived both a full CATGTG E-
box and a GATA motif that is similarly spaced to the paired motif derived from
Tal1/Gata1 co-occupied regions.
Unfortunately in both muscle and erythropoiesis these new motifs appear to map
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to both active and inactive (pan and specific for muscle) cEnhancers, meaning that
they are not deterministic of (strong); or cell type specific enhancer function.
B.1 Figures (Appendix B)
Figure B.1: Summary of cEnhancer activity ranked by affiliated geneRNA transcript
ratio across the differentiation of C2C12 cells (High -> Low; myocyte/myoblast
ratio). The line on each plot represents the activity threshold at which tested
elements are considered enhancers in each cell state. Elements in myocyte are
proportionally more active compared to elements in the myoblast (Fisher’s exact
P=0.01).
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Figure B.2: EP300, H3K27ac and DHS signal in specific vs pan active enhancers
across myoblast to myocyte differentiation. The means of signal of EP300 (Welch
t-test p=0.018 - mean of 42.5 (specific) and 22.2 (pan)) and H3K27ac (Welch t-test
p=0.013 - mean of 16.5 (specific) and 36.0 (pan)) appear selectively different at the
p=0.05 level across these two classes of elements, with EP300 signal being stronger
in signal in elements recently accessed, while H3K27ac appears to have on average
stronger signal in elements that were already active at the myoblast state.
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Figure B.3: Motifs derived from specific vs pan active enhancers across myoblast
to myocyte differentiation.
Figure B.4: EP300 and H3K27ac ChIP-seq signal in myoblast for pan active en-
hancers; ranked by MyoD signal.
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Figure B.5: Erythroid cREs and negative control elements tested in K562 cells, by
activity.
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A p p e n d i x C
ENCODE CHIP-SEQ DATA SUBMISSION
Although these early measurements provided much of the groundwork for selecting
candidate elements for my thesis, it was necessary for ChIP-Seq measurements
to match the new standards in the field (1PCR) and provide independently grown
duplicates for each of these measurements with matched background samples so
that the data could be ran through modern IDR based analysis pipelines. With a
robotic ChIP-Seq platform developed by Clarke Gasper in the PEC (Gasper WC,
2014), I produced a new set of factor occupancy measurement for several of the key
muscle differentiation factors (Mef2, MyoD, Myogenin, E12/HEB) as well as key
co-activators such as the HAT EP300. I measured the H3K27ac, H3K4me1 and
H3K4me2 histone marks in order to contrast their biochemical occupancy with my
enhancer assay results. These ChIP-seq measurements are summarized in the table
provided in Appendix C. We have also modern DHS data kindly provided by the
Mortazavi Lab for C2C12 cells at both myoblasts and myocytes which was used
for much of the analysis presented in Chapter 3. The modern occupancy landscape
of these and other factors involved in the differentiation process are illustrated for
reference in Supplementary Figure 3.5.
The following tables summarize this ChIP-Seq data:
http : //woldlab.caltech.edu/~gdesalvo/RobotChIPSeq2015 − 2016.xlsx
All of the listed libraries, where possible, were called by Dr. Georgi Marinov using
the ENCODE 3 pipeline (https : //www.encodeproject .org/pipelines/) and are
available in on our Lab cluster ChIP repository.
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A p p e n d i x D
COMBINATORICS (SOM) BASED CANDIDATE ENHANCER
ELEMENTS
The following set of Self Organizing Maps (SOMs) were generated using SOMatic
(available at http : //crick .bio.uci.edu/SOMatic/) as part of an effort to analyze
my enhancer assay data. Although thesemapswere not used as part of themanuscript
they still represent a resource for future analysis of the C2C12 and multi-tissue
comparisons of TF; CTCF, Pol2, DNAse and histone marks. All of these SOMs
may be requested.
Custom SOM Viewer
I helped develop a beta version of a custom viewer in collaboration with Santiago
Lombeyda at the Caltech CD3 which can be viewed here:
http : //woldlab.caltech.edu/~gdesalvo/d3 − viewer − v.0.31/viewer .html
mm9.200.C2Only.HDPP SOM Includes Histone Marks; DNAse; Pol2; CTCF
and EP300 in both C2C12 exponential and differentiated states.
C2C12-D-DHS-DnaseHSC2C12-D-HM-H3K27acC2C12-D-HM-H3K27me3C2C12-
D-HM-H3K36me3 C2C12-D-HM-H3K4me1 C2C12-D-HM-H3K4me2 C2C12-D-
HM-H3K4me3 C2C12-D-PM-Pol2-4h8 C2C12-D-TF-CTCF C2C12-D-TF-EP300
C2C12-D-ZI-input C2C12-E-DHS-DnaseHS C2C12-E-HM-H3K27ac C2C12-E-
HM-H3K27me3 C2C12-E-HM-H3K36me3 C2C12-E-HM-H3K4me1 C2C12-E-
HM-H3K4me2C2C12-E-HM-H3K4me3C2C12-E-PM-Pol2-4h8C2C12-E-TF-CTCF
C2C12-E-TF-EP300 C2C12-E-ZI-input
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mm9.200.C2Only Includes the following datasets:
C2C12-D-DHS-DnaseHSC2C12-D-HM-H3K27acC2C12-D-HM-H3K27me3C2C12-
D-HM-H3K36me3 C2C12-D-HM-H3K4me1 C2C12-D-HM-H3K4me2 C2C12-D-
HM-H3K4me3C2C12-D-PM-Pol2-4h8C2C12-D-TF-CTCFC2C12-D-TF-E2AC2C12-
D-TF-EP300 C2C12-D-TF-GABP C2C12-D-TF-HEB C2C12-D-TF-Mef2 C2C12-
D-TF-MyoDC2C12-D-TF-myogenin C2C12-D-TF-SP1C2C12-D-TF-SRFC2C12-
D-TF-ZFP143C2C12-D-ZI-inputC2C12-E-DHS-DnaseHSC2C12-E-HM-H3K27ac
C2C12-E-HM-H3K27me3C2C12-E-HM-H3K36me3C2C12-E-HM-H3K4me1C2C12-
E-HM-H3K4me2 C2C12-E-HM-H3K4me3 C2C12-E-PM-Pol2-4h8 C2C12-E-TF-
CTCF C2C12-E-TF-E2A C2C12-E-TF-EP300 C2C12-E-TF-FOSL1 C2C12-E-TF-
HEBC2C12-E-TF-Mef2C2C12-E-TF-MyoDC2C12-E-TF-SRFC2C12-E-TF-ZFP143
C2C12-E-ZI-input
mm9.200.G1EOnly.HDPP
G1E-D-DHS-DNAseHS G1E-D-HM-H3K27ac G1E-D-HM-H3K27me3 G1E-D-
HM-H3K36me3 G1E-D-HM-H3K4me1 G1E-D-HM-H3K4me3 G1E-D-PM-Pol2-
4H8G1E-D-TF-CTCFG1E-D-ZI-inputG1E-E-DHS-DNAseHSG1E-E-HM-H3K27ac
G1E-E-HM-H3K27me3 G1E-E-HM-H3K36me3 G1E-E-HM-H3K4me1 G1E-E-
HM-H3K4me3 G1E-E-PM-Pol2-4H8 G1E-E-TF-CTCF G1E-E-ZI-input G1S-M-
TF-EP300mm9.200.G1EOnlyG1E-D-DHS-DNAseHSG1E-D-HM-H3K27acG1E-
D-HM-H3K27me3 G1E-D-HM-H3K36me3 G1E-D-HM-H3K4me1 G1E-D-HM-
H3K4me3 G1E-D-PM-Pol2-4H8 G1E-D-TF-CTCF G1E-D-TF-GATA1 G1E-D-
TF-GATA2 G1E-D-TF-Tal1 G1E-D-ZI-input G1E-E-DHS-DNAseHS G1E-E-HM-
H3K27ac G1E-E-HM-H3K27me3 G1E-E-HM-H3K36me3 G1E-E-HM-H3K4me1
G1E-E-HM-H3K4me3G1E-E-PM-Pol2-4H8G1E-E-TF-CTCFG1E-E-TF-GATA1
G1E-E-TF-GATA2 G1E-E-TF-Tal1 G1E-E-ZI-input G1S-M-TF-EP300
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mm9.200.C2EROnly.HDPP
C2C12-D-DHS-DnaseHSC2C12-D-HM-H3K27acC2C12-D-HM-H3K27me3C2C12-
D-HM-H3K36me3 C2C12-D-HM-H3K4me1 C2C12-D-HM-H3K4me2 C2C12-D-
HM-H3K4me3 C2C12-D-PM-Pol2-4h8 C2C12-D-TF-CTCF C2C12-D-TF-EP300
C2C12-D-ZI-input C2C12-E-DHS-DnaseHS C2C12-E-HM-H3K27ac C2C12-E-
HM-H3K27me3 C2C12-E-HM-H3K36me3 C2C12-E-HM-H3K4me1 C2C12-E-
HM-H3K4me2C2C12-E-HM-H3K4me3C2C12-E-PM-Pol2-4h8C2C12-E-TF-CTCF
C2C12-E-TF-EP300C2C12-E-ZI-inputG1E-D-DHS-DNAseHSG1E-D-HM-H3K27ac
G1E-D-HM-H3K27me3 G1E-D-HM-H3K36me3 G1E-D-HM-H3K4me1 G1E-D-
HM-H3K4me3 G1E-D-PM-Pol2-4H8 G1E-D-TF-CTCF G1E-D-ZI-input G1E-E-
DHS-DNAseHSG1E-E-HM-H3K27acG1E-E-HM-H3K27me3G1E-E-HM-H3K36me3
G1E-E-HM-H3K4me1 G1E-E-HM-H3K4me3 G1E-E-PM-Pol2-4H8 G1E-E-TF-
CTCF G1E-E-ZI-input G1S-M-TF-EP300
mm9.200.C2EROnly
C2C12-D-DHS-DnaseHSC2C12-D-HM-H3K27acC2C12-D-HM-H3K27me3C2C12-
D-HM-H3K36me3 C2C12-D-HM-H3K4me1 C2C12-D-HM-H3K4me2 C2C12-D-
HM-H3K4me3C2C12-D-PM-Pol2-4h8C2C12-D-TF-CTCFC2C12-D-TF-E2AC2C12-
D-TF-EP300 C2C12-D-TF-GABP C2C12-D-TF-HEB C2C12-D-TF-Mef2 C2C12-
D-TF-MyoDC2C12-D-TF-myogenin C2C12-D-TF-SP1C2C12-D-TF-SRFC2C12-
D-TF-ZFP143C2C12-D-ZI-inputC2C12-E-DHS-DnaseHSC2C12-E-HM-H3K27ac
C2C12-E-HM-H3K27me3C2C12-E-HM-H3K36me3C2C12-E-HM-H3K4me1C2C12-
E-HM-H3K4me2 C2C12-E-HM-H3K4me3 C2C12-E-PM-Pol2-4h8 C2C12-E-TF-
CTCF C2C12-E-TF-E2A C2C12-E-TF-EP300 C2C12-E-TF-FOSL1 C2C12-E-TF-
HEBC2C12-E-TF-Mef2C2C12-E-TF-MyoDC2C12-E-TF-SRFC2C12-E-TF-ZFP143
C2C12-E-ZI-inputG1E-D-DHS-DNAseHSG1E-D-HM-H3K27acG1E-D-HM-H3K27me3
G1E-D-HM-H3K36me3 G1E-D-HM-H3K4me1 G1E-D-HM-H3K4me3 G1E-D-
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PM-Pol2-4H8 G1E-D-TF-CTCF G1E-D-TF-GATA1 G1E-D-TF-GATA2 G1E-D-
TF-Tal1 G1E-D-ZI-input G1E-E-DHS-DNAseHS G1E-E-HM-H3K27ac G1E-E-
HM-H3K27me3G1E-E-HM-H3K36me3G1E-E-HM-H3K4me1G1E-E-HM-H3K4me3
G1E-E-PM-Pol2-4H8G1E-E-TF-CTCFG1E-E-TF-GATA1G1E-E-TF-GATA2G1E-
E-TF-Tal1 G1E-E-ZI-input G1S-M-TF-EP300
Muscle (+EP300) vs ER (+EP300) vs embryo
C2C12-D-DHS-DnaseHSC2C12-D-HM-H3K27acC2C12-D-HM-H3K27me3C2C12-
D-HM-H3K36me3 C2C12-D-HM-H3K4me1 C2C12-D-HM-H3K4me2 C2C12-D-
HM-H3K4me3C2C12-D-PM-Pol2-4h8C2C12-D-TF-CTCFC2C12-D-TF-E2AC2C12-
D-TF-EP300 C2C12-D-TF-GABP C2C12-D-TF-HEB C2C12-D-TF-Mef2 C2C12-
D-TF-MyoD C2C12-D-TF-SP1 C2C12-D-TF-SRF C2C12-D-TF-ZFP143 C2C12-
D-TF-myogeninC2C12-D-ZI-inputC2C12-E-DHS-DnaseHSC2C12-E-HM-H3K27ac
C2C12-E-HM-H3K27me3C2C12-E-HM-H3K36me3C2C12-E-HM-H3K4me1C2C12-
E-HM-H3K4me2 C2C12-E-HM-H3K4me3 C2C12-E-PM-Pol2-4h8 C2C12-E-TF-
CTCF C2C12-E-TF-E2A C2C12-E-TF-EP300 C2C12-E-TF-FOSL1 C2C12-E-TF-
HEBC2C12-E-TF-Mef2C2C12-E-TF-MyoDC2C12-E-TF-SRFC2C12-E-TF-ZFP143
C2C12-E-ZI-inputG1E-D-DHS-DNAseHSG1E-D-HM-H3K27acG1E-D-HM-H3K27me3
G1E-D-HM-H3K36me3 G1E-D-HM-H3K4me1 G1E-D-HM-H3K4me3 G1E-D-
PM-Pol2-4H8 G1E-D-TF-CTCF G1E-D-TF-GATA1 G1E-D-TF-GATA2 G1E-D-
TF-Tal1 G1E-D-ZI-input G1E-E-DHS-DNAseHS G1E-E-HM-H3K27ac G1E-E-
HM-H3K27me3G1E-E-HM-H3K36me3G1E-E-HM-H3K4me1G1E-E-HM-H3K4me3
G1E-E-PM-Pol2-4H8G1E-E-TF-CTCFG1E-E-TF-GATA1G1E-E-TF-GATA2G1E-
E-TF-Tal1G1E-E-ZI-inputG1S-M-TF-EP300H3K27ac-EmbryonicFacialProminence-
E11.5H3K27ac-EmbryonicFacialProminence-E14.5H3K27ac-Forebrain-E11.5H3K27ac-
Forebrain-E14.5 H3K27ac-Forebrain-P0 H3K27ac-Heart-E11.5 H3K27ac-Heart-
E14.5 H3K27ac-Heart-P0 H3K27ac-Hindbrain-E11.5 H3K27ac-Hindbrain-E14.5
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H3K27ac-Hindbrain-P0H3K27ac-Intestine-E14.5H3K27ac-Intestine-P0H3K27ac-
Kidney-E14.5 H3K27ac-Kidney-P0 H3K27ac-Limb-E11.5 H3K27ac-Limb-E14.5
H3K27ac-Liver-E11.5 H3K27ac-Liver-E14.5 H3K27ac-Liver-P0 H3K27ac-Lung-
E14.5H3K27ac-Lung-P0H3K27ac-Midbrain-E11.5H3K27ac-Midbrain-E14.5H3K27ac-
Midbrain-P0 H3K27ac-NeuralTube-E11.5 H3K27ac-NeuralTube-E14.5 H3K27ac-
Stomach-E14.5 H3K27ac-Stomach-P0 H3K27me3-EmbryonicFacialProminence-
E11.5H3K27me3-EmbryonicFacialProminence-E14.5H3K27me3-Forebrain-E11.5
H3K27me3-Forebrain-E14.5H3K27me3-Forebrain-P0H3K27me3-Heart-E11.5H3K27me3-
Heart-E14.5H3K27me3-Heart-P0H3K27me3-Hindbrain-E11.5H3K27me3-Hindbrain-
E14.5H3K27me3-Hindbrain-P0H3K27me3-Intestine-E14.5H3K27me3-Intestine-
P0H3K27me3-Kidney-E14.5H3K27me3-Kidney-P0H3K27me3-Limb-E11.5H3K27me3-
Limb-E14.5 H3K27me3-Liver-E11.5 H3K27me3-Liver-E14.5 H3K27me3-Liver-
P0H3K27me3-Lung-E14.5H3K27me3-Lung-P0H3K27me3-Midbrain-E11.5H3K27me3-
Midbrain-E14.5H3K27me3-Midbrain-P0H3K27me3-NeuralTube-E11.5H3K27me3-
Stomach-E14.5H3K27me3-Stomach-P0H3K36me3-EmbryonicFacialProminence-
E11.5H3K36me3-EmbryonicFacialProminence-E14.5H3K36me3-Forebrain-E14.5
H3K36me3-Forebrain-P0H3K36me3-Heart-E11.5H3K36me3-Heart-E14.5H3K36me3-
Heart-P0 H3K36me3-Hindbrain-E11.5 H3K36me3-Hindbrain-E14.5 H3K36me3-
Hindbrain-P0H3K36me3-Intestine-E14.5H3K36me3-Intestine-P0H3K36me3-Kidney-
E14.5H3K36me3-Kidney-P0H3K36me3-Limb-E14.5H3K36me3-Liver-E11.5H3K36me3-
Liver-E14.5H3K36me3-Liver-P0H3K36me3-Lung-E14.5H3K36me3-Lung-P0H3K36me3-
Midbrain-E14.5H3K36me3-Midbrain-P0H3K36me3-NeuralTube-E11.5H3K36me3-
NeuralTube-E14.5H3K36me3-Stomach-E14.5H3K36me3-Stomach-P0H3K4me1-
EmbryonicFacialProminence-E11.5H3K4me1-EmbryonicFacialProminence-E14.5
H3K4me1-Forebrain-E11.5H3K4me1-Forebrain-E14.5H3K4me1-Heart-E11.5H3K4me1-
Heart-E14.5H3K4me1-Heart-P0H3K4me1-Hindbrain-E11.5H3K4me1-Hindbrain-
E14.5 H3K4me1-Hindbrain-P0 H3K4me1-Intestine-E14.5 H3K4me1-Intestine-P0
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H3K4me1-Kidney-E14.5H3K4me1-Kidney-P0H3K4me1-Limb-E11.5H3K4me1-
Limb-E14.5H3K4me1-Liver-E11.5H3K4me1-Liver-E14.5H3K4me1-Liver-P0H3K4me1-
Lung-E14.5 H3K4me1-Lung-P0 H3K4me1-Midbrain-E11.5 H3K4me1-Midbrain-
E14.5H3K4me1-NeuralTube-E11.5H3K4me1-NeuralTube-E14.5H3K4me1-Stomach-
E14.5H3K4me1-Stomach-P0H3K4me2-EmbryonicFacialProminence-E11.5H3K4me2-
EmbryonicFacialProminence-E14.5H3K4me2-Forebrain-E11.5H3K4me2-Forebrain-
E14.5H3K4me2-Forebrain-P0H3K4me2-Heart-E11.5H3K4me2-Heart-E14.5H3K4me2-
Heart-P0H3K4me2-Hindbrain-E11.5H3K4me2-Hindbrain-E14.5H3K4me2-Hindbrain-
P0H3K4me2-Intestine-E14.5H3K4me2-Intestine-P0H3K4me2-Kidney-E14.5H3K4me2-
Kidney-P0 H3K4me2-Limb-E11.5 H3K4me2-Limb-E14.5 H3K4me2-Liver-E11.5
H3K4me2-Liver-E14.5H3K4me2-Liver-P0H3K4me2-Lung-E14.5H3K4me2-Lung-
P0 H3K4me2-Midbrain-E11.5 H3K4me2-Midbrain-E14.5 H3K4me2-Midbrain-P0
H3K4me2-NeuralTube-E11.5H3K4me2-NeuralTube-E14.5H3K4me2-Stomach-E14.5
H3K4me2-Stomach-P0 H3K4me3-EmbryonicFacialProminence-E11.5 H3K4me3-
EmbryonicFacialProminence-E14.5H3K4me3-Forebrain-E11.5H3K4me3-Forebrain-
E14.5H3K4me3-Forebrain-P0H3K4me3-Heart-E11.5H3K4me3-Heart-E14.5H3K4me3-
Heart-P0H3K4me3-Hindbrain-E11.5H3K4me3-Hindbrain-E14.5H3K4me3-Hindbrain-
P0H3K4me3-Intestine-E14.5H3K4me3-Intestine-P0H3K4me3-Kidney-E14.5H3K4me3-
Kidney-P0 H3K4me3-Limb-E11.5 H3K4me3-Limb-E14.5 H3K4me3-Liver-E11.5
H3K4me3-Liver-E14.5H3K4me3-Liver-P0H3K4me3-Lung-E14.5H3K4me3-Lung-
P0 H3K4me3-Midbrain-E11.5 H3K4me3-Midbrain-E14.5 H3K4me3-Midbrain-P0
H3K4me3-NeuralTube-E11.5H3K4me3-Stomach-E14.5H3K4me3-Stomach-P0H3K9ac-
EmbryonicFacialProminence-E11.5H3K9ac-EmbryonicFacialProminence-E14.5H3K9ac-
Forebrain-E11.5 H3K9ac-Forebrain-E14.5 H3K9ac-Forebrain-P0 H3K9ac-Heart-
E11.5 H3K9ac-Heart-E14.5 H3K9ac-Heart-P0 H3K9ac-Hindbrain-E11.5 H3K9ac-
Hindbrain-E14.5H3K9ac-Hindbrain-P0H3K9ac-Intestine-E14.5H3K9ac-Intestine-
P0H3K9ac-Kidney-E14.5H3K9ac-Kidney-P0H3K9ac-Limb-E11.5H3K9ac-Limb-
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E14.5H3K9ac-Liver-E11.5H3K9ac-Liver-E14.5H3K9ac-Liver-P0H3K9ac-Lung-
E14.5H3K9ac-Lung-P0H3K9ac-Midbrain-E11.5H3K9ac-Midbrain-E14.5H3K9ac-
Midbrain-P0H3K9ac-NeuralTube-E11.5H3K9ac-NeuralTube-E14.5H3K9ac-Stomach-
E14.5H3K9ac-Stomach-P0H3K9me3-EmbryonicFacialProminence-E11.5H3K9me3-
Forebrain-P0H3K9me3-Heart-E11.5H3K9me3-Hindbrain-E11.5H3K9me3-Limb-
E11.5 H3K9me3-Liver-E11.5 H3K9me3-Midbrain-E11.5 H3K9me3-NeuralTube-
E11.5 Input-EmbryonicFacialProminence-E11.5 Input-EmbryonicFacialProminence-
E14.5 Input-Forebrain-E11.5 Input-Forebrain-E14.5 Input-Forebrain-P0 Input-Heart-
E11.5 Input-Heart-E14.5 Input-Heart-P0 Input-Hindbrain-E11.5 Input-Hindbrain-
E14.5 Input-Hindbrain-P0 Input-Intestine-E14.5 Input-Intestine-P0 Input-Kidney-
E14.5 Input-Kidney-P0 Input-Limb-E11.5 Input-Limb-E14.5 Input-Liver-E11.5 Input-
Liver-E14.5 Input-Liver-P0 Input-Lung-E14.5 Input-Lung-P0 Input-Midbrain-E11.5
Input-Midbrain-E14.5 Input-Midbrain-P0 Input-NeuralTube-E11.5 Input-NeuralTube-
E14.5 Input-Stomach-E14.5 Input-Stomach-P0
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A p p e n d i x E
MUSCLE-SPECIFIC ENHANCER DATABASE
These enhancerswere drawn froma resourcewhich I recapitulate here. This resource
was a muscle specific database providing a catalog of regulatory elements that was
up-kept by James W. Fickett is no longer available on the web.
(Adolph EA, 1993; Amacher S, 1993; Andres V, 1995; Argenin S, 1994; Asakura
A, 1993; Baldwin TJ, 1989; Baldwin TJ, 1988; BanerjeeBasu S, 1993; Barbieri G,
1990; Barnea E, 1990; BasselDuby R, 1993; BasselDuby R, 1992; Bauvagnet PF,
1987; Berberich C, 1993; Bergsma DJ, 1986; Bessereau JL, 1993; Biben C, 1994;
Bishoprie NH, 1992; Black BL, 1995; Blanchetot N, 1986; Boheler KR, 1992;
Bonne G, 1993; Boxer LM, 1989; Brennan TJ, 1990; Buchberger A, 1994; Bucher
EA, 1988; Buonanno A, 1993; Buskin JN, 1989; Capetanaki Y, 1989b; Capetanaki
Y, 1989a; Carnac G, 1993; Carroll SL, 1988; Catala F, 1995; Chakraborty T,
1991; Cheng TS, 1992; Cheng TS, 1993; Chow KL, 1990; Christensen TH, 1993;
Chung AB, 1992; Cogan JG, 1995; Collo G, 1993; Cooper TA, 1985; Corin SJ,
1994; Cribbs LL, 1989; Cserjesi P, 1992; Cserjesi P, 1994; Danilition SL, 1991;
Daubas P, 1988; Davey HW, 1995; Dechesne CA, 1994; Deschamps J, 1985;
Devlin BH, 1989; Dickson G, 1988; Donoghue M, 1988; Donoghue MJ, 1991;
Duan C, 1996; Duclert A, 1993; Dunwoodie SL, 1994; Dürr I, 1994; Dutton EK,
1993; Edmondson DG, 1992; Edwards JG, 1992; Edwards JG, 1994; Eftimie R,
1991; Ernst H, 1991; Essig DA, 1991; Ewart GD, 1991; Ewton DZ, 1995; Fabrizi
GM, 1992; Farrell FX, 1990; Fisch TM, 1987; Flink IL, 1990; Flink IL, 1992;
Foster DN, 1992; French BA, 1991; FujisawaSehara A, 1991; FujisawaSehara A,
1992; Gardner DG, 1989; Gardner DG, 1988; Garzon RJ, 1994; Getman DK, 1995;
Giallongo A, 1993; Gilgenkrantz H, 1992; Gilmour BP, 1991; Gilmour BP, 1995;
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Glembotski CC, 1993; Goldhamer DJ, 1995; Goldhamer DJ, 1992; Gorski DH,
1993; Gossett LA, 1989; Graber SG, 1986; Grayson J, 1995; Greenberg ME, 1987;
Greenberg ME, 1986; Grichnik JM, 1987; Grichnik JM, 1988; Guicherit OM,
1991; Gupta MP, 1994; Gupta MP, 1996; Gustafson TA, 1987; Han VKM, 1996;
Hashimoto N, 1995; Hayes TE, 1987; Hidaka RA, 1993; Horlick RA, 1989; Horlick
RA, 1990; Houzelstein D, 1992; Huang CF, 1994; Huang WY, 1997; Iannello RC,
1991; Ip HS, 1994; Izumo S, 1986; James PL, 1993; Jaynes JB, 1986; Jaynes JB,
1988; Joh K, 1991; Johnson JE, 1992; Johnson JE, 1989; Kariya K, 1993; Kariya
K, 1994; Karns LR, 1995; Kawamoto T, 1988; Keller A, 1995; Kelly R, 1995;
Klamut HJ, 1990; Klarsfeld A, 1987; Klip A, 1994; Knotts S, 1994; Kou K, 1995;
KovacicMilivojevic G, 1993; Kovacs AM, 1993; Lamandé N, 1995; Lamandé N,
1989; LaPointe MC, 1988; Lassar AB, 1989; LeeT.C. ChowKL, 1991; Lee TC,
1994; Lee Y, 1997; Leibham D, 1994; Lenka N, 1996; LePage DF, 1994; Leung E,
1993; Lev AA, 1987; Lewis AL, 1996; Li H, 1993; Li H, 1994a; Li H, 1994b; Li K,
1990; Li Z, 1991; Li Z, 1993; Li Z, 1989; Lilienbaum A, 1990; Liu ML, 1994; Liu
M, 1994; Liu Z, 1991; Lohse P, 1988; Lompre AM, 1984; Long SD, 1996; LucasM,
1992; Lyons GE, 1990; Mably JD, 1993; MacLellan WR, 1994; Mahdavi V, 1982;
Maire P, 1987; Malik S, 1995; Mar JH, 1986; Mar JH, 1988; Martin KA, 1994;
Matsumoto T, 1996; McHugh KM, 1988; McNamara CA, 1995; Mendelzon D,
1994; Merlie PJ, 1989; Merlie PJ, 1994; Mesnard L, 1993; Min BH, 1990; Minty A,
1986; Mitsumoto Y, 1994; Miwa T, 1987; Miwa T, 1991; MohunT. G, 1987;
Mohun TJ, 1986; Mohun TJ, 1989; Molkentin JD, 1993; Molkentin JD, 1994a;
Molkentin JD, 1996; Molkentin JD, 1994b; Morkin E, 1993; Moss JB, 1994; Moss
JB, 1996; MouraNeto V, 1996; Murre C, 1989; Muscat GEO, 1987; Mutero A,
1995; Naidu PS, 1995; Nakamura N, 1995; Nemer M, 1986; Noursadeghi M, 1993;
Nudel U, 1988; Numberger M, 1991; Ohshima Y, 1989; Ojamaa K, 1996; Olva D,
1995; Pari G, 1991; Pariasamy M, 1989; Parker TG, 1992; Parmacek MS, 1994;
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Parmacek MS, 1992; Parsons WJ, 1993; PedrazaAlva G, 1994; PeriasamyM, 1985;
Perkins EB, 1995; Peshavaria M, 1991; Peterson CA, 1992; PhanDinhTuy F, 1988;
Pieper FR, 1988; Pieper FR, 1987; Pieper FR, 1992; Piette J, 1989; Piette nan,
1990; Piette J, 1992; Prody CA, 1991; Prody CA, 1992; Quax W, 1985; Quax
W, 1984; Quitschke WW, 1989a; Quitschke WW, 1989b; Rao MV, 1996; Renz
M, 1985; Rindt H, 1993; Rindt H, 1995; Rittling SR, 1989; Rosenthal N, 1990;
Rosenthal N, 1989; Rotwein P, 1995; Ryan KJ, 1996; Saggin L, 1990; Sakimura K,
1990; Salminen A, 1991; Salminen M, 1996; Salminen M, 1994; Salvetti A, 1993;
Santoro IM, 1991; Sartorelli V, 1990; Sartorelli V, 1992; SassoneCorsi P, 1987;
Sawtell NM, 1989; Sax CM, 1989; Sax CM, 1988; Sax CM, 1993; Schlerf A, 1988;
Schreier T, 1990; Seidel U, 1989; Seidman DE, 1987; Shillace R, 1994; Shimizu
N, n.d.[b]; Shimizu M, 1993; Shimizu N, n.d.[a]; Simon AM, 1993; Skerjanc IS,
1994; Smith EO, 1993; Sommers CL, 1994; Song WK, 1992; Sprenkle AB, 1995;
Sternberg EA, 1988; Stover DM, 1992; Su CT, 1995; SubramaniamA, 1990; Sunyer
T, 1993; Swiderski RE, 1990; Sympson CJ, 1993; Szucsik JC, 1995; Talib S, 1993;
Tanaka M, 1985; Tapscott SJ, 1992; Taylor MV, 1991; Taylor JM, 1995; Taylor
MV, 1989; Tebbey PS, 1994; Thompson WR, 1991; Trask RV, 1988; Treisman R,
1986; Trouche D, 1993; Trouche D, 1995; Underwood LE, 1987; FA, 1992; FA,
1994; JJM, 1994; Vosberg HP, 1992; Walke W, 1994; Walsh K, 1988; Walsh K,
1989; Wan B, 1995; Wang G, 1994; Wang XM, 1990; Wang Y, 1988; Watanabe T,
1997; Wefald FC, 1990; Weintraub H, 1990; Weintraub H, 1991; Weller PA, 1986;
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